L’innovation en Ophtalmologie va bien au-delà des médicaments

Téléchargez l’Application Retina Base pour tablettes tactiles sur l’App Store® ou le Google Play® et découvrez plus de 120 cas cliniques de pathologies rétiniennes rédigés par des experts, disponibles en Français et en Anglais.

- Naviguez à travers l’organisation planétaire des pathologies et cas cliniques.
- Recherchez facilement les clichés grâce au moteur de recherche intuitif et filtrez les résultats par mot-clé, technique d’imagerie et auteur.
- Recevez les notifications dès que de nouveaux cas sont disponibles.

Rendez-vous sur www.viaopta.fr pour découvrir ou redécouvrir tous les services ViaOpta™ dédiés à l’ophtalmologie.
Dear EVER members, colleagues and friends,

As President of EVER 2015, I would like to take this opportunity to welcome you again to Nice, France. This pearl on the French Riviera has now been the home of EVER for three years, and, in agreement with your vote, will be that for another four.

EVER continues to be a dynamic, strong organisation with the annual Meeting acting as a conduit for researchers, clinician-scientists and clinicians, as well as industry partners in the field of vision and eye disease to exchange ideas, learn, enthuse and stimulate, with solid science in a relaxed atmosphere and an Old World charming environment.

The latter ensures that the interactions between participants can continue beyond those at the Meeting, in a setting of a historic city with a thriving restaurant scene for all budgets, and good weather. In addition, you may sometimes just want to go for a bit of culture, a shopping spree or absorb some Indian summer sunrays. The Annual EVER Meeting offers all of that.

Over the years in Nice, we have seen a steady rise in the number of participants, which encourages the EVER Board to continue on the same path. A fantastic mix of opinion leaders, basic researchers, clinicians and clinician-scientists from Europe and far beyond, all flock to Nice, to interact, explain and absorb the latest novelties in our field. Strong support from our Industry partners has helped EVER flourish over its history, in particular during the last few years in Nice. Gratitude for their support is abundant.

The Annual EVER Meeting is certainly large enough to have the scientific clout required for an international meeting, but at the same time small enough not to overwhelm and allow one to meet those one really wants to. The Meeting program offers a wide variety of scientific exchange formats in ophthalmology and vision research, and includes plenary lectures by internationally renowned leaders in their fields, special interest symposia and courses by the experts, and free paper and poster sessions to present new results.

I’m very grateful that you are joining us in Nice for the EVER 2015 Meeting, and thank you in advance for sharing your insights, knowledge and new ideas.

Bart P LEROY
President EVER 2015
We’ll see you through your drug development every step of the way, supporting your ocular research with scientific excellence and a unique suite of services:

- Laboratory support
- Custom disease models
- Specialized administration
- Advanced imaging
- Model-based ocular surgery

Visit us at our booth to meet one of our scientists, or find out more at www.criver.com/ever.
### Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Word from the president</td>
<td>1</td>
</tr>
<tr>
<td>About EVER</td>
<td>4</td>
</tr>
<tr>
<td>Composition of the board 2015</td>
<td>8</td>
</tr>
<tr>
<td>Congress information</td>
<td>10</td>
</tr>
<tr>
<td>Grants and prizes</td>
<td>14</td>
</tr>
<tr>
<td>Floorplan</td>
<td>16</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>17</td>
</tr>
<tr>
<td>Partners of EVER</td>
<td>18</td>
</tr>
<tr>
<td>About the programme book</td>
<td>20</td>
</tr>
<tr>
<td>Scientific sections 2015</td>
<td>21</td>
</tr>
<tr>
<td>Industry Sponsored Symposia</td>
<td>22</td>
</tr>
<tr>
<td>Courses</td>
<td>23</td>
</tr>
<tr>
<td><strong>Wednesday, October 7</strong></td>
<td>25</td>
</tr>
<tr>
<td>Noon session</td>
<td>26</td>
</tr>
<tr>
<td>First afternoon session</td>
<td>30</td>
</tr>
<tr>
<td>Opening Ceremony</td>
<td>33</td>
</tr>
<tr>
<td>Second afternoon session</td>
<td>34</td>
</tr>
<tr>
<td>European Ophthalmology Heritage lecture</td>
<td>38</td>
</tr>
<tr>
<td>Keynote lecture - Brenda GALLIE</td>
<td>39</td>
</tr>
<tr>
<td>Welcome reception</td>
<td>41</td>
</tr>
<tr>
<td><strong>Thursday, October 8</strong></td>
<td>43</td>
</tr>
<tr>
<td>First morning session</td>
<td>44</td>
</tr>
<tr>
<td>EVER-Acta lecture</td>
<td>49</td>
</tr>
<tr>
<td>Second morning session</td>
<td>50</td>
</tr>
<tr>
<td>Lunchtime session - CIS</td>
<td>55</td>
</tr>
<tr>
<td>Ophthalmic Research lecture</td>
<td>57</td>
</tr>
<tr>
<td>First afternoon session</td>
<td>58</td>
</tr>
<tr>
<td>Coffee with the Prof</td>
<td>62</td>
</tr>
<tr>
<td>Poster session 1</td>
<td>63</td>
</tr>
<tr>
<td>Second afternoon session</td>
<td>71</td>
</tr>
<tr>
<td>Third afternoon session</td>
<td>75</td>
</tr>
<tr>
<td>Evening session - CIS</td>
<td>79</td>
</tr>
<tr>
<td><strong>Friday, October 9</strong></td>
<td>81</td>
</tr>
<tr>
<td>First morning session</td>
<td>82</td>
</tr>
<tr>
<td>Keynote lecture - Reza DANA</td>
<td>87</td>
</tr>
<tr>
<td>Second morning session</td>
<td>88</td>
</tr>
<tr>
<td>Lunchtime sessions - CIS</td>
<td>92-93</td>
</tr>
<tr>
<td>First afternoon session</td>
<td>94</td>
</tr>
<tr>
<td>Poster session 2</td>
<td>98</td>
</tr>
<tr>
<td>Section Business Meetings</td>
<td>107</td>
</tr>
<tr>
<td>Second afternoon session</td>
<td>108</td>
</tr>
<tr>
<td>General Assembly</td>
<td>113</td>
</tr>
<tr>
<td>Congress dinner</td>
<td>114</td>
</tr>
<tr>
<td><strong>Saturday, October 10</strong></td>
<td>115</td>
</tr>
<tr>
<td>First morning session</td>
<td>116</td>
</tr>
<tr>
<td>Poster session 3</td>
<td>120</td>
</tr>
<tr>
<td>Keynote lecture - Bita ESMAELI</td>
<td>127</td>
</tr>
<tr>
<td>Second morning session</td>
<td>128</td>
</tr>
<tr>
<td>Lunchtime session - CIS</td>
<td>133</td>
</tr>
<tr>
<td>Afternoon session</td>
<td>134</td>
</tr>
<tr>
<td>Prize award ceremony and conclusion of the congress</td>
<td>138</td>
</tr>
<tr>
<td>Presenting first authors</td>
<td>147</td>
</tr>
<tr>
<td>Presenting all authors</td>
<td>155</td>
</tr>
<tr>
<td>Time schedule</td>
<td>164</td>
</tr>
<tr>
<td>Sponsors</td>
<td>back cover</td>
</tr>
</tbody>
</table>
The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress.

**Membership**

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections. Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 Scientific Sections that best represents his or her primary area of interest.

The benefits of EVER membership are:

- significantly reduced registration fees for annual meeting
- submission of abstracts at annual meeting
- organizing Special Interest Symposia (SIS) and Courses
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.844)
- voting rights for the election of the Board Members
- travel grants and poster prizes
- quarterly E-Newsletter

**Elections 2015**

In 2015 new representatives of the scientific sections

- NSPH  Neuro-ophthalmology / Strabismology / Paediatric Ophthalmology / History of Ophthalmology
- PO  Pathology / Oncology

will be elected through electronic voting. Voting 2015 will close on October 8, midnight. The result of the elections will be announced at the General Assembly on Friday 9 October 2015, 17:55-18:30.
About EVER
European Association for Vision and Eye Research

Affiliation to scientific sections

- 16% Cornea / Ocular Surface (COS)
- 15% Retina / Vitreous (RV)
- 14% Pathology / Oncology (PO)
- 13% Glaucoma (G)
- 9% Lens / Cataract (LC)
- 8% Neuro-ophthalmology / Strabismology / Paediatric / History (NSPH)
- 7% Physiology / Biochemistry / Pharmacology (PBP)
- 6% Immunology / Microbiology (IM)
- 5% Electrophysiology, physiological Optics, Vision Sciences (EOVS)
- 5% Molecular Biology / Genetics / Epidemiology (MBGE)
- 3% Anatomy / Cell Biology (ACB)

Congress participants:

Clinical with or without research: 73 %
Research only: 27 %
We aim to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has members from over 50 countries and is represented by 11 scientific sections. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

In 2010, the EVER Foundation was created to raise money to organize EVER Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

**Fellowships 2015:**
1. Dr. Sepehr FEIZI, Iran - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Sabina SAPETA, Poland - host institute: Medical University of Vienna, Austria

**Fellowships 2014:**
1. Dr. Ganne PRATYUSHI, India - host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Mohamed Shafik Mohamed ELALFY, Egypt - host institute: Queens Medical Centre, Nottingham, UK

**Fellowships 2013:**
1. Dr. Reka ALBERT, Hungary - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Minika JASIENSKA, Poland - host institute: Department of Experimental Ophthalmology at the Charite University Medicine in Berlin, Germany

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.844)
Composition of the board

Executive committee

Bart P LEROY
President

Constantin POURNARAS
Past President

Catherine CREUZOT
Secretary General

Aki KAWASAKI
President Elect

Steffen HEEGAARD
Treasurer

Werner SPILEERS
Vice President

Marcela VOTRUBA
Programme Secretary

Nadia KNOP
Vice President

Leopold SCHMETTERER
EVER liaison

Laurence DESJARDIINS
Vice-President Elect

EVER office by Mecodi

Marlene VERLAECKT
Executive Officer

Lies VAN EYCKEN
Executive Assistant

Mieke AKKERS
Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - ever@ever.be

www.mecodi.eu
Section chairs

Kai KAARNIRANTA
Anatomy / Cell Biology

Thomas FUCHSLUGER
Cornea / Ocular Surface

Miguel CASTELO-BRANCO
Electrophysiology, physiological Optics, Vision Sciences

Alain BRON
Glaucoma

Andrew DICK
Immunology / Microbiology

Rafael BARRAQUER
Lens / Cataract

Jochen GRAW
Molecular Biology / Genetics / Epidemiology

Aki KAWASAKI
Neuro-ophthalmology / Strabismology / Paediatric / History

Laurence DESJARDINS
Pathology / Oncology

Gerhard GARHÖFER
Physiology / Biochemistry / Pharmacology

Peter WIEDEMANN
Retina / Vitreous

EVER representatives in Acta Board

Constantin POURNARAS
Leopold SCHMETTERER

Senior advisory committee

Jean-Jacques DE LAEY
Jost JONAS

Graham HOLDER
Einar STEFANSSON

Representatives

Bozena ROMANOWSKA-DIXON
Representative East Europe

Jean-Pierre CAUJOLLE
Local representative France
Venue

EVER 2015 will be held at the Acropolis Convention Center in Nice, France
⇒ www.nice-acropolis.com

The scientific programme of the EVER congress starts on Wednesday, October 7 at 12:00 and concludes on Saturday, October 10 at 16:00.

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee. Onsite registration starts on Wednesday, Oct 7, 9:00.

Please note that:
• being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
• if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
• if you register as an Eye-care, Technician or Nurse, you need to prove your status with a document signed by the Head of your Department

Registration fees on-site

|                          | EUR | EUR  *
|--------------------------|-----|-----*
| EVER member / Course invited speakers | 455 | 390 * |
| Member-in-training       | 250 | 200 * |
| Non-member               | 800 | 645 * |
| Non-member-in-training   | 400 | 310 * |
| Eye-Care / Technician / Nurse | 200 | 180 * |
| Congress Dinner (member / non-member) | 90  | 90  |
| Congress Dinner (in training) | 60  | 60  |

* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunisia, Ukraine

Cancellation policy

Refunds - up to 75% of the advance registration fee will be granted for cancellation received in writing prior to Sept 15, 2015. Refunds will not be granted for later cancellations or no-shows.

Website

The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can

• obtain up-to-date information about the scientific programme and the EVER 2015 meeting and view the status (session, hour, place) of your presentation
• pay on-line and print your invoice
• access general information about EVER
• access Acta Ophthalmologica, the EVER journal
• cast your vote for officers
• print CME certificate after each congress you attended
Housing

AdvancedFair has negotiated special rates for accommodation in several categories of hotels.

www.advancedfair.com

Travel

The Nice Côte d’Azur Airport is located at 7 km from the city centre. The tramway line connects most of the hotels with the Acropolis Convention Center.

Weather

In Nice there is an average 6 hours of sunshine/day during October so it remains warm and pleasant. It is a perfect time of year to go and explore the city and discover for yourself the many fantastic historic and cultural landmarks Nice has. There are also a variety of museums and art galleries that can be a worthwhile way to while away a day in the city.

Welcome reception

The Welcome reception is open for all participants and exhibitors.

• Wednesday 19:30 - 21:00 in the Exhibition area, Acropolis Convention Center

Congress dinner

Registration required.
Members / non-members: 90 EUR - Members in training: 60 EUR
Space is limited.

• Friday 20:00 in Hotel NEGRESCO - 37, promenade des Anglais, Nice

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting. In addition coffee & croissants will be served early morning.

Internet access

Wi-Fi internet access is available in the Convention Center.

Photographs

It is strictly forbidden to take photographs or videos of the presentations in all lecture halls.
Publication of the abstracts

The abstracts of the EVER 2015 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

Section Business Meetings

EVER Section Business Meetings of the scientific sections
Friday, 15:45 - 16:15

- ACB ............................................ Gallieni 5
- COS ........................................... Rhodes 2
- EOVS .......................................... Rhodes 1
- G ................................................ Rhodes 1
- IM ................................................ Rhodes 4
- LC ............................................... Hermes
- MBGE .......................................... Gallieni 1 & 2
- NSHP .......................................... Rhodes 2
- PO ............................................... Rhodes 3
- PBP ............................................. Rhodes 3
- RV ............................................... Hermes

The sections
- IM - Immunology / Microbiology
- PBP - Physiology / Biochemistry / Pharmacology

will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2016.

Agenda see page 107

EVER General Assembly

Friday, 17:55 - 18:30 in room Hermes

Agenda see pages 113

Prize award ceremony and conclusion of the congress

Saturday, 15:30 - 16:00 in room Hermes

Agenda see page 138

Women 4 EVER

NEW!

Wednesday 7 October 2015 from 17:00 to 18:30

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed. See page 34.
Coffee with the Prof

Thursday, October 8 2015 from 15:15 - 16:00 in poster area

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a 45 minute session called “Coffee with the Prof”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers.

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

This new initiative is scheduled on Thursday, Oct 8, 15:15 - 16:00 in the poster area. See page 62.

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 22 European CME credits (ECMEC) to the EVER 2015 congress on Oct 7 - 10 in Nice, France. CME credit certificates can be printed from the EVER website after the congress.

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

EVER 2015 congress App

All congress information in a nutshell:

- About EVER
- Floorplan and sponsors
- My congress bag
- My schedule
- News Feeds
- Photo sharing
- Session rating
- etc.
EVER section travel grants

We are pleased to announce that the following 14 members have received an EVER section travel grant of 750 EUR each:

- **ACB - Jong Hwa JUN - South Korea**
  4171 - MicroRNA-124 Regulates Transforming Growth Factor β1-induced Epithelial-Mesenchymal Transition in the Retinal Pigment Epithelium by Down-regulating Expression of the RhoG

- **COS - Lana FARAJ - United Kingdom**
  1344 - In-vitro anti angiogenic effects of cryo-preserved amniotic membrane

- **COS - Zhiguo HE - France**
  2431 - Mass production of high quality corneal endothelial cells from old donors

- **EOVS - Naznin MIRZA - United Kingdom**
  F050 - Testing of an automated tablet-based method for the determination of low contrast near visual acuity in ophthalmic patients

- **G - Camilla SANDBERG MELIN - Sweden**
  2544 - Pigment epithelium central limit - Inner limit of the retina, Minimal Distance, PIMD, a morphometrical variable for glaucoma follow-up

- **G - Seskoati PRAYITNANINGSIH - Indonesia**
  3571 - The Effect of Hypertension on Intraocular Pressure and Apoptosis of Retinal Ganglion Cell Through ET-1 Signaling Pathway Activation in Trabecular Meshwork of Hypertension Rat Model

- **IM - Micheal O’ROURKE - Ireland**
  2572 - The role of dendritic cells in non-infectious anterior uveitis

- **LC - Erin THORNELL - Australia**
  3251 - αB-Crystallin Phosphorylation as a Precursor to Cataractogenesis

- **MBGE - Cerys EVANS - United Kingdom**
  3163 - Investigation of genotype-phenotype correlation of TGFBI mutations reveals c.1868G>A; p.(Gly623Asp) is associated with a variable clinical phenotype, including epithelial basement membrane dystrophy

- **NSPH - Kristina IRSCH - France**
  3454 - The influence of lingering fusional adaptation on the Bielschowsky head tilt test in superior or oblique paresis

- **PBP - Madhu NATH - India**
  F045 - Angiotensin Receptor Blockade in Retinopathy of Prematurity: An Experimental Study

- **PO - Martina ANGI - United Kingdom**
  4145 - Proteomic analysis of the uveal melanoma (UM) secretome reveals novel insights and potential biomarkers

- **RV - Elizabeth STEWART - United Kingdom**
  S054 - Dexamethasone Reverses the Effects of High Glucose on Human Retinal Endothelial Cells In Vitro

- **RV - Robert SCOTT - United Kingdom**
  4272 - Cell Penetrating Peptide Constructs: A novel Drug Delivery to the Eye
EVER Poster Prizes

Poster prizes of 500 EUR will be awarded for the best posters across all sections. The winners will be chosen by the poster moderators and will be announced in the Prize award ceremony on Saturday, 15:30 - 16:00 in room Hermes. No prize will be given after the congress.

quartett diagnostica Research Award

3 grants supported by quartett for best paper in COS

- Translational Research Award
- Basic Science Research Award
- Clinical Research Award

The papers will be chosen during the congress and the grants will be handed over during quartett diagnostica Research Award Session on Friday, 9 October 2015 from 13:30 - 15:00 in room Rhodes 2.
Acropolis Convention Center, 2nd floor

Rhodes 1
Rhodes 2
Rhodes 3
Rhodes 4

Gallieni 5

Gallieni 1&2
Mykonos restaurant

Registration area
Exhibition area
Poster area

Hermes
Preview room
ARVO
Association for Research in Vision and Ophthalmology  www.arvo.org

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. See page 128.

EBO
European Board of Ophthalmology  ebo-online.org

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress. See pages 27, 31.

EUPO
European University Professors of Ophthalmology  www.eupo.eu

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2016 course on Neuro-ophthalmology and Strabismus will be organized in conjunction with the EVER congress in Nice, France.

FAN
European Fluorescein Angiography Club  www.fan-int.org

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. See page 94.
FRO
Belgian Fund for Research in Ophthalmology www.fro-online.org

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. See pages 130, 136.

GOA
Groupe Ophtalmo Allergo

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated. See page 85.

OOG
The Ophthalmic Oncology Group www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. See pages 117, 129 and 135.
Sessions

- **Business Meeting**
- **Joint Meeting**
- **Course**
- **Keynote lecture**
- **Industry Sponsored Symposium**
- **Special Interest Symposium**
- **Free Paper session**
- **Social**
- **General Assembly**
- **Poster session**
- **Plenary session**

Symbols

- EVER section travel grant recipient
- Rapid fire presentation
- Conflict of interest disclosed

Scientific sections

- **ACB** = Anatomy / Cell Biology
- **COS** = Cornea / Ocular Surface
- **EOVS** = Electrophysiology, Physiological Optics, Vision Sciences
- **G** = Glaucoma
- **IM** = Immunology / Microbiology
- **LC** = Lens and Cataract
- **MBGE** = Molecular Biology / Genetics / Epidemiology
- **NSPH** = Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology
- **PBP** = Physiology / Biochemistry / Pharmacology
- **PO** = Pathology / Oncology
- **RV** = Retina / Vitreous Section programme secretaries
Programme Secretary, Marcela VOTRUBA

Section programme secretaries

ACB  Anatomy/Cell Biology  Goran PETROVSKI
COS  Cornea/Ocular Surface  Jean-Jacques GICQUEL
EOVS Electrophysiology, Physiological Optics, Vision Sciences  Rebekka HEITMAR
G  Glaucoma  Francesca CORDEIRO
IM  Immunology/Microbiology  Piergiorgio NERI
LC  Lens and Cataract  Stefan LöFGREN
MBGE Molecular Biology/Genetics/Epidemiology  Petra LISKOVA
NSPH Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/History of Ophthalmology  Antonella BOSCHI
PBP Physiology/Biochemistry/Pharmacology  Alexandre MOULIN
PO  Pathology/Oncology  Neville OSBORNE
RV  Retina/Vitreous  Stephanie BAILLIF
The Industry Sponsored Symposia throughout the EVER 2015 congress:

Thursday, October 8

THÉA Pharma 12:00 - 13:00 Rhodes 2 Ocular surface: What’s new? .................................................. 55

THÉA Pharma 19:00 - 20:30 Hermes How to create a new generation of glaucoma patient? ...... 79

Friday, October 9

BAYER 12:30 - 13:30 Rhodes 2 Macular edema: from basic science to clinical evidences... 92

Santhera Pharmaceuticals

12:30 - 13:30 Rhodes 3 A rare breakthrough in mitochondrial medicine: changing the patient journey in LHON .................................. 93

Saturday, October 10

ALLERGAN 13:00 - 14:00 Rhodes 2 Update in the management of DME, RVO and Uveitis ..... 133
The courses throughout the EVER 2015 congress:

### Wednesday, October 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Diabetic Retinopathy: A neurodegenerative</td>
<td>RV - 12:00 - 13:30 Diabetic Retinopathy: A neurodegenerative disease</td>
</tr>
<tr>
<td></td>
<td>disease</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>EBO course: Intraocular inflammation and</td>
<td>IM - 12:00 - 13:30 EBO course: Intraocular inflammation and infection</td>
</tr>
<tr>
<td></td>
<td>infection (Part I)</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>How to perform Deep Anterior Lamellar</td>
<td>COS - 12:00 - 13:30 How to perform Deep Anterior Lamellar Keratoplasty</td>
</tr>
<tr>
<td></td>
<td>Keratoplasty</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Papilloedema and its Mimics: What's new in</td>
<td>NSPH - 12:00 - 13:30 Papilloedema and its Mimics: What’s new in</td>
</tr>
<tr>
<td></td>
<td>Pseudotumor Cerebri Syndrome?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>for a successful result</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Mistakes in the diagnosis of fundus tumors</td>
<td>PO - 13:30 - 15:00 Mistakes in the diagnosis of fundus tumors</td>
</tr>
<tr>
<td>13:30</td>
<td>EBO course: Intraocular inflammation and</td>
<td>IM - 13:30 - 15:00 EBO course: Intraocular inflammation and infection</td>
</tr>
<tr>
<td></td>
<td>infection (Part II)</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>In vivo confocal microscopy in corneal</td>
<td>IM - 13:30 - 15:00 In vivo confocal microscopy in corneal disorders</td>
</tr>
<tr>
<td></td>
<td>disorders</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>How to publish - hints and “tricks”</td>
<td></td>
</tr>
</tbody>
</table>

### Thursday, October 8

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Ultrasound Course</td>
<td>PBP - 8:00 - 9:30 Ultrasound Course</td>
</tr>
<tr>
<td>16:00</td>
<td>Nystagmus and non-nystagmic abnormal</td>
<td>NSPH - 16:00 - 17:30 Nystagmus and non-nystagmic abnormal spontaneous</td>
</tr>
<tr>
<td></td>
<td>spontaneous eye movements</td>
<td></td>
</tr>
</tbody>
</table>

### Friday, October 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Degenerative myopia</td>
<td>RV - 8:30 - 10:00 Degenerative myopia</td>
</tr>
<tr>
<td>8:30</td>
<td>Eyelid tumors</td>
<td>PO - 8:30 - 10:00 Eyelid tumors</td>
</tr>
</tbody>
</table>

### Saturday, October 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>ABC in retina structure and function</td>
<td>NSPH - 8:30 - 10:00 ABC in retina structure and function</td>
</tr>
</tbody>
</table>
EVER 2015
Wednesday, Oct 7
Diabetic retinopathy is the first cause of visual impairment and blindness in the adult working-age population. This complication of diabetes mellitus has been considered primarily a retinal microvascular disorder nevertheless, some recent studies have demonstrated that retinal neurodegeneration is present even before the development of clinically detectable microvascular damage. Early recognition of retinal changes in diabetic patients is essential in the prevention of vision loss. Recently, optical coherence tomography (OCT) has been introduced into clinical practice as one method to visualize the retina. It allowed to performed quantitative and qualitative measurements of different retinal layers. Considering the impact of an early detection of retinopathy diabetic, the idea behind the Course is to try to sum up the data of what the recognition of the neurodegeneration is an important target worth looking from a clinical point of view.

FERREIRA J, VUJOSEVIC S

**1111** 12:00 Diabetic retinopathy - pathophysiology
MARQUES-NEVES C - Lisbon

**1112** 12:22 Neurodegeneration and vascular impairment in the eye of diabetic patients
SIMO R, Hernández C - Barcelona

**1113** 12:44 The changes of the retinal layers in diabetic patients without retinopathy

**1114** 13:06 The changes of the retinal layers in diabetic patients with retinopathy
VUJOSEVIC S, Bini S, Berton M, Midena G, Martini F, Midena E - Padova

---

G: Virtual review: Setting new standards in glaucoma care

Glaucoma specialists are increasingly using technology to support follow up care for low risk patients and screen new referrals to maximise the use of existing resources. We will explore various systems of virtual review and hear first hand the experiences of pioneers and users of the technology.

CRAWLEY L, AHMED F

**1121** 12:00 Virtual review- in glaucoma and beyond
CRAWLEY L - London

**1122** 12:22 Managing a 100 patient glaucoma clinic
AHMED F - London

**1123** 12:44 Early adopters- ahead of the curve and lessons learned
LONGSTAFF S - Sheffield

**1124** 13:06 New software for an old problem
DIAMOND J - Bristol
**IM: EBO course: Intraocular inflammation and infection (Part 1)**

The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

**BODAGHI B , HERBORT CP**

1131  12:00  Pathophysiology of uveitis  
*DICK A - Bristol*

1132  12:15  Classification of uveitis  
*ANDROUDI S - Thessaloniki*

1133  12:30  Signs and symptoms of uveitis  
*NERI P, Arapi I, Pirani V, Gresti G - Agugliano*

1134  12:45  Laboratory work-up and specialized investigations  
*PLEYER U - Berlin*

1135  13:00  Imaging in uveitis: techniques and indications  
*HERBORT C P - Lausanne*

1136  13:15  Therapeutic management of uveitis  
*DICK A - Bristol*

**COS: How to perform deep anterior lamellar keratoplasty**

Deep anterior lamellar keratoplasty (DALK) is the preferred transplant option for corneal stromal pathology. This course will aim as beginners and intermediate level surgeons taking them in a step by step manner through the indications, case selection for beginners, different techniques with emphasis on the most popular big bubble technique, what deviations from the ‘routine’ can occur and how to recognise and address them and the post-operative management and care required for best visual outcome including how to recognise rejection in DALK grafts. At the end, at least 20-30 minutes will be devoted to interaction with the course delegates to answer specific questions they have related to their technique(s) and problems they have encountered. Besides power point and videos we will also make use of flip chart or blackboard to make drawings to explain fine details as and when required. All delegates will be given a pdf of the powerpoint presentations and some illustrative and instructional videos as part of the package offered on behalf of EVER.

**DUA H S**

1141  12:00  DALK Techniques from manual to femtolaser  
*NUBILE M, Salgari N, De Nicola C, Mastropasqua L - Chieti*

1142  12:18  Big Bubble DALK: The ladder to success, step by step  
*KATAMISH T - Cairo*

1143  12:36  DALK: Intraoperative pitfalls and how to manage them  
*DUA H S - Nottingham*

1144  12:54  DALK: Post-operative management  
*SAID D - Maadi, Cairo*

1145  13:12  Discussion, Questions and Answers  
*DUA H S - Nottingham*
NSPH: Papilloedema and its Mimics: What’s new in pseudotumor cerebri syndrome?

This course will cover 3 areas:
- The differential diagnosis of papilloedema
- The work up of the patient with suspected pseudotumor cerebri syndrome
- The follow-up and decision making on treatment choices of the patient with established pseudotumor cerebri syndrome

KAWASAKI A, PARSA C

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1151</td>
<td>12:00</td>
<td>Differential diagnosis of papilloedema</td>
<td>KAWASAKI A - Lausanne</td>
</tr>
<tr>
<td>1152</td>
<td>12:30</td>
<td>Work up of the patient with suspected pseudotumor cerebri syndrome</td>
<td>PARSA C - Paris</td>
</tr>
<tr>
<td>1153</td>
<td>13:00</td>
<td>Follow-up and decision making on treatment choices of the patient with established pseudotumor cerebri syndrome</td>
<td>PARSA C - Paris</td>
</tr>
</tbody>
</table>
**EVER 2015**
**Wednesday, Oct 7 - First afternoon session**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>HERMES</td>
<td>RV: Macular hole surgery: New facts and tips for a successful result</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advanced</td>
</tr>
<tr>
<td></td>
<td></td>
<td>We are aiming to present new pathophysiological and clinical facts regarding macular hole and give tips in order to perform safer and affective surgery. Expert speakers will present their views in different subjects of macular hole problem. They will present the use of novel advance technology in practice. There will also be panel discussion for the controversial issues of the condition in order to set guidelines for treatment and approach.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PAPPAS G</td>
</tr>
<tr>
<td>1211</td>
<td>13:30 Pathophysiology of macular hole formation</td>
<td>STAPPLER T - Liverpool</td>
</tr>
<tr>
<td>1212</td>
<td>13:48 Macular hole peeling</td>
<td>FERRARA V - Borgomanero</td>
</tr>
<tr>
<td>1213</td>
<td>14:06 Posturing or not</td>
<td>SIMCOCK P - Exeter</td>
</tr>
<tr>
<td>1214</td>
<td>14:24 Myopic macular holes</td>
<td>MURA M - Amsterdam</td>
</tr>
<tr>
<td>1215</td>
<td>14:42 Partial thickness Macular holes and pharmaceutical treatment of FTMH</td>
<td>POURNARAS JA - Lausanne</td>
</tr>
<tr>
<td>13:30</td>
<td>RHODES 1</td>
<td>PO: Mistakes in the diagnosis of fundus tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intermediate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>This course will describe the diagnosis and management of fundus tumors insisting on the main difficulties: tumors developing in children, problems with the practical attitude in front of a suspicious choroidal naevus, difficulties in the diagnosis of achromic tumors, special problem encountered in the diagnosis of intraocular lymphomas and for all these difficult cases the indications and results of the different imaging tools.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DESJARDINS L, ZOGRAFOS L</td>
</tr>
<tr>
<td>1221</td>
<td>13:30 Mistakes in the diagnosis of children intraocular tumors</td>
<td>CASSOUX N - Paris</td>
</tr>
<tr>
<td>1222</td>
<td>13:48 Suspicious choroidal naevi: when to observe when to treat</td>
<td>KIVELÄ T - Helsinki</td>
</tr>
<tr>
<td>1223</td>
<td>14:06 Difficulties in the diagnosis of achromic and hemorrhagic lesions</td>
<td>DESJARDINS L - Paris</td>
</tr>
<tr>
<td>1224</td>
<td>14:24 Problems in the diagnosis of intraocular lymphoma</td>
<td>CASSOUX N - Paris</td>
</tr>
<tr>
<td>1225</td>
<td>14:42 Indications and interpretations of various imaging techniques</td>
<td>ZOGRAFOS L - Lausanne</td>
</tr>
</tbody>
</table>
### IM: EBO course: Intraocular inflammation and infection (Part 2)

**Intermediate**

The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

**BODAGHI B, HERBORT C P**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1231</td>
<td>13:30</td>
<td>B27-associated uveitis, Fuchs uveitis</td>
<td>WILLERMAIN F - Bruxelles</td>
</tr>
<tr>
<td>1232</td>
<td>13:48</td>
<td>Infectious uveitis</td>
<td>PLEYER U - Berlin</td>
</tr>
<tr>
<td>1233</td>
<td>14:06</td>
<td>Behçet's disease, VKH, sarcoidosis</td>
<td>KHAIRALLAH M, Kahloun R, Ksiaa I - Monastir</td>
</tr>
<tr>
<td>1234</td>
<td>14:24</td>
<td>Inflammatory choroiditis</td>
<td>HERBORT C P - Lausanne</td>
</tr>
<tr>
<td>1235</td>
<td>14:42</td>
<td>Retinal vasculitis</td>
<td>BODAGHI B - Paris</td>
</tr>
</tbody>
</table>

### COS: In vivo confocal microscopy in corneal disorders

**Beginner**

Corneal confocal microscopy in vivo makes it possible to analyze corneal architecture on ultrastructural level, including single corneal cells as well as accompanying structures. Introduction with tips how to perform successfully confocal examination – type of used devices and additional lenses, conditions of examination room and preparation of patient that increase quality of obtained scans and improve proper interpretation of images.

**WYLEGALA E, SMEDOWSKI A**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1241</td>
<td>13:30</td>
<td>Introduction of confocal examination</td>
<td>WYLEGALA E - Katowice</td>
</tr>
<tr>
<td>1242</td>
<td>13:45</td>
<td>Confocal features of healthy cornea</td>
<td>DOBROWOLSKI D - Katowice</td>
</tr>
<tr>
<td>1243</td>
<td>14:00</td>
<td>Infectious and non infectious keratitis</td>
<td>SMEDOWSKI A - Katowice</td>
</tr>
<tr>
<td>1244</td>
<td>14:15</td>
<td>Corneal dystrophies</td>
<td>NOWINSKA A - Bytom</td>
</tr>
<tr>
<td>1245</td>
<td>14:30</td>
<td>Corneal degeneration</td>
<td>WOWRA B - Katowice</td>
</tr>
<tr>
<td>1246</td>
<td>15:00</td>
<td>Case examples summarizing knowledge of course</td>
<td>WYLEGALA E - Katowice</td>
</tr>
</tbody>
</table>
EVER 2015
Wednesday, Oct 7 - First afternoon session

13:30 - 15:00 | RHODES 4

**MBGE: Grand rounds in ophthalmic genetics**

Cases in ophthalmic genetics. Clinical cases will be shown. Everyone is encouraged to present unknown of interesting diagnostic cases in inherited eye disease. Submission of cases can be done in the room where the Grand Rounds in Ophthalmic Genetics are being held.

LEROY B , HAMEL C

<table>
<thead>
<tr>
<th>Time</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>1251</td>
<td>13:30 Cases HAMEL C - Montpellier</td>
</tr>
<tr>
<td>1252</td>
<td>13:48 Cases BLACK G C , Hall G , Ramsden S - Manchester</td>
</tr>
<tr>
<td>1253</td>
<td>14:06 Cases AUDO I - Paris</td>
</tr>
<tr>
<td>1254</td>
<td>14:24 Cases HOLDER G - London</td>
</tr>
<tr>
<td>1255</td>
<td>14:42 Cases LEROY B - Ghent</td>
</tr>
</tbody>
</table>
15:30 - 17:00 | HERMES
Opening ceremony

15:30
Welcome by the President EVER 2015
LEROY B - Ghent

15:50
EVER Fellowship highlights
SCHMETTERER L - Vienna
Introduction by Bart Leroy

16:00
EVER Past president lecture:
Retinal Vein Occlusions:
From pathophysiological mechanism to clinical
therapeutical issues
POURNARAS C - Genève
Introduction by Bart Leroy

16:40
European Ophthalmology Heritage - A celebration
Homage at Professor Ignacio Barraquer
Melanoma of the ciliary body.
Iridocyclectomy (1968)
BARRAQUER J - Barcelona
Introduction by Bart Leroy
Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed.

**DESJARDINS L, KAWASAKI A**

**G: OCT in glaucoma: Clinical and experimental applications**

Optical Coherence Tomography has a leading role in glaucoma management. Hardware and software innovations have given the possibility of studying structures previously inaccessible. Novel objective assessments of structural abnormalities could lead to a change in current diagnostic paradigms. One of the objectives of this SIS is to discuss how to establish new OCT parameters for clinical practice. After diagnosis, robust follow-up methods are essential. Current OCT instruments are equipped with useful progression analysis software which have moderate capability of discrimination between age-related changes, instrument's intrinsic noise, and pathological changes. A second objective of this SIS is to discuss the latest novelties in assessing glaucoma progression with OCT. Due to their accessibility and usefulness, animal models of glaucoma are playing a major role in understanding some of the underlying causes of glaucoma. Optical coherence tomography has been used extensively in animal models of glaucoma and has given the exceptional advantage of longitudinal in-vivo assessments of the natural history of the disease. The third objective of this SIS is to discuss the current applications of OCT in animal models of glaucoma.

**NORMANDO E M, GARWAY-HEATH D, CORDEIRO MF**

**1321** 17:00 Establishing new OCT parameters: Is race-specific phenotyping necessary?

**CHAUHAN B - Halifax, NS**

**1322** 17:30 OCT in assessing glaucoma progression

**GARWAY-HEATH D - London**

**1323** 18:00 OCT in animal models

**NORMANDO E M - London**
### MBGE: Monogenic corneal disorders

Monogenic corneal disorders comprise a group of more than 20 clinically distinct entities. During the last two decades most disease-causing genes have been identified. The special interest symposium will provide an overview of the molecular genetic mechanisms underlying corneal disorders inherited in a Mendelian fashion, advances in the field of genetic testing, the current status of gene-based therapies and how knowledge gained so far has influenced the clinical management of disease.

**LISKOVA P, DAVIDSON A**

**1331** 17:00  Understanding the molecular genetic causes of inherited corneal disorders  
*DAVIDSON A - London*

**1332** 17:22  The impact of genetics on the clinical management of patients with monogenic corneal diseases  
*TUFT S J, Evans C, Davidson A, Hardcastle A - London*

**1333** 17:44  Monogenic corneal disorders in children  
*KHAN A - Riyadh*

**1334** 18:06  The Czech Republic experience in a corneal clinic  
*LISKOVA P - Prague*

### COS: Free paper session - Cornea and ocular surface inflammation

**GICQUEL JJ**

**1341** 17:00  Comparative Study ofTacrolimus and Bevacizumab on Corneal Neovascularization in Rabbits  
*KIM S E, Park J H, Chung S K - Seoul*

**1342** 17:12  HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Japanese and Korean populations  

**1343** 17:24  Expression of Tissue inhibitor of metalloproteinase in ocular Stevens-Johnson Syndrome: An Immunohistochemical Study  
*VENUGOPAL R, Sen S, Kashyap S, Sharma A, Agarwal T, Sharma N - New Delhi*

**1344** 17:36  In-vitro anti angiogenic effects of cryo-preserved amniotic membrane  
*FARAJ L, Stewart E, Albert R, Allen C, Petrovski G, Dua H, Amoaku W - Nottingham*

**1345** 17:48  Intratarsal injection of kenacort in the treatment of severe cases of VKC  
*LAZREG S - Dar el Beida*

**1346** 17:54  3D model of pterygium and corneal limbus: Investigating histopathology and stem cell distribution.  
*BLOM N, Andreasen A, Heegaard S, Hjortdal J, Nielsen K - Aarhus C*

**1347** 18:00  Analysis of molecular mechanisms that predispose patients to develop post-PRK haze  
*RAJIV KUMAR N, Ghosh A, Shetty R, Pahuja N - Bangalore*

**1348** 18:06  Corneal lenticules as an ex-vivo model to study keratocyte biology  
*SHROFF R, Shetty R, Kumar D, Kumar S, Pahuja N, GHOSH A - Bangalore*
How to publish - hints and “tricks”.....

How to get your research published? Pleyer U, Dua H, Kivelä T, Stefánsson E. The goal of this session will be to provide some “keys” to write a high quality paper that will help to transform your ideas and findings into a research article. The panelists will discuss major aspects of the editorial process including basic decisions. We will raise the discussion on issues like: How to choose a journal? How to organize your paper? What are the characteristics of a good manuscript? How to interpret the letter from the editor? How to write a good reply to the reviewers? What to do when your paper is rejected? When can it be appropriate to request a reevaluation of a rejected paper? How to keep your work published – do we have to expect the unexpected....? Most important: The personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

PLEYER U

1351 17:00 Reviewer - friend or foe?
PLEYER U - Berlin

1352 17:22 What do we need...
DUA H S - Nottingham

1353 17:44 How to keep your research published
KIVELÄ T - Helsinki

1354 18:06 Ingredients of a good paper...
STEFANSSON E - Reykjavik

LC: But doctor, will this IOL last my lifetime?

Intraocular lenses were first successfully introduced in cataract surgery in 1950. Initial lenses were plagued by design issues and clinical problems including uveitis, glaucoma and hyphaema. Current lenses are considered to be effective and safe, but is this really the case? This course will review methods of evaluation of IOL biomaterials and contemporary issues that have been identified with lenses.

GRZYBOWSKI A, BEIKO G

1361 17:00 History of IOLs - did it start in Poland?
GRZYBOWSKI A - Poznan

1362 17:18 Visual quality assessment and imaging techniques used to study biomaterials
SPALTON D - London

1363 17:36 Does IOL choice impact on Driving Performance?
BEIKO G - St. Catharines

1364 17:54 Opacification of intraocular lens
MATSUSHIMA H - Tochigi

1365 18:12 Current problems with IOLs.
AUFFARTH G - Heidelberg
Changes in retinal or choroidal blood flow/oxygenation have been found in several eye diseases. In some diseases, the change may be a primary event in the pathogenesis. In other diseases, the change in blood flow/oxygenation may be a secondary response to other processes, such as tissue atrophy. The technology for non-invasive measurements of blood flow and oxygenation is continuously improving and ongoing studies may help us better understand the diseases in question as well as allowing us to objectively measure their progression. This SIS will address the general physiology of blood flow and oxygenation of the retina and choroid and how these parameters change in ischemic and atrophic diseases as well as how the changes can be measured.

HARDARSON S, SIN M

1371 17:00  Physiology of retinal oxygenation  
       STEFANSSON E - Reykjavik

1372 17:22  Blood flow and oxygenation in atrophic diseases  
       TODOROVA M - Basel

1373 17:44  Relation of oxygen saturation to stage of diabetic retinopathy  
       SIN M, Chrapek O, Sinova I, Stanakova L, Rehak J - Olomouc

1374 18:06  Choroidal blood flow and thickness measurements  
       SCHMIDL D - Vienna
Visual impairment in opera characters

AYDIN P - Ankara

Summary:
Opera brings the work of singers and musicians together in a theatrical pageant of musical colour and dramatic art. The librettists who devise the stories in works of opera have variously used characters with eye diseases or blindness as major or minor characters in the plots of these stories. This talk will present an array of those operatic characters, along with the possible cause or diagnosis of their eye problems, and will explore the roles which they play in the operas in which they appear, along with their dramatic significance in the flow and resolution of the plot.

Biography Pinar Aydin O’Dwyer:
Award of the EVER Certificate of Honour

Award of the EVER Certificate of Honour Prof Aydin O’Dwyer, completed her ophthalmology training in Turkey and founded the Baskent University Ophthalmology Department, Ankara. She serves as: member of Academia Ophthalmologica Internationalis (AOI, chair LVI), member of the Board of Trustees, Head of the Ethics Committee, member of Eye Care Delivery Committee, member of the Examinations Committee and member of the Fellowships Committee of the International Council of Ophthalmology (ICO). She has served as the past treasurer and Neuro-ophthalmology section program officer of the European Association for Vision and Eye Research (EVER), and the immediate past treasurer of the European Neuro-ophthalmology Society (EUNOS). Author of some 200 scientific publications and editor of 28 books on ophthalmology in Turkish, she has been managing editor and editorial board member on several ophthalmic journals and has given many conferences and courses internationally. Her main interests include neuro-ophthalmology and coaching young academicians, particularly integrating local perspectives into an international approach recognizing cultural distinctiveness. She likewise aims to promote consensus and fellowship through art and music by her presentations on 'Ophthalmology in Art', and the pursuit of her hobbies of playing flute and cello, dancing ballet and writing opera critics. She has two published books on arts: The Book of Ballet (2012) and The Book of Opera (2015).
Rare retinoblastoma: a goldmine for discovery of fundamental principles of biology and healthcare

GALLIE B - Toronto, Ontario

Summary:
Study of retinoblastoma, a rare eye cancer in children, revealed the essential genetic basis of cancer and delivered personalized medicine for families. Where awareness and resources are available, 98% of children survive retinoblastoma. Next big impact will be the unique opportunity to conduct clinical trials of molecular retinoblastoma prevention trials. However, globally 70% of children with retinoblastoma still die. To address this disparity, One Retinoblastoma World, using a “constellation model” of collaboration, has emerged with multiple innovative partnerships. Ongoing studies map (www.1rbw.org) centres and link to a global learning health system, directly providing evidence from the bedside to optimize care of each newly diagnosed child. Retinoblastoma will become a “Zero Death” cancer.

Award of the EVER Certificate of Honour

Biography Brenda Gallie:
Dr. Brenda Gallie is Director of the Retinoblastoma Program at SickKids Hospital, Professor of Ophthalmology, Molecular Genetics, and Medical Biophysics, University of Toronto, and Senior Scientist at the Princess Margaret Cancer Centre, University Health Network. Dr. Gallie received the Order of Ontario for implementing genetic knowledge in care of children with retinoblastoma.
Wednesday, Oct 7 - EVER Welcome Reception

19:30 - 21:00

EVER Welcome Reception in Exhibition area
8:00 - 9:30 | HERMES

RV: Focus on fundus autofluorescence imaging: review and perspectives

This SIS will focus on importance of autofluorescence imaging analysis in fundus pathologies. Autofluorescence technique and photobleaching will be explained and clinical application will be shown in most of retinal and choroidal pathologies. Perspectives of this technique will be developed.

MAUGET-FAYSSE M, WOLFF B

2111  8:00  Fundus autofluorescence and Photobleaching: Definitions

2112  8:18  Fundus autofluorescence imaging in White Dot Syndromes

2113  8:36  Fundus autofluorescence imaging in Toxic Retinopathies and in Gravitational descending atrophic retinal pigmented epithelial tracks

2114  8:54  Fundus autofluorescence imaging in Ocular Oncology
SCEMAMA TIMSIT C, Mauget-Fayisse M, Wolff B - Paris

2115  9:12  Fundus autofluorescence imaging in AMD and in Retinal Dystrophies and Perspectives
UZZAN J - Rouen

8:00 - 9:30 | RHODES 1

G: All you ever wanted to know about the EGS!

The European Glaucoma Society stands for Innovation, Education and Communication in the field of glaucoma. Indeed the Society offers a wide range of educational opportunities, such as various publications including the EGS Guidelines and several books, educational videos, monthly clinical Tips and Journal Club items, but also Fellowship programs and Travel Grants. An overview of these educational opportunities will be provided. In 2014, an updated version of the EGS Guidelines was published, which is now freely downloadable from the EGS website. The highlights of the EGS Guidelines will be summarized during this SIS. Moreover, the EGS closely collaborates with the European Board of Ophthalmology (EBO). In a joint effort, an EGS-EBO subspecialty diploma was developed. The required curriculum and practical aspects of the examination will be summarized.

STALMANS I, HOMMER A

2121  8:00  The EGS Guidelines: from diagnosis to medical management
TRAVERSO C E - Savona

2122  8:18  The EGS Guidelines: a surgical approach to glaucoma
HOMMER A - Vienna

2123  8:36  The link with the EBO: the glaucoma subspecialty diploma
SUNARIC MEGEVAND G - Geneva

2124  8:54  Discovering the treasures of the EGS website: from educational opportunities to newsletter
STALMANS I - Leuven

2125  9:12  Future and perspectives
TUULONEN A - Tampere
Ophthalmic ultrasound is an important clinical tool for the characterization of intraocular and orbital pathology. A- and B-scan contact and immersion techniques which are widely used for the characterization of intraocular and orbital pathology. The physical principle underlying ultrasound is the generation of sound waves at MHz frequencies and its reflection by tissue interfaces. The present course first gives an introduction into ultrasound technology and summarizes new developments in the field. The next talk will deal with high-frequency ultrasound and its ability for the diagnosis of anterior segment disease. Another presentation will focus on the use of ultrasound in the diagnosis of orbital disease. A final talk will discuss Doppler ultrasound techniques and their ability to assess ocular blood flow.

**SCHMETTERER L, KISSELEVA T**

<table>
<thead>
<tr>
<th>2131</th>
<th>8:00</th>
<th>New development in clinical ultrasound</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>SCHMETTERER L - Vienna</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2132</th>
<th>8:22</th>
<th>Ultrasound biomicroscopy in diagnosis of anterior segment pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>RAMAZANOVA K, Kiseleva T, Lugovkina K - Moscow</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2133</th>
<th>8:44</th>
<th>Ultrasonography in the management of orbital diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>GUTHOFF R F - Rostock</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2134</th>
<th>9:06</th>
<th>Ultrasound methods in the assessment of ocular blood flow</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>KISELEVAT, Ramazanova K, Gavrilenko A, Kuklin A, Adzhemyan N, Chudin A - Moscow</td>
</tr>
</tbody>
</table>

---

The coupling between blood flow and neuronal function is a fundamental mechanism for the central nervous system homeostasis. It has recently been shown that also in the human retina, glia cells and blood vessels are tightly coupled. As such, increased neural activity in the retina leads to a subsequent increase in blood flow in the optic nerve head as well as in the retinal vasculature. It is now understood that also in the human retina, the coupling between neural activity and blood flow is an essential physiological mechanism to assure constant supply of the ocular tissue with oxygen and nutrients. This SIS aims to summarize our current knowledge on the physiological importance of the relationship between neurons, glia cells and blood vessels. In addition, the molecular mechanisms potentially involved in this regulation process will be covered. Finally the role of neuro-vascular coupling and its potential application in the diagnosis and follow up in neuro-degenerative diseases will be discussed.

**GARHÖFER G**

<table>
<thead>
<tr>
<th>2141</th>
<th>8:00</th>
<th>Monocarboxylate transporters and their functions in the retina</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>OSBORNE N - Oxford</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2142</th>
<th>8:22</th>
<th>Doppler Optical Coherence Tomography - A New Method For The Assessment Of Neurovascular Coupling In The Retina</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>WERKMEISTER R, Aschinger G, Schmetterer L - Vienna</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2143</th>
<th>8:44</th>
<th>Neuro-vascular coupling – molecular mechanisms and potential clinical applications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>GARHOFER G - Vienna</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2144</th>
<th>9:06</th>
<th>Candidate Retinal Biomarkers in CNS Neurodegenerative Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HUDSON C - Waterloo</td>
</tr>
</tbody>
</table>
8:00 - 9:30 | RHODES 4

**IM: Uveitis in the East and West**

This Special Interest Symposium is presented in partnership between the Society of Ophthalmology, Immunology, and Infectiology in Europe (SOIE), members of the Japanese Ocular Inflammation Society (JOIS), and EVER. The aim is to address specific aspects in the appraisal of uveitis between Japan and Europe.

NERI P, TAKEUCHI M

2151 8:00  Behçet’s uveitis in Japan: evaluation of the long-term efficacy and safety of infliximab treatment
TAKEUCHI M - Tokyo

2152 8:12  Behçet’s uveitis in Turkey, why is it still number one?
TUGAL-TUTKUN I - Istanbul

2153 8:24  Choroidal thickness in acute and convalescent VKH disease
TAKASE H - Tokyo

2154 8:36  Stromal choroiditis in East (VKH) and West (birdshot)
HERBORT C P - Lausanne

2155 8:48  Relationship of ocular disease activities before and after starting infliximab using Behçet’s disease ocular attack score 24

2156 9:00  The CD4/CD8 ratio in vitreous fluids is of high diagnostic value in sarcoidosis
MARUYAMA K - Sendai

2157 9:12  Viral retinopathies: a spectrum of disease from East to West
BODAGHI B - Paris

8:00 - 9:30 | GALLIENI 1+2

**NSPH: New perspectives on the funny looking disc**

This symposium addresses the optic disc that simply does not look normal. In some cases, it is a congenital anomaly. Several examples will be presented, notably optic disc hypoplasia with its neurologic and genetic considerations. We also discuss acquired structural alterations of the optic disc, notably myopia-associated changes. The participant will have a better understanding of congenital and acquired changes in optic disc appearance.

KAWASAKI A, OHNO-MATSUI K

2161 8:00  Myopia-associated changes of the optic disc
OHNO-MATSUI K - Tokyo

2162 8:22  Optic nerve hypoplasia: Evaluation and genetic considerations
YU-WAI-MAN P - Newcastle upon Tyne

2163 8:44  Optic disc tumors
BOSCHI A - Bruxelles

2164 9:06  Using OCT to evaluate the funny looking disc
BORRUAT FX - Lausanne
This SIS will focus on cell biology applications in corneal stem cells research, spanning from topics on the use of induced pluripotent cells to adult stem cells, as well as gene modification applications from benchside to bedside.

**PETROVSKI G, MOE M**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2171</td>
<td>8:00</td>
<td>Human pluripotent stem cells as a source of corneal epithelium</td>
<td>SKOTTMAN H, Tampere</td>
<td></td>
</tr>
<tr>
<td>2173</td>
<td>8:36</td>
<td>Novel techniques in corneal regeneration and bioscaffold engineering</td>
<td>LAGALI N, Rafat M, Xeroudaki M, Koulikovska M, Fagerholm P, Linköping</td>
<td></td>
</tr>
<tr>
<td>2174</td>
<td>8:54</td>
<td>Clinical results and in vitro characterization of cornea limbal epithelial stem cells cultured in autologous serum</td>
<td>MOE M, Oslo</td>
<td></td>
</tr>
<tr>
<td>2175</td>
<td>9:12</td>
<td>Long-term cultivation of corneal stem cells - possible applications from benchside to bedside</td>
<td>PETROVSKI G, Szeged</td>
<td></td>
</tr>
</tbody>
</table>
Regulating the body clock – The unrecognised role of the eye

**Summary:**
Little more than a decade ago discussion that the eye might contain another photoreceptor, different from the rods and cones, generated either polite amusement or a hostile rebuttal. The dogma was that all light detection took place by these photoreceptors whilst the other cells of the retina act only to process visual signals. However, several lines of research led to the discovery that the vertebrate eye, including humans, contains another class of photoreceptor based upon a small number of photosensitive retinal ganglion cells (pRGCs). These specialised neurons detect environmental irradiance and regulate a wide range of physiology and behaviour including the regulation of 24h body clocks, sleep, alertness, mood and even pupil size. Furthermore, the pRGCs have been shown to utilize a novel light signalling pathway based upon the photopigment melanopsin. Collectively these findings have transformed our understanding of how the eye detects light and are redefining our assessment, treatment and care of individuals with eye disease. The discovery and current understanding of this “third” class of ocular photoreceptor will be reviewed in this presentation.

Award presentation

**Biography Russell FOSTER:**
Russell is Professor of Circadian Neuroscience at the University of Oxford, Chair of the Nuffield Laboratory of Ophthalmology, Director of the Sleep and Circadian Neuroscience Institute (SCNi), Fellow of Brasenose College and was elected to the Royal Society in 2008 and the Academy of Medical Sciences in 2013. His research considers the mechanisms that regulate and generate circadian rhythms and sleep; and what happens when these systems are disrupted in brain disease. He has over 180 publications and co-authored “Rhythms of Life”; “Seasons of Life” and most recently “Sleep a very short introduction” for OUP. He is Chair of the Cheltenham Science Festival; Member of Council for BBSRC; Member of the Governing Council, The Sainsbury-Wellcome Centre; In March 2012 he was awarded BBSRC Social Innovator of the Year.
10:30 - 12:00 | HERMES

RV: Free paper session - Diabetes

CREUZOT C, STAURENGHI G

2211  10:30  Intravitreal Aflibercept (IVT-AFL) for Diabetic Macular Edema (DME): 3 Year Data from VIVID-DME and VISTA-DME
STAURENGHI G, Metzig C - Milan

2212  10:42  Impact of Intravitreal Aflibercept (IVT-AFL) on Diabetic Retinopathy in the VIVID-DME and VISTA-DME Studies
LARSEN L M, Metzig C - Glostrup

2213  10:54  Evaluation of the Variation in Thickness of the Different Retinal Layers in Diabetic Patients with OCT

2214  11:06  Choroidal Thickness in Diabetic Patients without Diabetic Retinopathy

2215  11:18  Choroidal Thickness and Systemic Examination in Diabetic Patients with out Diabetic Retinopathy

2216  11:24  Automatic method to distinguish manifestation areas of early diabetic retinopathy from image artefacts by using L\*u\*v\* colour space
SUZUKI N, Yamane K - Numazu

2217  11:30  Dexamethasone Reverses the Effects of High Glucose on Human Retinal Endothelial Cells In Vitro
STEWART E, Saker S, Amoaku W - Nottingham

10:30 - 12:00 | RHODES 1

G: Lifetime risk of blindness from glaucoma

With the growing older population, the number of patients diagnosed and monitored with glaucoma is increasing. These patients are set to have lifelong ophthalmology care, but just what is their risk of blindness once diagnosed and are we managing our patients appropriately with respect to their risk? This SIS will tackle some of these questions and encourage a discussion on whether we need to reassess our management strategies for this group of patients.

KOTECHA A, MCNAUGHT A

2221  10:30  Risk management: how does patient management in ophthalmology compare with those of other medical disciplines?
KOTECHA A - London

2222  10:48  Are we over prescribing in Glaucoma?
TUULONEN A - Tampere

2223  11:06  Detecting and managing blindness risk in glaucoma
MCNAUGHT A - Cheltenham

2224  11:24  Risk of visual impairment from glaucoma
CRABB D - London

2225  11:42  Automated 'big-data' analysis to risk stratify your patients
JOHNSTON R - Gloucestershire
### Thursday, Oct 8 - Second morning session

#### RHODES 2

**COS: Free paper session - Tear film exploration and dry eye**

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2231</td>
<td>10:30</td>
<td>The Four Seasons of Dry Eye Disease: Seasonal Variations in Presenting Symptoms and Signs of Dry Eye Disease in Norway</td>
<td>Eidet J R, Ræder S, Chen X, Badian R, Utheim Ø, Utheim T P - Oslo</td>
</tr>
<tr>
<td>2232</td>
<td>10:42</td>
<td>Altered micro-RNA21 expression correlates with enhanced peripheral IL-23p19 levels patients with primary Sjögren’s syndrome</td>
<td>Ni Gabhann J, Pilson Q, Jefferies C, Murphy C - Dublin</td>
</tr>
<tr>
<td>2233</td>
<td>10:54</td>
<td>Standardising the Schirmer Test by Enclosing the Strip in a Waterproof Sheath.</td>
<td>Willshire C, Buckley R, Bron A - Cambridge</td>
</tr>
<tr>
<td>2234</td>
<td>11:06</td>
<td>A Fresh Look at Tear Film Structure and Dynamics</td>
<td>Bron A J, Yokoi N, Georgiev G - Oxford</td>
</tr>
<tr>
<td>2235</td>
<td>11:18</td>
<td>Novel role of PELI3 as a potential biomarker for Sjögren’s syndrome related dry eyes</td>
<td>Pilson Q, Ni Gabhann J, Murphy C C - Dublin</td>
</tr>
<tr>
<td>2237</td>
<td>11:30</td>
<td>Randomised, controlled study of the efficacy and safety of a new eye-drop formulation for moderate to severe dry eye syndrome</td>
<td>Doan S, Baudouin C, Khairallah M - Paris</td>
</tr>
</tbody>
</table>

#### RHODES 3

**PBP: Free paper session - Pharmacology / drug delivery / physiology**

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2244</td>
<td>11:00</td>
<td>Use of retinal oximetry in estimating cerebral tissue oxygenation</td>
<td>Van Keer K, Abeção Pinto L, Stalmans I, Vandewalle E - Leuven</td>
</tr>
<tr>
<td>2245</td>
<td>11:12</td>
<td>The diameter regulation of retinal arterioles during systemic hypoxia is impaired in diabetic patients without retinopathy</td>
<td>Petersen L, Bek T - Aarhus</td>
</tr>
</tbody>
</table>
Diabetic retinopathy (DR) is the commonest microvascular complication of diabetes and remains one of the leading causes of blindness worldwide. The two most important visual complications of DR are diabetic macular edema and proliferative diabetic retinopathy. Many of the molecular and functional changes that are characteristic of inflammation have been detected in retinas from diabetic animals or humans, and in retinal cells under diabetic conditions. A large body of evidence supports the role of proinflammatory cytokines, chemokines, matrix metalloproteinases and other inflammatory mediators in pathogenesis of diabetic retinopathy leading to persistent low grade inflammation, and influx of leukocytes contributing to damage to the retinal vasculature and neovascularization. The causal relationship between inflammation and angiogenesis is now widely accepted. An emerging issue in diabetic retinopathy research is the focus on the mechanistic link between activation of subclinical inflammation and angiogenesis. Leukostasis has been found to be significantly increased in retinas of diabetic animals and might contribute to the capillary nonperfusion in diabetic retinopathy. Leukostasis has been postulated to be a factor in death of endothelial cells and breakdown of the blood-retinal barrier. Leukocyte recruitment and adhesion to the retinal vasculature correlate with increased expression of retinal intercellular adhesion molecule-1 and elevated expression of the β-integrin subunit CD18 on neutrophils. In addition, the increased expression of many inflammatory proteins are regulated at the level of gene transcription through the activation of proinflammatory transcription factors such as NF-κB.

**ABU EL ASRAR A**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2251</td>
<td>Matrix metalloproteinase in diabetic retinopathy</td>
<td>OPDENAKKER G - Leuven</td>
</tr>
<tr>
<td>2253</td>
<td>Inflammatory mediators of diabetic retinopathy: lessons from proteomic analysis</td>
<td>SIMO R , Simó-Servat O , Hernández C - Barcelona</td>
</tr>
<tr>
<td>2254</td>
<td>Immune cell activation in diabetic retinopathy</td>
<td>XU H , Chen M - Belfast</td>
</tr>
<tr>
<td>2218</td>
<td>Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT)</td>
<td>ABU EL ASRAR A , De Hertogh G , Van den Eynde K , Alam K , Van Raemdonck K , Opdenakker G , Van Damme J , Geboes K , Struyf S - Riyadh</td>
</tr>
</tbody>
</table>

---

**MBGE: Mitochondrial optic neuropathies - classical disease and novel manifestation**

A decline in mitochondrial function plays a role in the ageing process and increases the incidence of age-related disorders. A better understanding of mitochondrial function, including dynamics, is revealing that functional and structural changes in mitochondrial morphology are important factors in diseases of ageing in the eye and visual system. Key proteins have been discovered which control the balance of mitochondrial fusion and fission and have a range of other functions, such as controlling maintenance of mitochondrial DNA, cell death, autophagy, mitochondrial metabolism and redox signalling. This SIS will explore clinical aspects of mitochondrial optic neuropathy.

**VOTRUBA M , YU-WAI-MAN P**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2262</td>
<td>LHON and extracocular features</td>
<td>YU-WAI-MAN P - Newcastle upon Tyne</td>
</tr>
<tr>
<td>2263</td>
<td>Vascular supply in mitochondrial optic neuropathy and glaucoma</td>
<td>BARBONI P - Bologna</td>
</tr>
<tr>
<td>2264</td>
<td>Early-onset Behr syndrome due to compound heterozygous mutations in OPA1</td>
<td>BONNEAU D , Lenaers G , Procaccio V , Amati-Bonneau P , Reynier P - Angers</td>
</tr>
<tr>
<td>2265</td>
<td>Leber’s Hereditary Optic Neuropathy (LHON) mtDNA mutations cause cell death by overproduction of reactive oxygen species</td>
<td>SADUN A , Carelli V , La Morgia C , Karanjia R - Los Angeles</td>
</tr>
</tbody>
</table>
Academic Convocation Board: Inflammation, wound healing and tear proteomics

Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. The system has its own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ophthalmic surgeries e.g. corneal, refractive and glaucoma surgery. It consists of many overlapping processes like inflammation, fibroblast activation, ECM production and remodeling of the ECM and there are many mechanisms and mediators involved in it. Tear proteomics is a powerful tool to diagnose and detect mechanisms and drugable targets of the ophthalmic and systemic diseases. SIS is focusing in the proteomics and biomarkers of the tears and anterior surface of the eye in relation these diseases.

**UUSITALO H, BEUERMAN R**

**2271** 10:30  Tear proteomics in health and disease  
*BEUERMAN R* - Singapore

**2272** 10:52  Environmental factors in ocular surface disease  

**2273** 11:14  Inflammation, wound healing and tear proteomics in glaucoma  
*UUSITALO H* - Tampere

**2274** 11:36  Bioinformatics in tear proteome  
*NYKTER M* - Tampere
12:00 - 13:00 | RHODES 2

**Ocular surface: What’s new ?**

<table>
<thead>
<tr>
<th>Session No.</th>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2331</td>
<td>12:00</td>
<td>New paradigm in Dry Eye Disease (DED)</td>
<td>BAUDOUIN C - Boulogne Billancourt</td>
<td></td>
</tr>
<tr>
<td>2332</td>
<td>12:12</td>
<td>Visual function impairment in Dry Eye Disease (DED)</td>
<td>PIESELLA P J - Tours</td>
<td></td>
</tr>
<tr>
<td>2333</td>
<td>12:24</td>
<td>MEIBUM survey: a closer look at the eyelids</td>
<td>DIAZ VALLE D - Madrid</td>
<td></td>
</tr>
<tr>
<td>2334</td>
<td>12:36</td>
<td>New treatment to improve Tear film thickness in Dry Eye Disease (DED)</td>
<td>SCHMETTERER L - Vienna</td>
<td></td>
</tr>
</tbody>
</table>
Degenerative myopia and its treatment

Summary:
High myopes are handicapped by visual impairment and degenerative complications eventually leading to blindness. Myopic refraction can be corrected by refractive lens exchange. Retinal detachment may be the consequence and a possible prevention by vitrectomy will be discussed. However, the fundamental problems of degenerative myopia, the features of myopic fundus disease and the posterior staphyloma cannot be treated. Scleral cross linking possibly stiffens the sclera. By this means we could stop eye growth and possibly reduce myopic complications. Experiments to stop eye growth by scleral crosslinking will be presented.

Biography Peter WIEDEMANN:
Peter Wiedemann is a specialist in medical and surgical retina and head of the Department of Ophthalmology at Leipzig University, Germany. He studied medicine in Bochum, Rennes, Stanford, and Erlangen. Then he spent 4 years in pharmacology. At the Doheny Eye Institute in Los Angeles he worked with Stephen J. Ryan, Stephen J. Ryan and K. Heimann, who later became his teacher at the University of Cologne, were his mentors. Along with his clinical work in Leipzig, he continued his research work in the field of macular degeneration, diabetic retinopathy and proliferative vitreoretinopathy (PVR). He is co-editor of Ryan’s RETINA.

Honors and awards
13:45 - 15:15 | HERMES

RV: Free paper session - Surgery

BERROD J, POURNARAS C

2411 13:45 The “complete vitrectomy performed early” treatment philosophy

2412 13:57 Early experiences with intravitreal ocriplasmin: a series of cases with vitreomacular traction
SCHULZ C, Saunders D, Lockwood A, Begum S - Portsmouth

2413 14:09 Anatomic and functional follow-up of foveal microstructures after macula-off retinal detachment surgery

2414 14:21 Anterior chamber aqueous flare in retinal detachment surgery.

2415 rf 14:33 Improvement in retinal vessel oxygen saturation after vitrectomy
LIM S L, Tan L, Perera S - Singapore

2416 rf 14:39 Imaging of intravitreal injected solution dispersion.

2417 rf 14:45 The use of intraoperative spectral domain optic coherence tomography in vitreoretinal surgery: The evaluation of efficacy.
LYTVYNCHUK L, Glittenberg C, Binder S - Lviv

2418 rf 14:51 Epiretinal membrane peeling for eyes with asteroid hyalosis: A case-control study

13:45 - 15:15 | RHODES 1

G: Does glaucoma affect only retinal ganglion cells in the retina?

The progressive loss of RGCs, and their axons, with concomitant insidious defects in the visual field, as well as changes in the optic disc, has been the classic hallmark of the glaucomatous optic neuropathies (GON). This concept however, has evolved and it is now well established that GON involve not only the RGC population, the nerve fiber layer of the retina, the optic disc and optic nerve head, but also the main retinorecipient subcortical and cortical nuclei of the primary visual pathway, such as the lateral geniculate nucleus and primary and secondary visual areas of the cortex. In addition, several groups have documented important molecular, functional and structural changes in the outer retinal layers of the retina in human glaucoma studies, as well as in non-human primate and rodent models of glaucoma or ocular hypertension. Thus, the concept of glaucoma as a solely disease of the retina and optic nerve has evolved to broader implications of the primary visual pathway. The Symposium will present studies focussing on changes in the non-retinal ganglion cell layers of the retina and will provide ample opportunity for interaction among scientists attending the conferences.

VIDAL-SANZ M, NORK T M

2421 13:45 Transneuronal degeneration in human glaucoma: A novel multiphoton-DAPI approach
MORGAN J E - Cardiff

2422 14:15 Ocular hypertension in adult rodents does not affect non-RGC neurons in the ganglion cell layer but results in severe loss of cone-photorceptors

2423 14:45 Anatomic, biochemical and functional evidence for cone injury in glaucoma
NORK T M, Kim C BY, Nickells RW, Ver Hoeve J N - Madison
### COS: Free paper session - Corneal bioengineering

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>2431</td>
<td>Mass production of high quality corneal endothelial cells from old donors</td>
<td>HE Z, Forest F, Perrache C, Cognasse F, Cognasse H, Gain P, Thuret G - Saint Priest en Jare</td>
<td></td>
</tr>
<tr>
<td>2433</td>
<td>Ultrastructural maintenance of decellularized corneas using dextran</td>
<td>LYNCH A, Wilson S, Ahearne M - Dublin</td>
<td></td>
</tr>
<tr>
<td>2434</td>
<td>Self-complementary vectors for optimization of AAV2-mediated gene-therapy of corneal endothelial cells</td>
<td>GRUENERT A, Buening H, Schnoedt M, Schmeer M, Schleef M, Kruse F E, Fuchsluger T A - Erlangen</td>
<td></td>
</tr>
<tr>
<td>2435</td>
<td>Designing an innovative bioreactor destined to improve the endothelial viability of stored corneas</td>
<td>RAGEADE D, Bernard A, Nangoum-Fosso T, Herbeipin P, He Z, Perrache C, Piselli S, Acquart S, Thuret G, Gain P - Saint Priest en Jarez</td>
<td></td>
</tr>
</tbody>
</table>

### NSPH: The role of the corpus callosum in binocularity and strabismus

The role of the corpus callosum in binocularity and strabismus in placental mammals seems to be an important role for the corpus callosum in binocularity. The corpus callosum represents the midline. In order to perceive a smooth sensory fusion of the right and the left body parts, the middle is represented on both sides. The same holds true for vision. To be able to fuse the right and left visual field, the retina contains both crossed and uncrossed ganglion cells. A small strip in the middle of the visual field is seen by both the right and the left visual cortex. The corpus callosum is likely involved in human binocular motor fusion and disparity detection. In mammals like rats, binocularity almost completely depends on callosal transfer. Binocularity of the visual cortex is realized by both the signal of the contralateral eye through the geniculate pathway, and the signal from the ipsilateral eye through the contralateral geniculate and back through the corpus callosum. Transection of crossing ganglion cells in the cat chiasm does not change disparity detection of the cortex much. Animal and human data regarding the role of the corpus callosum in binocularity and strabismus are presented.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>2441</td>
<td>Sensory and motor fusion</td>
<td>HOUTMAN A C - Brussel</td>
<td></td>
</tr>
<tr>
<td>2442</td>
<td>Normal vision, strabismus and the corpus callosum in animals</td>
<td>MILLERET C - Saint Gratien</td>
<td></td>
</tr>
<tr>
<td>2443</td>
<td>The origins of strabismus and loss of binocular vision. Implication of the corpus callosum</td>
<td>BUI QUOC E - Paris</td>
<td></td>
</tr>
<tr>
<td>2444</td>
<td>The corpus callosum in human binocularly and strabismus</td>
<td>TEN TUSSCHER M - Brussel</td>
<td></td>
</tr>
</tbody>
</table>
Diabetic retinopathy (DR) is the commonest microvascular complication of diabetes and remains one of the leading causes of blindness worldwide. The two most important visual complications of DR are diabetic macular edema and proliferative diabetic retinopathy. Many of the molecular and functional changes that are characteristic of inflammation have been detected in retinas from diabetic animals or humans, and in retinal cells under diabetic conditions. A large body of evidence supports the role of proinflammatory cytokines, chemokines, matrix metalloproteinases and other inflammatory mediators in pathogenesis of diabetic retinopathy leading to persistent low grade inflammation, and influx of leukocytes contributing to damage to the retinal vasculature and neovascularization. The causal relationship between inflammation and angiogenesis is now widely accepted. An emerging issue in diabetic retinopathy research is the focus on the mechanistic link between activation of subclinical inflammation and angiogenesis.

Leukostasis has been found to be significantly increased in retinas of diabetic animals and might contribute to the capillary nonperfusion in diabetic retinopathy. Leukostasis has been postulated to be a factor in death of endothelial cells and breakdown of the blood-retinal barrier. Leukocyte recruitment and adhesion to the retinal vasculature correlate with increased expression of retinal intercellular adhesion molecule-1 and elevated expression of the β-integrin subunit CD18 on neutrophils. In addition, the increased expression of many inflammatory proteins are regulated at the level of gene transcription through the activation of proinflammatory transcription factors such as NF-κB.

**ABU EL ASRAR A**

13:45 - 15:15 | RHODES 4

**IM: Inflammation in diabetic retinopathy-part 2**

Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a clinical key feature. The commonest causes worldwide is mutation in mitochondrial DNA (causing Leber’s Hereditary Optic Neuropathy) and OPA1 mutations (causing Autosomal Dominant Optic Atrophy: ADOA). 60-80% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. Inherited optic neuropathy is an ‘orphan’ disease. However, the disease prevalence is not so low (1: 20,000 to 35,000), and it is estimated that there are 5000 to 8000 distinct rare diseases, affecting 6-8% of the population of the European Union [27-36 million people]. Recent trials of the drug idebenone, a co-enzyme Q10 analogue, in patients with the mitochondrial optic neuropathy, Leber’s hereditary optic neuropathy, have shown the first glimmer of hope for the treatment of this group of patients. At this exciting time this SIS will focus on disease mechanisms and potential avenues towards therapy.
ACB: New wine in new tubes - The re-advancement of scleral lenses in ocular surface disease

Even though the scleral "contact lens" - a precorneal lens with very large diameter that rests on the sclera and safely covers the cornea via a tear-filled vault zone - was the originally invented type of a contact lens it has rapidly lost the interests of eye doctors and patients after the advent of small diameter corneal lenses and eventually after the invention of soft contact lenses. Still, the large scleral lenses have certain advantages since they can safely bathe the cornea in a moist chamber that allows a surprising improvement and healing of chronic pathological processes at the ocular surface. Scleral lenses can often be the only possible way to restore acceptable or even perfect vision in corneas with higher order refractive disorders and/or keratoconus. Therefore scleral lenses can often preserve or restore vision without "needing a knife" - which may be an important advantage not only in countries with a less developed health system. In recent years new lens designs and high tech materials have distinctly improved the fitting as well as the wearing of scleral lenses. To some surprise, patients often consider, after an adaption phase, a scleral lens as that type of contact lens that is causing the least ocular irritation as compared to other contact lens types.

KNOP E, MEKKI M B

2471 13:45 Is there something like a "Healthy Contact Lens"?
KNOP E, Knop N - Berlin

2472 14:00 Longterm restoration of ocular surface function with scleral lenses
CARRASQUILLO K G - Boston

2473 14:15 Scleral lenses in the management of exposure/neurotrophic keratopathy in patients with cranial nerve palsy
SCHORNACK M - Rochester

2474 ★ 14:30 Scleral lens as a first therapeutic weapon in severe ocular burns
MEKKI M B, Yahiaoui S, Titah O, Belaoudmou R - Algiers

2475 ★ 14:45 Indications for scleral lenses
LEYSEN I - Edegem

2476 15:00 Improving vision and comfort of patients with corneal deformations with implementation of ultraHealth and ultraHealth FC S-H Hybrid Lenses
MANCZAK H - Poznan
In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a 45 minute session called “Coffee with the Prof”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers. The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

The Profs are:
- Pinar AYDIN
- Russell FOSTER
- Reza DANA
- Constantin POURNARAS
- Peter WIEDEMANN
- Marcela VOTRUBA
- Bart LEROY

Registration required and will open onsite at registration. First come first served.
**ACB: Anatomy / Cell Biology**

**PETROVSKI G, KAARNIRANTA K**

**T001**  
Fisetin and Luteolin decrease inflammation and oxidative stress-induced cytotoxicity in ARPE-19 cells  
*Hytti M, Piippo N, Korhonen E, Kaarniranta K, Kauppinen A - Kuopio*

**T002**  
Cis-Urocanic acid prevents inflammation and cell death in UVB-treated ARPE-19 cells  
*Korhonen E, Piippo N, Hytti M, Kaarniranta K, Kauppinen A - Kuopio*

**T003**  
Nrf2- and PGC-1α-deficient mice: A novel animal model for impaired autophagy in AMD?  

**T004**  
Hypoxia induces an inflammatory response in ARPE-19 cells  
*Arjamaa O, Aaltonen V, Piippo N, Kaarniranta K, Kauppinen A - Turku*

**T005**  
Autophagy stimulus affects different kinase pathways and promotes HuR protein activation and SOSTM1/p62 protein synthesis in ARPE-19 cells  
*Amadio M, Marchesi N, Govoni S, Pascale A, Kaarniranta K - Pavia*

**T006**  
SOSTM1/p62 depletion leads to the Rab7 accumulation and inflammatory response in ARPE-19 cells  
*Piippo N, Hyttinen J, Hytti M, Korhonen E, Kaarniranta K, Kauppinen A - Kuopio*

**T007**  
Lack of collagen XVIII in mice evokes age-dependent deficiency in retinal pigment epithelium proteostasis  
*Kivinen N, Fiala M, Aikio M, Piivala J, Kaarniranta K - Kuopio*

**T008**  
Interventions against VEGF overexpression, available strategies and future developments  

**T009**  
Reversal of ischemic retinopathy in ocular ischemic syndrome following carotid artery stenting  
*Esteban O, Nuñez E, Ascaso J, Perez I, Idoate A, Sanchez J, Cristobal J - Zaragoza*

**T010**  
Lactate transport and receptor actions: Potential roles in inner retinal function and disease  

**T011**  
The effect of macular edema on the measurement of retinal nerve fiber layer thickness and the thickness of peripapillary retina  
*Kim S, Lee S, Lee J - Busan*

**T012**  
Mitochondrial DNA haplogroups associated with neovascular age-related degeneration in a Spain population  
*Esteban O, Ascaso F, Calvo T, Montoya J, Ruiz-Pesino E, Martinez M, Almenara C, Del Buey M, Cristobal J - Zaragoza*

**T013**  
Nuclear factor-erythroid 2-related factor-2 (Nrf2) and peroxisome proliferator-activated receptor coactivator-1 (PGC-1) regulates proteolysis in cornea  

**T014**  
Anterior lens epithelium in cataract patients with retinitis pigmentosa - scanning and transmission electron microscopy study  
*Andjelic S, Draslar K, Hvala A, Howell M - Ljubljana*

**T015**  
The study of needle tip aspirates and entry sites after intravitreal injections with different needle types  
*Lytvynchuk L, Savytska I, Sergienko A, Binder S, Petrovski G - Lviv*
15:15 - 16:00 | POSTER AREA

MBGE: Molecular Biology / Genetics / Epidemiology

DAVIDSON A E, LISKOVA P

T016  Clinical aspects of Autosomic Recessive Retinitis Pigmentosa Caused by USH2A Mutations in Consanguineous Tunisian Families
CHEBIL A, LARGUECHE L, KORT F, HASSAIRI A, HABIBI I, MUNIER F, EL MATRI L - Tunis

T017  Exome sequencing confirms ZNF408 mutations as a cause of familial retinitis pigmentosa
HABIBI I, Chebil A, Kort F, Munier F, Schorderet D, El Matri L - Sion

T018  Two Sisters with Congenital Blindness caused by Osteoporosis-pseudoglioma Syndrome due to new Mutations in the LPR5 Gene
WELINDER L, Robitaille J M, Boerkoel C F, Rupps R, Lyons C - Aalborg

T019  A novel mutation in CNNM4 (G492C) associated with Jalili Syndrome
LOPEZ TORRES LT, Schorderet D, Valmaggia C, Todorova M - Basel

T020  Genotypes & Phenotypes in Belgian Patients with Albinism
DE BLESER E, Tack M, De Baere E, Leroy B P - Oostakker

T021  Retinitis pigmentos: a new feature in hypohidrotic ectodermal dysplasia
MEUNIER A, Vilain C, Abramowicz M - Bruxelles

T022  A variant rs613872 in TCF4 gene is responsible for the higher risk for Fuchs endothelial corneal dystrophy development- the results of study in Polish patients.
UDZIELA M, Oldak M, Ruszkowska E, Sciezynska A, Binczyk E, Ploski R, Szaflik J P - Warsaw

T023  Prospective study about activity of emergency unit in the Department of Ophthalmology (Nancy, University Hospital, France)
BAUDOT A, Ameloot F, Trechot F, Angioi K - Gondreville

T024  Is there a seasonal relationship with idiopathic anterior uveitis presentation?
SAUNDERS D, Schulz C, Lockwood A - Portsmouth

T025  Frequency of refractive errors and binocular vision anomalies in children with learning disability

T026  Homocysteine and risk of wet age-related macular degeneration: a meta-analysis
PINNA A, Zaccheddu F, Boscia F, Solinas G - Sassari
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors, Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>T027</td>
<td>The use of matrix therapy in the Treatment of corneal perforation</td>
<td>LAZREG S - Dar el Beida</td>
</tr>
<tr>
<td>15:15</td>
<td>T028</td>
<td>An unusual germ responsible for fungal keratitis: Metarrhizium Anisopliae</td>
<td>ZAI DI M, Bazard M C, Dorin J, Machouart M, Angioi K - Vandoeuvre les Nancy</td>
</tr>
<tr>
<td>15:15</td>
<td>T029</td>
<td>Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye.</td>
<td>CIMBOLINI N, Antonelli S, Mauro V, Feraille L, Elena P P - La Gaude</td>
</tr>
<tr>
<td>15:15</td>
<td>T031</td>
<td>A case of significant refractive change in nodular posterior scleritis</td>
<td>YOON S, Jeong H, Kim H, You T - Jeonju</td>
</tr>
<tr>
<td>15:15</td>
<td>T033</td>
<td>From devastation to restoration: trichosporon asahii can be beaten</td>
<td>AYDIN YAZ Y, Yıldırım N, Oz Y, Sahin A, Yaz Y - Eskisehir</td>
</tr>
<tr>
<td>15:15</td>
<td>T035</td>
<td>Safety and Efficacy of a Polyethylene Glycol/Propylene Glycol Based Lubricant Eye Drop in Patients with Dry Eye.</td>
<td>LABETOULLE M, Messmer E, Ogundele A, Mouriaux F, Baudouin C - Le Kremlin Bicêtre</td>
</tr>
<tr>
<td>15:15</td>
<td>T036</td>
<td>Clinical Efficacy of an Oli-based Lubricant Eye Drop in Dry Eye Patients with Lipid Deficiency.</td>
<td>LABETOULLE M, Maurino V, Ogundele A, Rossi G C M, Van der Meulen I, Mrukwa-Kominek E, Galarreta D, Boehringer D, Baudouin C - Le Kremlin Bicêtre</td>
</tr>
<tr>
<td>15:15</td>
<td>T037</td>
<td>Semi-automated reconstruction of inflammatory infiltration in infectious keratitis</td>
<td>SMEDOWSKI A, Tarnawska D, Wylegala E - Katowice</td>
</tr>
<tr>
<td>15:15</td>
<td>T038</td>
<td>Experience with the monoclonal anti IgE antibody Omalizumab in severe refractory vernal keratoconjunctivitis in children</td>
<td>DOAN S, Amat F, Gabison E, Just J, Cochereau I - Paris</td>
</tr>
<tr>
<td>15:15</td>
<td>T039</td>
<td>Assessment of the size spectrum of epithelial lesions of punctuate superficial keratitis during dry eye</td>
<td>COURRIER E, Lepinet T, Hor G, He Z, Chikh M, Thuret G, Gain P - Saint Priest en Jarez</td>
</tr>
<tr>
<td>15:15</td>
<td>T040</td>
<td>The inhibitory effect of Itraconazole on Corneal neovascularization in Rabbits</td>
<td>WON J Y, Chung S K - Seoul</td>
</tr>
</tbody>
</table>
## COS: Cornea / Ocular Surface

### T044
Analysis of the efficacy of the tissue regenerating agent (RGTA) 0.01% poly-carboxymethylglucose sulfate in the treatment of neurotrophic corneal ulcers and persistent epithelial defects  
*DEL BUEY M A, Casas P, Caramello C, Esteban O, Martínez M, Sánchez N, Pinilla I, Lanchares E - Zaragoza*

### T045
Ocular Sarcoidosis Surgery as the most effective option to avoid blindness  

### T046
Study of Xailln night physical Properties versus marketed ocular lubricant products  
*PILOTAZ F, Pecout A, Do M - Sophia Antipolis*

### T047
Study of XAIL IN HA Physical Properties versus Marketed Hyaluronate Based Ocular Lubricants  
*PILOTAZ F, Saldo J, Boix M - Sophia Antipolis*

### T048
Eyelid disorders evaluation in the Ophthalmic current practice in Belgium, Denmark, France, Netherland, Portugal and Turkey: The Meibum Study  
*DIAZ VALLE D, Doan S, Ya mur M, Benitez del Castillo J M - Madrid*

### T049
Neurotrophic keratitis (NK) in carotid cavernous fistulae (CCF)  
*STEPHAN S, Rouger H, Doan S, Lamirel C, Cochereau I, Gabison E - Paris*

### T050
Meibomian Gland Dysfunction (MGD) and Tear Cytokines after Cataract Surgery according to Preoperative Meibomian Gland Status  
*JUNG J W, Cho D, Kyoung Yul S - Incheon*

### T051
Dry Eye Disease Therapy: who are the non-responders?  
*EIDET J R, Ræder S, Chen X, Badian R, Utheim Ø, Utheim T P - Oslo*

### T052
Utility of peripheral lamellar corneal graft in PUK with corneal perforation treatment  

### T053
Advancing age does not strongly correlate with symptoms and signs of Dry Eye Disease in a large Norwegian cohort  
*BADIAN R A, Eidet J R, Ræder S, Utheim Ø, Chen X, Stoianovic A, Utheim T P - Oslo*

### T054
Healing of a resistant neurotrophic corneal ulcer using a new matrix therapy agent (RGTA): A case report  
*Zghal I, ZAHAF A, Fekih O, Zayani M, Bouguila H, Nacef L - Tunis*

### T055
Corneal nerve activity during ocular inflammatory processes  
*LUNA C, Quirce S, Belmonte C, Gallar J, Acosta M C - San Juan de Alicante*

### T056
Corneal surface temperature and tear secretion in young and adult aqueous tear deficient guinea pigs  
*GALLAR J, Luna C, Alonso E, Revert R, Quirce S, Aracil A, Belmonte C, Acosta M C - San Juan de Alicante*

### T057
The Effect of Ikervis® (1mg/mL Ciclosporin cationic emulsion) on severe keratitis in patients with dry eye disease participating in a phase III study  
*LEONARDI A, Labetoulle M, Ismail D, Garrigue J S, Rancho L, Brignole-Baudouin F, Amrane M, Baudouin C - Evry*

### T058
Posterior corneal anatomy in a newborn baby  
*FARAJ L, Yeung A, Said D, Branch M, El Alfy M, Dua H - Nottingham*

### T059
Microfluidic in vitro Drug Release from Contact Lens Materials  
Comparison between i-gel and endotracheal tube in corneal grafts: a randomized clinical trial

Investigating the blue sclera in osteogenesis imperfecta by in vivo confocal microscopy.

Upgrading wide field contact specular microscope

Genotype and phenotype correlation of monogenic corneal dystrophies in population of central Poland
UDZIELA M, Oldak M, Sciezynska A, Ploski R, Szaflik J P - Warsaw

Visual acuity increases up to 7 years after Descemet Stripping Automated Endothelial Keratoplasty
HANSEN M S, Correll M H, Julian H O - Hillerød

Assessment of corneal layers thickness with spectral-domain optical coherence tomography

Immediate Effect of Ultraviolet-A Collagen CXL Therapy on Biomechanics and Histology of Human Cornea

Ocular Chronic Graft Versus Host Disease after Bone Marrow Transplantation

New insights into the proliferative capacities of rabbit corneal endothelial cells
CROUZET E, He Z, Forest F, Perrache C, Piselli S, Peoc’h M, Gain P, Thuret G - Saint Priest en Jarez

Topical treatment with a new matrix therapy agent (RGTA, CACICOL) improves epithelial wound healing after penetrating keratoplasty in a rabbit model

Ex vivo porcine corneal storage using an innovative bioreactor

Comparison of corneal topographic indices of keratoconus versus normal eyes by using pentacam imaging
YEKTA A A, Khabazkhoob M, Hashemi H, Bakhshi S, Ostadimoghaddam H, Heravian J, Rezvan F, Yekta R - Mahhad

Ocular surface improvement after conjunctivochalasis (CCH) surgery.

Transfer of molecules into the endothelial cells of whole human corneas using carbon nanoparticles activated by femtosecond laser

Pore size assessment during corneal endothelial cell permeabilization by femtosecond laser-activated carbon nanoparticles
<table>
<thead>
<tr>
<th>15:15 - 16:00</th>
<th>POSTER AREA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COS: Cornea / Ocular Surface</strong></td>
<td></td>
</tr>
</tbody>
</table>

| T075 | Corneal Analysis before Cataract Surgery; Significance as the Clue for Unexplained Visual Complaint After Surgery  
| T076 | Long-term results orthokeratological therapy in patients with myopia  
BUSUYEVA N , Maliieva O - Odessa |
| T077 | The effect of trehalose 3% as adjuvant therapy on Lasik procedure.  
| T078 | Sterile corneal keratolysis in the rat at 300 nm  
KRONSCHLAGER M , Talebizadeh N , Yu Z , Löfgren S , Findl O - Vienna |
| T079 | Evaluation of the influence of corneal biomechanical properties on the central corneal curvature after a SUPRACOR procedure  
DELBARRE M , Rambaud C , Berguiga M , Sendon D , Graber M , Froussart-Maille F - Clamart |
| T080 | Intratarsal injection of kenacort in the treatment of severe cases of VKC  
LAZREG S - Dar el Beida |
| T081 | 3D model of pterygium and corneal limbus: Investigating histopathology and stem cell distribution.  
BLOM N , Andreasen A , Heegaard S , Hjortdal J , Nielsen K - Aarhus C |
| T082 | Analysis of molecular mechanisms that predispose patients to develop post-PRK haze  
RAJIV KUMAR N , Ghosh A , Shetty R , Pahuja N - Bangalore |
| T083 | Corneal lenticules as an ex-vivo model to study keratocyte biology  
| T084 | Novel role of PEL13 as a potential biomarker for Sjogren's syndrome related dry eyes  
PILSON Q , Ni Gabhann J , Murphy C C - Dublin |
| T085 | Randomised, controlled study of the efficacy and safety of a new eye-drop formulation for moderate to severe dry eye syndrome  
DOAN S , Baudouin C , Khairallah M - Paris |
| T086 | Efficacy of Dry Eye Disease Treatment based on the 2007 Report of the International Dry Eye WorkShop (DEWS)  
| T087 | Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high risk penetrating keratoplasty: a 2-year follow-up study  
| T088 | Differential molecular signature of ectatic and non-ectatic areas from Keratoconus patient corneas.  
PAHUJA N , Rajivkumar N , Shetty R , Shroff R , Ghosh A - Bangalore |
| T089 | Assessment of the performances of a handheld in vivo confocal microscope for the analysis of human corneal innervation  
| T090 | Contribution of Optical Coherence Tomography (OCT) with real-time OCT of the Femtosecond laser, and per operative OCT of the microscope in deep anterior lamellar keratoplasty (DALK) for keratoconus: a new technique  
NGUYEN DT , Stephan S , Gleize S , Cochereau I , Gabison E - Paris |
POS | IM: Immunology / Microbiology

**WILLERMAIN F , XU H**

**T091**  
The P2X7 receptor is a potential therapeutic target for the treatment of Uveitis  
*TEMPEST-ROE S , Tam F , Taylor S - London*

**T092**  
Role of macrophages in the course of an in vivo murine model of Anterior Ischemic Optic Neuropathy  
*KOKONA D , Häner N S , Ebneter A , Zinkernagel M S - Bern*

**T093**  
Contribution of virtual reality in clinical practice in ophthalmology  
*FLORES M , Mauris N , Anne Charlotte L , Thibaud M F , Saleh M - Besancon*

**T094**  
Hyperreflective Dots in Spectral Domain Optical Coherence Tomography as Phenotypic Marker in Uveitis-Associated Cystoid Macular Edema  
*SELLAM A , Massamba N , Fel A , LeHoang P , Bodaghi B - Paris*

**T095**  
Therapeutics course of childhood noninfectious uveitis  
*TARFAOUI N , Lala E , Uettwiller F , Marot Y , Hoarau C , Lelez M L , Arsene S , Pisella P J - Tours*

**T096**  
Efficacy and safety of TOXO KO vaccine to prevent ocular toxoplasmosis in congenital murine model  
*TARFAOUI N , Morisse S , Lemee G , Dimier-Poisson I , Seche E , Pisella P J - Tours*

**T097**  
Occult non-metallic intraocular foreign body causing recurrent anterior uveitis  
*MORREALE BUBELLA R - Agrigento*

**T098**  
Changes in lamina cribrosa and prelaminar tissue in anterior ischemic optic neuropathy  

**T099**  
The added value of undiluted vitreous biopsy samples processed by the Cellient® tissue processor (Hologic) in unsolved uveitis.  
*VAN CALSTER J , Van Ginderdeuren R - Leuven*

**T100**  
APMPPPE as a window on systemic granulomatous inflammation  
*LABALETTE P , Bouabane I , Maurage C A - Lille*

**T101**  
Relapsing Polychondritis and its Orbital Manifestations  
*TEO L , Choo CT - Singapore*
16:00 - 17:30 | HERMES

**RV: Diabetic retinopathy and macular edema**

The pathogenesis of diabetic retinopathy and macular edema will be detailed. Speakers will present diabetic classification and the interest for screening and follow-up of our patients. Macular complications will be detailed as well as the different therapeutic options. Clinical cases of diabetic retinopathy with or without diabetic macular edema will be discussed with the audience. These cases will define the role and the pros and cons of different therapeutic options.

**CREUZOT C , MIDENA E**

2511 16:00  Pathogenesis of diabetic retinopathy and macular edema  
*BEHAR-COHEN F - Paris*

2512 16:18  Classification of diabetic retinopathy: from screening to diagnosis  
*WIEDEMANN P - Leipzig*

2513 16:36  Macular complication: from edema to ischemia  
*MIDENA E - Padova*

2514 16:54  Therapeutic options: how does it work?  
*POURNARAS C J - Genève*

2515 17:12  Clinical cases  
*CREUZOT C - Dijon*

16:00 - 17:30 | RHODES 1

**RV: Free paper session - AMD**

**LEYS A , LAWRENSON J**

2521 16:00  Dietary interventions for age-related macular degeneration: a review of the evidence  
*LAWRENSON J , Evans J - London*

2522 16:12  Prevalence of age-related macular diseases in an old French population (the MONTRACHET Study)  
*DE LAZZER A , Dossarps D , Gabrielle P H , Pailot C , Daniel S , Binquet C , Tzourio C , Bron A M , Creuzot C - Dijon*

2523 16:24  Subretinal drusenoid deposits in an elderly population with age-related macular degeneration (MONTRACHET study: Maculopathy, Optic Nerve, nTRition, neurovascular and HEarT diseases)  

2524 16:36  Lens status and macular pigment optical density in an old French population (MONTRACHET's study: Maculopathy, Optic Nerve, nTRition, neuroAsCular and HEarT diseases)  
*FLECK O , Koehrer P , Alassane S , Binquet C , Bretillon L , Acar N , Tzourio C , Bron A M , Creuzot C - Dijon*

2525 *rf* 16:48  The Protective Effect of Anti-blue Lens Against Photo-induced Cell Death  
*YU W Y , Shan S W , To C H , Chan H H L - Hong Kong*

2526 *rf* 16:54  Age Macular Degeneration-Lipidomic Study: Relevance and interest of Lipidomic study in screening, follow-up and etiopathology of AMD  
*GONZALEZ C , Bertrand-Michel J - Toulouse*

2527 *rf* 17:00  Endophthalmitis associated with intravitreal Ranibizumab: Microbiology and visual outcomes.  
*PENWARDEN A , Weston K , Lockwood A - Portsmouth*

2528 *rf* 17:06  Microbiology of conjunctiva sac in intravitreal injections.  
*GRZYBOWSKI A , Gaca-Wysocka M , Paluch M - Olsztyn*
### SIS | RHODES 2

**G: New and/or underdiagnosed entities in glaucoma**

This SIS will address a variety of topics, all associated with raised IOP or glaucoma that are either recently described or underdiagnosed.

**STEVENS A-M, KESTELYN P**

- **2531** 16:00 Bilateral acute iris transillumination
  **TUGAL-TUTKUN I - Istanbul**

- **2532** 16:22 Cystoid macular oedema in endstage glaucoma
  **BIFRARE D - Sion**

- **2533** 16:44 Radius Maumenee Syndrome
  **KESTELYN P - Gent**

- **2534** 17:06 Drug induced glaucoma: old and new drugs
  **LAMBRÉCHT P - Gent**

---

### FP | RHODES 3

**G: Free paper session - Imaging and biomechanics**

**CORDEIRO MF, CORDEIRO SOUSA D**

- **2541** 16:00 Influence of intraocular pressure in anterior lamina cribrosa depth – a prospective observational study in a healthy Portuguese population
  **CORDEIRO SOUSA D, Leal I, Pinto Ferreira N, Pinto J, Abegao Pinto L, Pinto F, Marques-Neves C - Lisbon**

- **2542** 16:12 Intra and inter-rater agreement of anterior lamina cribrosa depth measurements using enhanced-depth imaging optical coherence tomography
  **LEAL I, Cordeiro Sousa D, Couceiro R, Barata A, Abegao Pinto L, Pinto F, Marques-Neves C - Lisbon**

- **2543** 16:24 Evaluation of the lamina crivosa thickness and depth, the prelaminar nerve tissue thickness and the Bruch’s membrane opening-based minimum rim width in eyes with and without primary open-angle glaucoma: an enhanced depth imaging OCT study of the optic nerve head and the correlation between anatomy and function
  **GAMA I, Almeida L, Gonçalves I, Monteiro-Grillo M - Lisbon**

- **2544** 16:36 Pigment epithelium central limit - Inner limit of the retina, Minimal Distance, PMID, a morphometrical variable for glaucoma follow-up
  **SANDBERG MELIN C, Malmberg F, Malmqvist L, Talebizadeh N, Yu Z, Söderberg P - Uppsala**

- **2545** 16:48 Subjective versus objective vertical cup-disc-ratio assessment in open angle glaucoma patients.
  **VANDEWALLE E, Willekens K, Van Keer K, Abegao Pinto L, Stalmans I - Leuven**

- **2546** 17:00 Gender specific IOP measurement using induced corneal vibration analysis - a multicenter clinical trial
COS: Free paper session - Ocular surface anatomy updates

BORDERIE V, RUGGERI A

2551 16:00 Three-dimensional structure of the mammalian limbal stem cell niche
BORDERIE V, Grieve K, Ghoubay D, Georgeon C, Thouvenin O, Bouharaoua N, Pâques M - Paris

2552 16:12 Assessing the microstructures of the human cornea using Gabor-Domain optical coherence microscopy with large field of view and high resolution

2553 16:24 Posterior corneal surface: new insights in curvature and astigmatism
PATEL S, Wacker K - Rochester

2554 16:36 Computerized analysis of human corneal endothelium morphology
RUGGERI A, Scarpa F - Padua

2555 rf 16:48 Differential molecular signature of ectatic and non-ectatic areas from Keratoconus patient corneas
PAHUJA N, Rajivkumar N, Shetty R, Shroff R, Ghosh A - Bangalore

2556 rf 16:54 Assessment of the performances of a handheld in vivo confocal microscope for the analysis of human corneal innervation

2557 rf 17:00 Contribution of Optical Coherence Tomography (OCT) with real-time OCT of the Femtosecond laser, and per operative OCT of the microscope in deep anterior lamellar keratoplasty (DALK) for keratoconus: a new technique
NGUYEN D T, Stephan S, Gleize S, Cochereau I, Gabison E - Paris

NSPH: Nystagmus and non-nystagmic abnormal spontaneous eye movements

16:00 - 17:30 | GALLIENI 1+2

Intermediate

This course is intended for beginners and intermediate levels A patient presenting with spontaneous abnormal eye movements can be challenging to the clinician. Interruption of fixation can result from many types of nystagmus and non-nystagmic spontaneous abnormal eye movements. Being able to identify the various mechanisms and etiologies of disorders which can interrupt the stability of fixation is mandatory. This course aims at providing participants with a structured approach to identify correctly the most frequent and important types of spontaneous abnormal eye movements and will consist of five sections:

1. Review of the anatomical and physiological bases of stability of gaze;
2. Congenital forms of nystagmus;
3. Acquired forms of nystagmus not to be missed;
4. Alterations of stabilization of the eyes under dynamic conditions;
5. Abnormal non nystagmic spontaneous eye movements. At the end of this course participants should have acquired a systematic and practical approach to the patient with abnormal spontaneous eye movements.

BORRUAT FX, KAESER P

2561 16:00 Review of the anatomical and physiological bases of stability of gaze
BORRUAT FX - Lausanne

2562 16:18 Congenital forms of nystagmus
KAESER PF - Lausanne

2563 16:36 Acquired forms of nystagmus not to be missed
BORRUAT FX - Lausanne

2564 16:54 Alterations of stabilization of the eyes under dynamic conditions
KAESER PF - Lausanne

2565 17:12 Abnormal non nystagmic spontaneous eye movements
BORRUAT FX - Lausanne
### IM: Free paper session - Mechanisms in inflammatory disease to outcomes of novel therapies, part 1

**2571** 16:00
Treg-based immunotherapy of non-infectious uveitis (NIU)
ASNAGLI H, Jacquin M, Belmonte N, Gertner-Dardenne J, Hubert M F, Sales A, Foussat A - Valbonne

**2572** 16:12
The role of dendritic cells in non-infectious anterior uveitis
O’ROURKE M, Canavan M, Sweeney C, Fletcher J, Fearon U, Murphy C - Dublin

**2573** 16:24
Interleukin 33/ST2 signaling regulates inflammatory response in choroidal stroma and ocular angiogenesis: implications for age-related macular degeneration.

**2574** 16:36
Systemic IL-1 production as a consequence of corneal HSV-1 infection – contribution to the development of Herpes Simplex Keratitis

**2575** 16:48
Changes in lamina cribrosa and prelaminar tissue in anterior ischemic optic neuropathy

**2576** 16:54
The added value of undiluted vitreous biopsy samples processed by the Cellient® tissue processor (Hologic) in unsolved uveitis.
VAN CALSTER J, Van Ginderdeuren R - Leuven

**2577** 17:00
APMPPE as a window on systemic granulomatous inflammation
LABALETTE P, Bouabane I, Maurage C A - Lille

**2578** 17:06
Relapsing Polychondritis and its Orbital Manifestations
TEO L, Choo CT - Singapore
## RV: New developments in OCT-Angiography

Optical coherence tomography angiography (OCTA), generates high-resolution, non-invasive angiograms qualitatively similar to conventional fluorescein angiography. OCTA may serve to detect abnormal microvasculature of the retinal or choroidal microvasculature either in healthy or diseased eyes.

POURNARAS C, ZOGRAFOS L

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2611</td>
<td>17:30</td>
<td>Principles &amp; Potential application of OCT-Angiography</td>
<td>COSCAS F - Creteil</td>
</tr>
<tr>
<td>2612</td>
<td>17:48</td>
<td>ANGIO-OCT &amp; DMLA (diagnosis and post-treatment follow-up)</td>
<td>COSCAS G, Lupidi M, Coscas F - Creteil</td>
</tr>
<tr>
<td>2613</td>
<td>18:06</td>
<td>OCT angiography in CNV quantitative follow up</td>
<td>LUMBROSO B - Rome</td>
</tr>
<tr>
<td>2614</td>
<td>18:24</td>
<td>OCT angiography for the evaluation of macular ischemic micro-angiopathies</td>
<td>POURNARAS C J, Frountzou E, Donati G - Genève</td>
</tr>
<tr>
<td>2615</td>
<td>18:42</td>
<td>En Face OCT and OCT-Angiography in ocular oncology</td>
<td>ZOGRAFOS L - Lausanne</td>
</tr>
</tbody>
</table>

## G: Neuroprotection in glaucoma: Coming of age?

Neuroprotection has been around for a while in glaucoma - or so it seems. Following a lull in enthusiasm, there appears more optimism in the glaucoma community. In practice, early detection and treatment is likely to be essential to protect the visual system against insults and prevent progression. This future scenario will be realised once sufficiently powered clinical trials with well chosen endpoints demonstrate benefits in terms of visual function or on validated surrogate endpoints of visual function. This session will review where we are and discuss new trial designs, new endpoints and new agents and review what lessons may have been learnt from before. Although confirmation of neuroprotective effects by randomized clinical trials is needed, there is demonstration of positive non-IOP dependent effects, which may be utilized in future trials.

CORDEIRO MF, LEVIN L

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2621</td>
<td>17:30</td>
<td>Is it becoming or coming of age</td>
<td>CORDEIRO M F - London</td>
</tr>
<tr>
<td>2622</td>
<td>18:00</td>
<td>Are we there yet?</td>
<td>LEVIN L A - Montreal</td>
</tr>
<tr>
<td>2623</td>
<td>18:30</td>
<td>To the clinic and back</td>
<td>GANDOLFI S - Parma</td>
</tr>
</tbody>
</table>
COS: Corneal imaging

In the recent years significant advances in corneal imaging were obtained. The current SIS first provides an overview of currently available techniques for corneal imaging. The other three talks are related to recent innovations in the field. Optical coherence tomography (OCT) has now become a standard procedure for imaging ocular tissues. Using broadband light source unprecedented resolution can be achieved allowing to visualize many structures within the cornea including the pre-corneal tear film. Confocal in vivo microscopy is a technique which provides excellent resolution although the field of view is small. The technique has been used to visualize many details of the cornea including endothelial cells and provides the unique opportunity to study corneal nerves. Finally recent advances in assessing corneal endothelial cells are provided. This includes ex vivo assessment of endothelial cell viability, 3D end cell count for eye banks and HD 3D imaging of cells with endothelial markers.

SCHMETTERER L, GUTHOFF RF

2631  17:30  Corneal Imaging Modalities - from Basic Science to Clinical Application  
STACHS O - Rostock

2632  17:52  Corneal ultra-high relocation OCT  
SCHMETTERER L - Vienna

2633  18:14  Clinical use of in vivo confocal microscopy  
GUTHOFF R F - Rostock

2634  18:36  Recent advantages in the imaging of human corneal endothelial cells  
THURET G - Saint Etienne

PO: It is a masquerade! Eye cancers lurking behind innocent appearances

Eye cancer is rare as compared to most benign eye diseases. This is a diagnostic challenge in general, especially in the office of the comprehensive ophthalmologist. It becomes a particular dilemma when a malignancy takes the disguise of another eye disease, in regard to symptoms or signs, and essentially becomes its look-a-like. Such a situation is known as a masquerade syndrome, and certain eye cancers are especially prone to produce one. This symposium highlights the most common situations in which an eye cancer lurks behind an innocent appearance, hopefully helping the audience to get their diagnosis right on the first visit of their next masquerade patient.

KIVELÄ T, DESJARDINS L

2641  17:30  Masquerade syndromes in children  
DESJARDINS L, Cassoux N - Paris

2642  17:48  Blepharitis, chalazion, stye - or rather not?  
LOEFFLER K - Bonn

2643  18:06  Photopsia, floaters, cataract - a systematic approach to correct diagnosis  
TALL M - Helsinki

2644  18:24  Uveitis - the classic masquerade in adults  
KIVELÄ T - Helsinki

2645  18:42  It is a masquerade! A potpourri of rapid cases  
KIVELÄ T - Helsinki
NSPH: An update on aniridia

Aniridia is a panocular disease. This rare bilateral ocular disorder occurs at a frequency of approximately 1 in 80,000. About one third of these aniridia are sporadic, with many variable expressivities of the features. PAX6 gene anomalies with 11p13 mutations or deletion are involved in aniridia. PAX6 mutations result in alterations in corneal cytokeratin expression, cell adhesion and glycoconjugate expression. Syndromic manifestations in aniridia patients with PAX6 point mutations will be described. Ocular anomalies in aniridia commonly associates limbal insufficiency, cataract, glaucoma, foveal aplasia with nystagmus and ptosis. Potential mechanism of limbal stem cell insufficiency will be exposed. Physiopathology of cornea fate or PAX6 and corneal homeostasia will be exposed. Innovation with therapeutic options will be discussed as medical treatment, limbal stem cell transplant technology or pluripotent stem cells.

BREMOND-GIGNAC D, LAUDERDALE J

17:30 - 19:00 | GALLIENI 1+2

RV: Free paper session - Retinal vasculopathy

LEYS A, BAILLIF S

17:30 - 19:00 | RHODES 4
Retinal pigment epithelial (RPE) cells have a critical role in the pathogenesis of many common retinal diseases. Therefore they have been regarded as important tools for the replacement therapy. The rapid technological development in the regenerative medicine has made RPE transplantations a clinically relevant option to treat retinal diseases in the future. This RPE SIS will focus in the critical topics of the development of this technology from laboratories to the clinics like differentiation of the RPE cells from hESC and iPSC, regulatory and clinical aspects like recruited biomaterial scaffolds, surgical techniques and safety issues.

**UUSITALO H, KAARNIRANTA K**

**2671**  
17:30 Introduction to the stem cell derived transplants  
**SKOTTMAN H - Tampere**

**2672**  
17:48 Induced to cure: Engineering iPSC cell derived RPE scaffolds to treat degenerative eye diseases  
**BHARTI K - Bethesda**

**2673**  
18:06 Subretinal implantation surgery and follow up in pig model  
**KIILGAARD J F - Copenhagen**

**2674**  
18:24 Subretinal implantation of human stem cell-derived RPE on ultrathin carriers in rabbits  
**STANZEL B V - Vienna**

**2675**  
18:42 Regulation of cell-based medicinal products  
**LODGE A - London**
19:00 - 20:30 | HERMES

**How to create a new generation of glaucoma patient?**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2711</td>
<td>19:00</td>
<td>New paradigms in Glaucoma?</td>
<td>NORDMANN J</td>
<td>Paris</td>
</tr>
<tr>
<td>2712</td>
<td>19:20</td>
<td>Can OCT be enough for glaucoma management?</td>
<td>NORDMANN J</td>
<td>Paris</td>
</tr>
<tr>
<td>2713</td>
<td>19:40</td>
<td>Efficacy, Safety, Observance: What is the optimal balance?</td>
<td>THYGESEN J</td>
<td>Glostrup</td>
</tr>
<tr>
<td>2714</td>
<td>20:00</td>
<td>Shall we wait Ocular surface disease to prescribe preservative free (PF) products in glaucoma?</td>
<td>SHORTT A</td>
<td>London</td>
</tr>
</tbody>
</table>
EVER 2015
Friday, Oct 9 - First morning session

8:00 - 8:30 | HERMES
Coffee and Croissants

8:30 - 10:00 | HERMES
RV: Degenerative myopia
Intermediate

Myopic disease can lead to severe visual impairment. This course aims to describe epidemiology of myopia and the recent genetic markers related to high myopia. Then macular complications, either medical or surgical, will be presented. Characteristics of retinal detachment linked to myopia will be considered. Finally, clinical cases will overview the different presentations of visual impairment in high myopic eyes.

CREUZOT C, LEVEZIEL N

3111 8:30 Epidemiology and genetic in degenerative myopia
LEVEZIEL N - Poitiers

3112 8:48 Macular diseases in myopia
CREUZOT C - Dijon

3113 9:06 Macular surgical diseases in myopia
POURNARAS JA - Lausanne

3114 9:24 Retinal detachment
BERROD J P, Conart J B - Nancy

3115 9:42 Clinical cases (all)
CREUZOT C - Dijon

8:30 - 10:00 | RHODES 1
G: Autonomic dysfunction in glaucoma

The known mechanisms behind glaucomatous damage have extended beyond intraocular pressure (IOP) to include those related to an underlying vascular dysfunction. One of the possible explanation for this vascular dysfunction is an impairment of the autonomic nervous system (ANS). This nervous structure is of paramount importance in regulating overall visceral activity and promoting that the proper response to a specific stimulus exists. Accordingly, a number of validated tests exist to determine whether an ANS dysfunction exists and to what extent. As glaucoma patients have been reported to exhibit both ocular and systemic signs of ANS dysfunction, this information may be of value to glaucoma management. This information could potentially be of use in early diagnosis, diagnostic confirmation and as prognostic value, particularly in patients where disease is progressing with an otherwise normal range IOP.

MARQUES-NEVES C, SCHMETTERER L

3121 8:30 Ocular Autonomic Regulation
ROCHA DE SOUSA A, Barbosa-Breda J - Porto

3122 8:48 Ocular tests and interpretation
MARQUES-NEVES C - Lisbon

3123 9:06 Ocular autonomic dysfunction in glaucoma
VANDEWALLE E - Leuven

3124 9:24 Systemic dysfunction in glaucoma
SCHMETTERER L - Vienna

3125 9:42 Clinical relevance of ANS dysfunction in glaucoma management
ABEGAO PINTO L - Lisbon
COS: Comprehensive lamellar keratoplasty

Endothelial keratoplasty is the mainstay in the management of corneal pathology leading to endothelial decompensation. Different techniques and modifications have evolved and the process is on-going. In this SIS we cover the full range of the procedures available supported by published evidence, so that the surgeon can understand the pros and cons of each technique and choose the one best suited for the patient and clinical indication. This will include Descemets stripping endothelial keratoplasty (DSEK) and ultrathin DSEK; Descemets membrane endothelial keratoplasty (DMEK) and Pre-Descemets endothelial keratoplasty (PDEK). The outcomes of each will be discussed and compared in the context of the learning curve, eye banking considerations regarding donor tissue required for each and post-operative issues related to graft detachment. The role of penetrating keratoplasty (PK) in modern day corneal transplantation and the strategies for enhancing graft survival will be covered as PK is performed more and more in cases with greater risk of failure. All speakers have been instructed to make their talk well illustrated; evidence based and cover practical applications supported by sound basic and clinical science.

DUA HS, SAID D

8:30 - 10:00 | RHODES 2

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3131</td>
<td>8:30</td>
<td>DALK versus PK for keratokonus</td>
<td>BORDERIE V - Paris</td>
</tr>
<tr>
<td>3132</td>
<td>8:48</td>
<td>Ultrathin DSAEK: The Present Status</td>
<td>BUSIN M - Forli</td>
</tr>
<tr>
<td>3133</td>
<td>9:06</td>
<td>Descemets membrane endothelial keratoplasty (DMEK)</td>
<td>KATAMISHT - Cairo</td>
</tr>
<tr>
<td>3134</td>
<td>9:24</td>
<td>Pre-Descemets Endothelial Keratoplasty (PDEK)</td>
<td>DUA H S - Nottingham</td>
</tr>
<tr>
<td>3135</td>
<td>9:42</td>
<td>There is still a place for Penetrating Keratoplasty (PK)</td>
<td>SAID D - Maadi, Cairo</td>
</tr>
</tbody>
</table>

PO: Eyelid tumors

8:30 - 10:00 | RHODES 3

Intermediate

Eyelid problems range from benign, to malignant. Fortunately, most eyelid disorders are not vision-threatening or life-threatening. Recognition and diagnosis of these problems are crucial to their proper management. For example, malignant eyelid tumors may be associated with lash loss and erosion of normal eyelid structures. Traditional surgical treatment of non-melanoma skin cancer includes excision with subsequent surgical margins, the “security” margins leading to determine the theoretical level of recurrences. Thus, some authors favor a clinical excision margin of 4 mm for basal cell carcinoma and 6 mm for squamous cell carcinoma. However, such “security” margins could not be applied in all cases of eyelids tumors for anatomic and functional considerations because such recommendations may lead to severe ocular complications. Thus the best assurance of minimal excision with complete excision is obtained by extemporaneous examination of the resection margins by frozen section or by surgery in two times. Knowledge of basis of reconstruction is important for avoid complications.

MOURIAUX F, LOEFFLER K

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3141</td>
<td>8:30</td>
<td>Benign or Malignant? Clinical features</td>
<td>LASUDRY J - Brussels</td>
</tr>
<tr>
<td>3142</td>
<td>8:52</td>
<td>Clinico-pathologic correlations of unusual lesions of eyelid tumors</td>
<td>LOEFFLER K - Bonn</td>
</tr>
<tr>
<td>3143</td>
<td>9:14</td>
<td>Which margins for which tumors?</td>
<td>MOURIAUX F - Rennes</td>
</tr>
<tr>
<td>3144</td>
<td>9:36</td>
<td>Basis of eyelid reconstruction after tumor resection</td>
<td>BRISCOE D - Savion</td>
</tr>
</tbody>
</table>
### SIS

**LC: Posterior capsular opacification**

Our SIS will cover subjects such as cell migration and fibrosis, treatment with different drug delivery methods and the prevention of capsular opacification for accommodative lens refilling.

**BARRAQUER R I , MICHAEL R**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Introduction and overview</td>
</tr>
<tr>
<td></td>
<td><strong>SPALTON D - London</strong></td>
</tr>
<tr>
<td>8:48</td>
<td>TGF beta and fibrosis-ironing out the wrinkles</td>
</tr>
<tr>
<td></td>
<td><strong>ELDRED J , Wormstone M - Norwich</strong></td>
</tr>
<tr>
<td>9:06</td>
<td>Migration of lens epithelial cells and IOL drug soaking</td>
</tr>
<tr>
<td>9:24</td>
<td>Sealed-capsule irrigation with distilled deionized water to prevent posterior capsule opacification</td>
</tr>
<tr>
<td></td>
<td><strong>REKAS M , Klu A , Kosatka M - Warsaw</strong></td>
</tr>
<tr>
<td>9:42</td>
<td>Capsular opacification and accommodative lens refilling</td>
</tr>
<tr>
<td></td>
<td><strong>KOOPMANS S - Groningen</strong></td>
</tr>
</tbody>
</table>

### MBGE: Free paper session

**LISKOVA P , VOTRUBA M**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Understanding and perceptions of inherited eye diseases and attitudes to genetic testing and gene therapy in a primary eye care setting</td>
</tr>
<tr>
<td></td>
<td><strong>GANNE P , Votruba M , Garrioch R - Ipswich</strong></td>
</tr>
<tr>
<td>8:42</td>
<td>Genetic variants in the TNFA are associated with Korean Dry Eye Disease</td>
</tr>
<tr>
<td></td>
<td><strong>YANG S , Na K S , Mok J W , Ju H J , Joo C K - Seoul</strong></td>
</tr>
<tr>
<td>8:54</td>
<td>Investigation of genotype-phenotype correlation of TGFBI mutations reveals c.1868G&gt;A; p.(Gly623Asp) is associated with a variable clinical phenotype, including epithelial basement membrane dystrophy</td>
</tr>
<tr>
<td></td>
<td><strong>EVANS C , Davidson A , Carnt N , Veli N , Tuft S , Hardcastle A - London</strong></td>
</tr>
<tr>
<td>9:06</td>
<td>Target region sequencing in sporadic congenital cataracts reveals a new genotype-phenotype relation for the GALK1 gene</td>
</tr>
<tr>
<td></td>
<td><strong>Li D , Yang J , Ye H , Tang Y , Luo Y , Lu Y - Shanghai</strong></td>
</tr>
<tr>
<td>9:18</td>
<td>Ocular fundus changes in patients with Down syndrome and pulmonary hypertension</td>
</tr>
<tr>
<td></td>
<td><strong>LEYS A , Delcroix M , Willems A , Wirix M , Nijs I - Leuven</strong></td>
</tr>
<tr>
<td>9:30</td>
<td>Two Sisters with Congenital Blindness caused by Osteoporosis-pseudoglioma Syndrome due to new Mutations in the LPR5 Gene</td>
</tr>
<tr>
<td></td>
<td><strong>WELINDER L , Robitaille J M , Boerkoel C F , Rupps R , Lyons C - Aalborg</strong></td>
</tr>
</tbody>
</table>
**NSPH: GOA Symposium : Tears in allergy: update**

Allergic ocular surface diseases affect subjects of all ages and increased all over the world with evolution of environment. These pathologies could lead to ulcers and sight-threatening corneal complications. Identification of inflammatory mediators in the tear fluid have been studied for a better understanding of the immune mechanisms involved in the ocular surface inflammation. Quantitative and qualitative characterization of the peptidoma of human tears will be developed and detailed in specific allergic keratoconjunctivitis as vernal keratoconjunctivitis. A possible disease marker may lead to identification of potential targets for therapeutic interventions. An update on severe ocular allergic disease and their treatment with current options will be reviewed with practical aspects and diverse clinical cases considering quality of life of the children and adults.

**BREMOND-GIGNAC D , FAUQUERT J**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3171</td>
<td>8:30</td>
<td>Allergic mediators in tears: what's new?</td>
<td>LEONARDI A - Padova</td>
</tr>
<tr>
<td>3172</td>
<td>9:00</td>
<td>Healing and corneal ulcers</td>
<td>GABISON E - Paris</td>
</tr>
<tr>
<td>3173</td>
<td>9:30</td>
<td>Immuno modulation</td>
<td>CALDER V - London</td>
</tr>
</tbody>
</table>
Translational applications in corneal and ocular surface diseases

DANA R - Boston MA

Summary
The field of Cornea and Ocular Surface has made significant advances in the recent past. Compared to our colleagues in Retina and Glaucoma where the principal leaps forward have been in pharmaco-therapy, in Cornea our primary advances have been in the realm of microsurgery and new technologies (e.g., DSEK/DMEK, femtosecond). Nevertheless, significant work has also been done in understanding the pathophysiology of common corneal and ocular surface disorders, with translational applications in our clinics. This talk will provide a short summary of some of the translational research performed by our team in understanding the pathogenic mechanisms and novel treatment options for corneal neovascularization, graft-versus-host disease (GVHD), and dry eye syndrome.

Award of the EVER Certificate of Honour

Biography Reza Dana:
Dr. Reza Dana, Senior Scientist, W Clement Stone Scholar, The Schepens Eye Research Institute; Claes Dohlman Chair in Ophthalmology; Professor of Ophthalmology at Harvard Medical School; Director, Cornea & Refractive Surgery, Massachusetts Eye & Ear Infirmary; Vice Chairman of Harvard Department of Ophthalmology and Director of the Harvard Medical School Cornea Center of Excellence. Dr. Dana completed his bachelor’s, graduate, and medical education at Johns Hopkins and performed his residency at the Illinois Eye and Ear Infirmary, followed by fellowships in Cornea and External Diseases at the Wills Eye Hospital, in Uveitis at the Massachusetts Eye and Ear, and in Ocular and Transplantation Immunology at The Schepens Eye Research Institute, Harvard Medical School. Dr. Dana, a ‘Gold Fellow’ of the Association for Research in Vision and Ophthalmology (ARVO), has authored over 230 peer-reviewed articles and over 100 reviews and book chapters, and has delivered more than 200 invited and named lectures worldwide. He has been the recipient of multiple awards, including the Special Scholar Award, Physician-Scientist Award, Lew R. Wasserman Award, and the Senior Scientific Investigator Award from Research to Prevent Blindness, the Cogan Award from ARVO, the LSU Chancellor’s Award in Neuroscience and Ophthalmology, and the Alcon Research Institute Award. Dr. Dana is Associate Editor of IOVS, and is on the editorial board of the journals Cornea and The Ocular Surface. In addition to his basic laboratory investigations, Dr. Dana leads a large translational research program at Mass. Eye and Ear that has received a number of IND permits from the FDA in just the last few years. Apart from his many clinical trainees, Dr. Dana has trained over 90 fellows and students from 30 countries in his laboratory to date.
Dr. Dana's principal research interests are in determining the molecular and cellular regulation of ocular immunity. The aims of Dr. Dana’s research program are to (1) unravel the molecular and cellular processes that are responsible for initiating and sustaining immuno-inflammatory responses in the cornea and anterior segment, and thereby (2) develop specific molecular targeting strategies to promote mechanisms that engender immune unresponsiveness without placing the eye or the patient at risk of toxicity or secondary infections. Areas of investigation include transplantation, angiogenesis, stem cells, and dry eye disease. Dr. Dana’s research is supported by several federal grants.
A large number of imaging technics are at our disposal since ten years or so. The progressive mastery of fundus autofluorescence clearly helped the differential diagnosis, separating atrophy resulting from heredo degeneration from that resulting age related degeneration. ICG angiography did improve our knowledge in discerning specific features of choriocapillaris atrophy or Haller layer atrophy. OCT and even more en face OCT provided us with additional information on the initial site of dysfunction in showing the morphology of the different retinal layers. The advent of Adaptive Optics opens new avenues in our understanding of the pathogenesis of atrophy and provides the possibility to use biological markers. In addition, the emerging approaches may allow to identify new diseases. The increase of knowledge obtained with all the means used in the daily life will be presented by the teams with most expertise in each field. The confrontation of all informations obtained may result in the identification of reliable prognostic markers for evaluation of clinical trial results.

SOUBRANE G

11:00 - 12:30 | HERMES

**RV: Lessons taught by imaging about atrophy in retinal disease**

Effective delivery of drugs for the treatment of ocular disorders is a challenge. Many potential active agents fail to progress because of not reaching their target. The unique anatomical and physiological barriers of the eye restrict the passage of drugs to the back of the eye, including the corneal epithelium, the blood-retinal barrier, systemic absorption, and drainage through the nasolacrimal ducts. The only mode of delivery currently for anti-VEGF treatments is through intravitreal delivery. These injections have put a strain on health service providers around the world. However, nanotechnology and small molecule advances mean that potentially intraocular injections may be a thing of the past. A different problem is encountered in glaucoma where often it is the task of daily eye-drop instillation that is associated with poor compliance. Again, advances in sustained release delivery promise to be potentially very useful.

CORDEIRO M F , SCHMETTERER L
**EVER 2015**

**Friday, Oct 9 - Second morning session**

### COS: Corneal wound healing

This session will focus on pathologies of the corneal strom and the corneal epithelium and will state-of-the-art present therapeutical options.

**BEUERMAN R, MELLER D**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3231</td>
<td>11:00</td>
<td>Limbal stem cell niche - New insights into structural and molecular composition</td>
<td>SCHLOTZER-SCHREHARDT U - Erlangen</td>
</tr>
<tr>
<td>3232</td>
<td>11:18</td>
<td>The epithelial-stromal TGFBI corneal dystrophies</td>
<td>LISCHW - Hanau</td>
</tr>
<tr>
<td>3233</td>
<td>11:36</td>
<td>Mechanisms of Stromal Fibrosis</td>
<td>BEUERMAN R - Singapore</td>
</tr>
<tr>
<td>3234</td>
<td>11:54</td>
<td>Limbal stem cells and their application in ocular surface reconstruction</td>
<td>MELLER D - Essen</td>
</tr>
<tr>
<td>3235</td>
<td>12:12</td>
<td>Biomaterials for ocular surface reconstruction and lamellar keratoplasty</td>
<td>FUCHSLUGER T - Erlangen</td>
</tr>
</tbody>
</table>

### EOVS: Doctor, I can’t see, but you can’t see why (Medically unexplained visual loss)

The SIS will address the challenging clinical problem of Medically Unexplained Visual Loss (MUVL). The content of the SIS will address the Initial Consultation, pointing out those elements of the routine clinical examination that require particular attention and how to attempt the distinction between non-organic and organic visual loss. The potential retinal and neuro-ophthalmic causes of MUVL will be discussed by an ophthalmologist and neurologist respectively, paying particular attention to disorders that may be mistaken for non-organic visual loss. Finally, the role of electrophysiology in providing objective assessment of visual pathway function, both retinal and intracranial, will be addressed using a case-based approach.

**HOLDER G**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3241</td>
<td>11:00</td>
<td>The Initial Consultation – when and how to suspect non-organic visual loss</td>
<td>SPIEERS W - Leuven</td>
</tr>
<tr>
<td>3242</td>
<td>11:22</td>
<td>Potential retinal causes: when and how to investigate</td>
<td>LEROY B P - Ghent</td>
</tr>
<tr>
<td>3243</td>
<td>11:44</td>
<td>Neuro-ophthalmic considerations and investigations</td>
<td>KAWASAKI A - Lausanne</td>
</tr>
<tr>
<td>3244</td>
<td>12:06</td>
<td>The role of electrophysiology</td>
<td>HOLDER G - London</td>
</tr>
</tbody>
</table>
11:00 - 12:30 | RHODES 4

LC: Free paper session

LÖFGREN S, BEIKO G

3251 11:00 dB-Crystallin Phosphorylation as a Precursor to Cataractogenesis
       THORNELL E, Ecroyd H, Aquilina A - Wollongong

3252 11:12 Endothelial cell loss after phacoemulsification according to different anterior chamber depths measured by IOL master
       HWANG H, Lyu B, Yim H, Lee N - Incheon

3253 11:24 Changes of intraocular pressure and cornea biomechanical properties after cataract phacoemulsification.
       YUGAY M, Ryabtzeva A - Moscow

3254 11:36 Increased Uptake of Intracameral Antibiotic Prophylaxis in Europe
       BARRY P - Dublin

3255 11:48 Impact of intracameral Cefuroxime on post-operative endophthalmitis in Languedoc Roussillon, France from 2010 to 2014
       DAIEN V, Papinaud L, Lacombe S, Daures J P, Villain M - Montpellier

3256 12:00 Anterior chamber and refractive parameters in diabetic patients according to metabolic status

11:00 - 12:30 | GALLIENI 1+2

MBGE: Ionizing radiation and cataract

The ocular lens is recognized as one of the most radio-sensitive tissues in the human body and cataracts are known to be initiated by exposures to relatively low doses of ionizing radiation. Recent new work on survivors of the Hiroshima atomic bomb and the Chernobyl atomic power plant together with epidemiological work on radiation technologists suggests that the question of the threshold dose for cataract development is open again. We will discuss recent findings on human cataracts together with mouse models.

GRAW J, WEGENER A

3261 11:00 Radiation-induced cataracts: governmental safety aspects
       AINSBURY E - Oxford

3262 11:22 Scheimpflug analysis in an epidemiological study
       WEGENER A - Bonn

3263 11:44 The EURALOC Project
       STRUELENS L - Mol

3264 12:06 Lifetime study in mice for radiation-induced cataracts
NSPH: An ophthalmological look at history

Studying history of ophthalmology we acknowledge the past of our profession, but also better understand the origins of our present knowledge. We can also often analyze the process of scientific discoveries and the progress in medical sciences. The eye has been often used in art as a symbol of the most delicate and important organ of human body, sometimes as a window to the soul. During the session unknown early descriptions of retinopathy in onchocerciasis, and military ophthalmia during the Napoleonic campaign will be presented. Moreover, obsession of the eyes in Luis Buñuel’s work and the biography of Friedrich Wegener will be discussed.

**GRZYBOWSKI A, ASCASO F**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3271</td>
<td>11:00</td>
<td>The obsession of the eyes in Luis Buñuel’s work (Spain, 1900- Mexico, 1983)</td>
<td>ASCASO F - Zaragoza</td>
</tr>
<tr>
<td>3272</td>
<td>11:22</td>
<td>The history of the description of retinopathy in onchocerciasis</td>
<td>KESTELYN P - Gent</td>
</tr>
<tr>
<td>3273</td>
<td>11:44</td>
<td>Military ophthalmia and the Napoleonic campaign in Egypt.</td>
<td>DE LAEY J J - Gent</td>
</tr>
<tr>
<td>3274</td>
<td>12:06</td>
<td>Wegener’s granulomatosis – should we change the name of the disease?</td>
<td>GRZYBOWSKI A - Poznan</td>
</tr>
<tr>
<td>Time</td>
<td>Session Description</td>
<td>Speaker, Location</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Blocking VEGF and PlGF: what is the interest in clinical practice?</td>
<td>DOT C - Lyon</td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td>Systemic exposure to anti-VEGF: what is the reality?</td>
<td>LEVY B - Paris</td>
<td></td>
</tr>
<tr>
<td>13:10</td>
<td>From basics to clinical evidences: Overview of efficacy &amp; safety across macular edema indications (RVO &amp; DME)</td>
<td>ZAMBROWSKI O - Créteil</td>
<td></td>
</tr>
</tbody>
</table>
### 12:30 - 13:30 | RHODES 3

**A rare breakthrough in mitochondrial medicine:**
changing the patient journey in LHON

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>Introducing a rare breakthrough in mitochondrial medicine</td>
<td></td>
</tr>
<tr>
<td>12:35</td>
<td>Optic neurodegeneration – the time to act is now</td>
<td>GUEVEN N - Hobart</td>
</tr>
<tr>
<td>12:50</td>
<td>Reaching key milestones in LHON – the idebenone clinical development program</td>
<td>METZ G - Liestal</td>
</tr>
<tr>
<td>13:00</td>
<td>Changing the patient journey in LHON: the evidence</td>
<td>KLOPSTOCK - München</td>
</tr>
<tr>
<td>13:20</td>
<td>Q&amp;A with panel</td>
<td></td>
</tr>
</tbody>
</table>
Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates. Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org

The optic nerve conference in Obergurgl, which is supported by EVER, explores the current state of our understanding of optic nerve degeneration, such as in glaucoma. To stimulate ideas and discussion, leading experts from a variety of fields will emphasize a cross-sectional, interdisciplinary approach. The conference brings together clinicians and basic scientists from different fields and will highlight translational research providing a platform for networking and stimulating discussions. The Focus area 2014 of the Obergurgl conference was "Neuroinflammation". In this SIG, some of the topics of the Obergurgl conference will be presented at EVER. Jonathan Crowston, Franz Grus, Keith Martin Conference Organizers, Obergurgl Optic Nerve Conference

GRUS F, MARTIN K, CROWSTON J

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>3421</td>
<td>13:30</td>
<td>Autophagy in neurodegeneration and inflammation and novel modulators of macroautophagy&lt;br&gt;BEHL C - Mainz</td>
</tr>
<tr>
<td>3422</td>
<td>13:48</td>
<td>Innate immunity in age-related retinal degeneration&lt;br&gt;LUHMANN U - Basel</td>
</tr>
<tr>
<td>3423</td>
<td>14:06</td>
<td>Heterogeneity of retina Müller glia and their possible role neuroprotecting retinal ganglion cells&lt;br&gt;VECINO E - Vizcaya</td>
</tr>
<tr>
<td>3424</td>
<td>14:24</td>
<td>Retinal innate immune activation in health and disease&lt;br&gt;XU H - Belfast</td>
</tr>
<tr>
<td>3425</td>
<td>14:42</td>
<td>Beta II tubulin as molecular marker of intraocular pressure in endothelial cells&lt;br&gt;PROKOSCH-WILLING V - Münster</td>
</tr>
</tbody>
</table>
Friday, Oct 9 - First afternoon session

13:30 - 15:00 | RHODES 2

COS quartett immunodagnostica Research Award Session

**FUCHSLUGER T**

3 grants supported by quartett for best paper in COS

- Translational Research Award
- Basic Science Research Award
- Clinical Research Award

The papers will be chosen during the congress and the grants will be handed over during quartett immunodagnostica Research Award Session

13:30 - 15:00 | RHODES 3

PO: Free paper session

**HEEGAARD S, MOULIN A**

**3441** 13:30 Improving the overall diagnosis of eyelid margin tumours with in vivo reflectance confocal microscopy


**3442** 13:42 New management of peri-ocular basal cell carcinoma using in vivo and ex vivo confocal microscopes


**3443** 13:54 Cyclin kinase inhibitor p27 is downregulated in conjunctival melanoma

MOULIN A, Schalenbourg A, Zografos L, Nicolas M - Lausanne

**3444** 14:06 Looking for the best mouse model to study retinoblastoma

LEMAITRE S, Poyer F, Cassoux N, Fréneaux P, Thomas C - Paris

**3445** 14:18 Orbital T-cell lymphoblastic lymphoma

HEEGAARD S, Stenman L - Copenhagen

**3446** 14:30 The effect of PAXgene fixation on preservation of morphology and nucleic acids in microdissected retinal tissue

EDWARD D, Liu Y - Baltimore
F13:30 - 15:00 | RHODES 4

**NSPH: Free paper session**

**PARSA C, GRZYBOWSKI A**

3451 13:30 Optic coherence tomography in analyzes of optic nerve and macula in neuro-ophthalmological patients


3452 13:42 Optic nerve Drüsens in black patients: a case series of 16 patients

*SUSTRONCK P, Jean-Charles A, Benzkri R, Merle H - Fort de France*

3453 13:54 Treatment of Leber’s hereditary optic neuropathy with EPI-743: the Brazilian experience


3454 14:06 The influence of lingering fusional adaptation on the Bielschowsky head tilt test in superior obliqueparesis

*IRSCH K, Guyton D, Ying H - Paris*

3455 14:18 Optic disc swelling: Prospective study of sixty-seven patients

*SITBON C, Fel A, Bodaghi B, Le Hoang P, TOUITOU V - Paris*

3456 14:24 Nonarteritic anterior ischemic optic neuropathy (NAION): A misnomer. A non-ischemic papillopathy caused by vitreous separation

*PARSA C, Hoyt W - Paris*

3457 14:30 Ophthalmic insert for pupillary mydriasis in neonates

*BREMOND-GIGNAC D, Jacqz-Aigrain E, Abdoul H, Beresniak A, Baud O, Alberti C - Paris*

3458 14:36 Homonymous hemimacular thinning in retrochiasmal lesions


**13:30 - 15:00 | GALLIENI 1+2**

**MBGE: Cataract genetics**

Cataracts are a major disorder at the eye. It becomes evident that at least in developed countries genetic congenital cataracts are due to mutations either present in a family over generations or appearing de novo in the germ line; recessive mutations become obvious in regions with a larger portion of consanguinity. In this SIS we will discuss recent findings on novel cataract-causing genes in humans and mice. Moreover, we will discuss also the advantage of next-generation sequencing in disease-specific applications.

**GRAW J**

3461 13:30 Mutations in Connexin-encoding genes

*BEYER E, Berthoud V - Chicago, IL*

3462 13:52 Mutation in the Ercc2 gene of the mouse causes cataracts

*GRAW J, Kunze S, Dalke C, Fuchs H, Klaften M, Sabrautzki S, Hrabé de Angelis M - Neuherberg*

3463 14:14 Whole exome sequencing in patients with congenital cataracts

*LISKOVA P - Prague*

3464 14:36 Gene panels and genomic testing for childhood cataract and lens dislocation disorders

*BLACK G C, Hall G, Ramsden S, Lloyd I C - Manchester*
13:30 - 15:00 | GALLIENI 5

EOVS: Free paper session - Oculophysiology assessments

LEINONEN M, WEBER M

3471 13:30 Light-Induced Retinopathy in neonatal rats: A new retinal degeneration slow model
LACHAPELLE P, Polosa A, Ait Igrine W, Chevrolat L A, Bessaklia B - Montreal Quebec

3472 13:42 Clinical evaluation of video imaging technology during visual field exams
CHARLIER J, Zanlonghi X, Defoort-Dhellemmes S - Perenchies

3473 13:54 Using reaction time in visual search and decision making task to measure visual field thresholds in multifixation perimetry
LEINONEN M, Mäntysalo T, Sampinen K, Ojala M - Turku

3474 14:06 Electrophysiological ON and OFF responses in Autosomal Dominant Optic Atrophy
MORNY E, Margrain T, Binns A, Votruba M - Cardiff

3475 14:18 Apparent Contradictions in Pupillomotor, Sensory Visual and Electrodiagnostic Findings in Chiasmal Compression
KRASTEL H, Landauer M, Diehm T, Kubarko A, Schlichtenbrede F - Neckargemünd

3476 14:30 Choroidal thickness changes in response to defocus in emmetropia and in myopia
WEBER M, Esmaeelpour M, Drexler W, Findl O - Vienna
15:00 - 15:45 | HERMES

G: Glaucoma

BLOOM P, SUNARIC MEGEVAND G, VIDAL-SANZ M

**F001**
Receptor-targeted liposome-peptide-siRNA nanoparticles represent a novel and efficient siRNA delivery system to prevent conjunctival fibrosis


**F002**
Leuven Eye Study - Baseline and methods


**F003**
Biomechanical properties of eyes with asymmetrical glaucoma defect

CELLINI M, GIZZI C, Finzi A, Campos E C - Bologna

**F004**
Multicenter clinical trial of high-intensity focused ultrasound treatment in glaucoma patients without previous filtering surgery


**F005**
Comparison of preservative-free latanoprost and bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial


**F006**
Double-hump sign on gonioscopy: definitive plateau iris? A cross-sectional study using ultrasound biomicroscopy

CORDEIRO SOUSA D, Leal I, Caiado F, Goncalves I, Reina M, Marques-Neves C, Prior Filipe H, Abegao Pinto L - Lisbon

**F007**
How accurate are optometrist referrals for glaucoma in the NICE era?

BOBAT H, Begum S, Lockwood A, Kirwan J F - Portsmouth

**F008**
A pilot study of survey on patient satisfaction and its meaning in an Glaucoma outpatient

POURJAVAN S, Vanhaecht K - Brussels

**F009**
Corneal and optic nerve head biomechanical changes after deep sclerectomy

MUNOZ - NEGRETE F J, Rebolleda G, Diez L, Oblanca-Llamazaes N, De Juan V, Casas-Llera P - Madrid

**F010**
Selective laser trabecuoplasty: Results on intraocular pressure and number of topical antiglaucoma medications


**F011**
Primary open angle glaucoma treated by high intensity focused ultrasound (HIFU) with the 2nd generation probe

ROULAND J F, Aptel F - Lille

**F012**
Glaucoma patient satisfaction after switching from preserved treatment to preservative-free latanoprost; results from the PASSY survey in three European countries

MUNOZ - NEGRETE F J, Lemij H, Erb C - Madrid

**F013**
Intraocular pressure in Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency

PINNA A, Blasetti F, Campesi I, Scanu B, Carru C - Sassari

**F014**
Normal tension glaucoma associated with lamina cribrosa defects and complicated of maculopathy: A case report

BESOMBES G, Bachtetti P, Labalette P, Rouland J F - Lille

**F015**
A high oxygen demand in normal tension glaucoma

TURKSEVER C, Todorova M, Orguel S - Baselland

**F016**
Estimated cerebrospinal fluid pressure and trans-lamina cribrosa pressure difference in open angle glaucoma. The Korea National Health and Nutrition Examination Survey 2009-2012


**F017**
Comparison of Humphrey visual field perimetry and new invented PC-based visual field testing system in healthy people and glaucoma patients.

15:00 - 15:45 | HERMES

G: Glaucoma

F018  
Glauc...
PBP: Physiology / Biochemistry / Pharmacology

OSBORNE N, SCHMETTERER L

F037 Nanomedicine and Ophthalmology: looking forward
CORDEIRO SOUSA D, Ferreira Q, Araujo J, Morgado M, Ferreira J, Leal I, Abegao Pinto L, Marques-Neves C - Lisbon

F038 Quantification of total retinal blood flow via dual-beam bidirectional Doppler optical coherence tomography for the assessment of neurovascular coupling
ASCHINGER G, Werkmeister R, Garhöfer G, Schmetterer L - Vienna

F039 Combination of Resveratrol with omega-3 fatty acids synergize to counteract VEGF-R pathway in sick retinal pigment epithelium cells mimicking AMD
CHALONS P, Scaglierini A, Courtaut F, Olmière C, Delmas D - Dijon

F040 Inhibition of micro-fibrillar associated protein 4 as a potential therapy targeting choroidal neovascularisation in age related macular degeneration

F041 Rescue of photoreceptor degeneration by progesterone in an animal model of retinitis pigmentosa

F042 Neuroprotection as a therapeutic target in diabetic retinopathy: a basic approach
DAL MONTE M, Amato R, Biagioni M, Cammalleri M, Casini G - Pisa

F043 Suprachoroidal pocket to collect drugs for treatment of ocular diseases
RODRIGO M J, Prieto E, Idiope M, García-Martín E, Otín S, Polo V - Zaragoza

F044 In-vivo microdialysis as a new technique to assess ocular pharmacokinetics of topically applied drugs in a rabbit model
GARHOFER G, Klaus R, Jäger W, Zeitlinger M, Richter-Müksch S, Schmetterer L - Vienna

F045 Angiotensin Receptor Blockade in Retinopathy of Prematurity: An Experimental Study
NATH M, Kumar A, Chandra P, Singh B, Deorari A K, Velpandian T - New Delhi

F046 Ghrelin inhibits choroid-retinal cell migration, proliferation and in vitro angiogenesis, under a high glucose environment

F047 The diameter regulation of retinal arterioles during systemic hypoxia is impaired in diabetic patients without retinopathy
PETERSEN L, Bek T - Aarhus
15:00 - 15:45 | POSTER AREA

**EOVS: Electrophysiology, Physiological Optics, Vision Sciences**

**LEROY B, PUELL M**

**F048**
Clinical evaluation of Nidek autorefractometer AR-360A
STOOR K, Karvonen E, Liinamaa J, Saarela V - Oulu

**F049**
Assessment of deviation angle and oblique muscle function in strabismus patients using analysis of two-dimensional eye globe pictures in diagnostic gaze positions
BUSHUYEVA N, Romanenko D - Odessa

**F050**
Testing of an automated tablet-based method for the determination of low contrast near visual acuity inophthalmic patients

**F051**
Assessment of interlinked double staircase acuity test
GIULVEZAN S, Gallagher K, Davies N - London

**F052**
Significance of Camouflage, Chromatic Acuity and Contour in the Design of Pseudoisochromatic Plates

**F053**
Comparability and reproducibility of four wavefront aberrometers for measuring lower and higher order aberrations in pseudophakic eyes
NGUYEN P M, Hirnschall N, Doeller B, Schuschtz S, Varsits R, Findl O - Wien

**F054**
The Repeatability of straylight measurements using the C-Quant in young and older adults
PUELL M, Barrio A R, Antona B - Madrid

**F055**
Mesopic Visual Acuity in Type2 Diabetes without Retinopathy

**F056**
Analysis of Mp-1 audio-biofeedback impact on fixation in low vision patient with maculopathy.
SATO G, RIZZO R, Villani G M, Camerucci C - Padova

**F057**
Frequency-Doubling Perimetry in Type2 Diabetes without Retinopathy

**F058**
Presbyopia compensation: looking for cortical predictors
IMBEAU L, Majzoub S, Thillay A, Bonnet-Brilhaut F, Pisella P J, Batty M - Tours

**F059**
Three family cases with Retinitis pigmentosa rod-cone dystrophy with autosomal dominant inheritance
KOEV K - Sofia

**F060**
Application of low-level Laser therapy (LLLT) in patients with Retinitis Pigmentosa (RP)
KOEV K - Sofia

**F061**
Female heterozygotes of X-linked ocular disease in the era of molecular diagnostics
KREPS E O, De Zaeytjid J, De Baere E, Leroy B P - Ghent

**F062**
Multifocal electroretinogram and en-face OCT in patients who underwent retinal detachment surgery
RICOUARD F, Bigan G, Tumahai P, Flores M, Castelbou M, Delbosc B, Saleh M - Besancon

**F063**
The STZ-induced diabetic rat as a model for studying neuronal pathologies of diabetic retinopathy
HERRMANN R, Zippel N, Haller J, Streicher R - Biberach an der Riss

**F064**
Evidence for a new model of the human eye - a holographic laser system, biophotonics. The holographic view
MANU M D, Plesu G - Iasi

**F065**
Bioluminescence - Biological Laser Phenomenon initiated by eye. Biophotonic tests.
MANU M D - Iasi

**F066**
Modulation of the contrast response function of V1 neurons by the pulvinar
CASANOVA C, Lai J, Thomas S - Montreal

**EVER 2015**
Friday, Oct 9 - Poster session 2
15:00 - 15:45 | POSTER AREA

LC: Lens and Cataract

LÖFGREN S, KRONSCHLÄGER M

F067 Evaluation of a portable manual stretching device to simulate accommodation
D’ANTIN J C, Pinilla Cortés L, Montenegro G A, Barraquer R I, Michael R - Barcelona

F068 Objective assessment of cataract: Comparison between the Lens Opacities Classification System III and a Scheimpflug camera

F069 Cataract surgery in adult patients with uveitis
BACQUET J L, Fel A, Butel N, Remond A L, Le Hoang P, Bodaghi B - Paris

F070 Anterior segment changes after femtosecond cataract surgery measured with optical coherence tomography and scheimpflug imaging technology

F071 Anterior chamber and refractive parameters in diabetic patients according to metabolic status

F072 New Parameter for Predicting the Postoperative IOL Position: Preoperative Lens Equator Depth measured By Three-Dimensional Anterior Segment Optical Coherence Tomography
HWANG K Y, Joo C K, Yoon G Y - Daejon

F073 Impact of a pre-cut on clear cornea incision architecture in cataract surgery
DRASCHL P, Hirnschall N, Doeller B, Nguyen P M, Findl O - Vienna

F074 Small pupil and pupil dilatation methods. Comparative study in cataract surgery

F075 Effects of optic’s shape for contraction of anterior capsulorhexis
MAYUMI N, Hiroyuki M, Tadashi S - Tochigi

F076 Effect of Preconditioning Intraocular Lenses in Moxifloxacin Solution

F077 Thermal cataract induced by near infrared radiation (IRR)
YU Z, Schulmeister K, Talebizadeh N, Kronschläger M, Söderberg P - Uppsala
PO: Poster session: Pathology / Oncology in Poster area

KILIC E , VAN GINDERDEUREN R

F078  
Uveal melanoma and renal cell carcinoma both metastatic to the liver  
TURUNEN J , Markkinen S , Wilka R , Kivelä T - Helsinki

F079  
Clinical Experience with the Ruthenium- plaque Brachytherapy in Case of Choroidal Melanoma  
GRAJEWSKI L , Kneifel C , Ciernik I , Ebrahimi F , Krause L - Dessau

F080  
The Liverpool Uveal Melanoma Prognosticator Online (LUMPO) for prognosing metastasis free survival in the absence of cytogenetic data after ruthenium brachytherapy for uveal melanoma  
ROSPOND-KUBIAK I , Wroblewska-Zierhoffer M , Twardosz-Pawlik H , Kociecki - Poznan

F081  
3D Sphere cultures of uveal melanoma reveal a molecular signature with a potential target for cancer therapy  
NESS C , Garred Ø , Eide N , Bærland T , Nicolaiissen B , Moe M C , Noer A - Oslo

F082  
Intravitreal chemotherapy in advanced retinoblastoma:results and complications  
HADJISTILIANOUT , Borri M , De Francesco S , Sparagna C - Sienna

F083  
Clinical characteristics and surgical outcomes of mesectodermal leiomyoma of the ciliary body and choroid  
PARK H J , Lee J H , Lee S C - Seoul

F084  
Case report of ring ciliary body and choroidal lymphoma.  
BOGDALI A , Markiewicz A , Jakubowska B , Romanowska-Dixon B - Krakow

F085  
Immunohistochemical characterization of a retinal hamartoma  
VAN GINDERDEUREN R , Stalmans P - Leuven

F086  
New device to applanate full thickness eyelid tumours for ex vivo confocal microscopy  

F087  
A case report of eyelid basal cell carcinoma with orbital invasion : an alternative to exenteration  
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>F088</td>
<td>Reduced retinal nerve fibre layer thickness in multiple sclerosis patients with and without history of optic neuritis</td>
<td>GRZYBOWSKI A, BOSCHI A</td>
</tr>
<tr>
<td>F089</td>
<td>Retinal thickness in children with anisohypermetropic amblyopia</td>
<td>TOMO N, Nahoko O - Kashihara</td>
</tr>
<tr>
<td>F090</td>
<td>Seasonal variation of the pupil light reflex</td>
<td>KOURTI P, Münch M, Collomb S, Kawasaki A - Lausanne</td>
</tr>
<tr>
<td>F094</td>
<td>Visual functions in children with congenital myopia and with amblyopia with the same refraction</td>
<td>BOYCHUK I, Mukhina A - Odessa</td>
</tr>
<tr>
<td>F095</td>
<td>Stereovision in patients with intermittent exotropia before and after surgical treatment</td>
<td>BOYCHUK I, Tarak A - Odessa</td>
</tr>
<tr>
<td>F097</td>
<td>Comparison of effective group and refractory group to alternative patch treatment in overcorrected intermittent exotropia</td>
<td>LEE S J, Kim J Y, Park J M - Busan</td>
</tr>
<tr>
<td>F098</td>
<td>Ptosis and diplopia after incidental botulinum powder exposure</td>
<td>CHO M - Seoul</td>
</tr>
<tr>
<td>F099</td>
<td>Consecutive esotropia in contralateral recess-resect for recurrent intermittent exotropia after unilateral recess-resect</td>
<td>CHO SY, Lee SY - Gyeongju</td>
</tr>
<tr>
<td>F100</td>
<td>Ophthalmic insert for pupillary mydriasis in neonates</td>
<td>BREMOND-GIGNAC D, Jacqz-Aigrain E, Abdoul H, Beresniak A, Baud O, Alberti C - Paris</td>
</tr>
<tr>
<td>F101</td>
<td>Comparison of long-term surgical outcomes of 2-muscle surgery in intermittent exotropia: Bilateral vs Unilateral</td>
<td>CHO SY, Lee SY, Bang S P, Lee Y C - Gyeongju</td>
</tr>
<tr>
<td>F102</td>
<td>Diplopia as presenting sign of Turcot syndrome</td>
<td>NINCLAUS V, Walreadt S, Baert E, Laureys G, De Zaeytijd J - Gent</td>
</tr>
<tr>
<td>F103</td>
<td>Double depressor palsy after bilateral paramedian thalamus infarction</td>
<td>KIM S J, Lee S - Busan</td>
</tr>
<tr>
<td>F104</td>
<td>Correlation between peripapillary retinal thickness and serum level of vascular endothelial growth factor in patients with POEMS syndrome</td>
<td>YOKOUCHI H, Baba T, Oshitari T, Yamamoto S - Chiba</td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>-----</td>
<td>-----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>F105</td>
<td>Late ocular changes after closantel (Flukiver) poisoning</td>
<td>ASOKLIS R, Augyte A, Cimbalas A - Vilnius</td>
</tr>
<tr>
<td>F106</td>
<td>Sarcoidosis of orbita and central nervous system presenting as a non-arteritic ischemic optic neuropathy.</td>
<td>DE BRUYN D, Ninclaus V, Leroy B, De Schryver I, De Zaeytijd J - Ghent</td>
</tr>
<tr>
<td>F107</td>
<td>Optic disc drusen with subretinal hemorrhage</td>
<td>HALFELD FURTADO DE MENDONCA R, De Oliveira Maia JR. O - Rome</td>
</tr>
<tr>
<td>F108</td>
<td>Sarcoidosis of orbita and central nervous system presenting as a non-arteritic ischemic optic neuropathy.</td>
<td>DE BRUYN D, Ninclaus V, Leroy B, De Schryver I, De Zaeytijd J - Ghent</td>
</tr>
<tr>
<td>F109</td>
<td>Optic disc drusen with subretinal hemorrhage</td>
<td>DE BRUYN D, Ninclaus V, Leroy B, De Schryver I, De Zaeytijd J - Ghent</td>
</tr>
<tr>
<td>F110</td>
<td>Optic disc swelling: Prospective study of sixty-seven patients</td>
<td>SITBON C, Fel A, Bodaghi B, Le Hoang P, Touitou V - Paris</td>
</tr>
<tr>
<td>F111</td>
<td>The Damato Multifixation Campimetry Online (DMCO) - A possible visual field test to detect neurological visual field defects</td>
<td>STEENSBERG AT, Olsen A S, Pinborg L H, Kolko M - Copenhagen</td>
</tr>
</tbody>
</table>
15:45 - 16:15

Section Business Meetings

- ACB .................. Gallieni 5
- COS .................. Rhodes 2
- EOVS ................ Rhodes 1
- G ..................... Rhodes 1
- IM ..................... Rhodes 4
- LC ..................... Hermes
- MBGE ............... Gallieni 1 & 2
- NSHP ............... Rhodes 2
- PO ..................... Rhodes 3
- PBP ..................... Rhodes 3
- RV ..................... Hermes

Agenda

1. Report of the chair of section

2. Report of the programme secretary

3. Next year’s meeting:
   - nomination of the 2016 section programme secretary (different from the section chair)
   - proposals of 2016 Special Interest Symposia (SIS)
   - proposals of 2016 Courses
   - proposals for 2017 Keynote speakers

4. Comment on the EVER activities

5. Other business

In addition to the agenda, the sections IM and PBP will nominate at least 2 candidates for section chair 2016-2021.
### RV: Vitreoretinal macular interface in various macular pathologies

Vitreoretinal macular interface disorders are of great interest since the introduction of vitreolysis as an alternative to surgical approach. Their association to different macular pathologies will be discussed separately, as idiopathic condition, diabetes, venous occlusions and High myopia.

**POURNARAS JA, LE MERY**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3511</td>
<td>16:20</td>
<td>Evaluation of the vitreoretinal interface</td>
<td>GUALINO V - Montauban</td>
<td></td>
</tr>
<tr>
<td>3512</td>
<td>16:38</td>
<td>Vitreoretinal traction syndrome</td>
<td>LE MERY - Paris</td>
<td></td>
</tr>
<tr>
<td>3513</td>
<td>16:56</td>
<td>Diabetic maculopathy</td>
<td>POURNARAS JA - Lausanne</td>
<td></td>
</tr>
<tr>
<td>3514</td>
<td>17:14</td>
<td>Venous occlusions</td>
<td>PAQUES M - Paris</td>
<td></td>
</tr>
<tr>
<td>3515</td>
<td>17:32</td>
<td>High myopia</td>
<td>STANGOS A - Geneva</td>
<td></td>
</tr>
</tbody>
</table>

### G: Healthcare delivery - The traditional role of the doctor is changing

Financial restrictions in healthcare delivery, imposed by the economical and social factors, leads inevitably to innovation in the organization of the care. There is a trend for disruptions of healthcare professionals, as specialists concentrate on curing the most complex and sickest patients, the "less-skilled" practitioners could take on more complex role (Christensen C, Harvard Business Review, 2000). Our SIS concentrates on "Lean management", "disruptive innovations in healthcare" and "patient-centeredness". The lecture of the first speaker, the CEO (non-medical professional) of the University Hospitals in Brussels concentrates on the challenges that a university hospitals encounters because of the governmental restrictions. The medical professionals explain the changing role of the specialists. Very interesting SIS to attend which gives new insights of organization of the healthcare for the professionals.

**POURJAVAN S, KOTECHA A**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3521</td>
<td>16:20</td>
<td>Healthcare delivery, not just about the doctor and the patient</td>
<td>MAZY R - Bruxelles</td>
<td></td>
</tr>
<tr>
<td>3523</td>
<td>16:56</td>
<td>Optometrists and the management of glaucoma; the Rotterdam experience</td>
<td>LEMIJ H - Rotterdam</td>
<td></td>
</tr>
<tr>
<td>3524</td>
<td>17:14</td>
<td>Can ophthalmic technicians be used to deliver glaucoma care?</td>
<td>KOTECHA A - London</td>
<td></td>
</tr>
<tr>
<td>3525</td>
<td>17:32</td>
<td>Patient-focused glaucoma care delivery, maintaining quality despite cost limitation</td>
<td>POURJAVAN S - Brussels</td>
<td></td>
</tr>
</tbody>
</table>
## COS: Immune regulation in cornea and ocular surface

This session will present new insights into the role of immune Regulation on physiology and pathology of cornea and ocular surface.

**DANA R , SABAN D**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3531</td>
<td>16:20</td>
<td>Corneal nerves maintain the immune privilege of the cornea</td>
<td>HAMRAH P - Wellesley</td>
</tr>
<tr>
<td>3532</td>
<td>16:38</td>
<td>Immune Responses at the Ocular Surface</td>
<td>SABAN D R - Durham</td>
</tr>
<tr>
<td>3533</td>
<td>16:56</td>
<td>Immunomodulation in allergic eye disease</td>
<td>CALDER V - London</td>
</tr>
<tr>
<td>3534</td>
<td>17:14</td>
<td>Tregs in corneal health and disease</td>
<td>DANA R - Boston MA</td>
</tr>
<tr>
<td>3535</td>
<td>17:32</td>
<td>The Role of Antigen Presenting Cells in the Pathophysiology of Dry Eye</td>
<td>STERN M E - Irvine</td>
</tr>
</tbody>
</table>

## PO: Ocular lymphomas

Lymphoproliferative diseases may affect the eye and the adnexae under two main patterns: on the one hand, high-grade, B-cell lymphomas affecting the vitreous, retina and central nervous system, and low-grade, ‘MALT’ lymphomas affecting the orbit and palpebral tissue on the other. The scope of this SIS is to bring together pathologists, clinical haematologists, orbital and retino-vitreal surgeons to focus on the histological, clinical, surgical and medical issues of ocular lymphomas in 2015.

**ROBERT P Y , COUPLAND S**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3541</td>
<td>16:20</td>
<td>Update on lymphoma diagnostic</td>
<td>COUPLAND S - Liverpool</td>
</tr>
<tr>
<td>3542</td>
<td>16:38</td>
<td>Vitreoretinal Lymphomas</td>
<td>CASSOUX N - Paris</td>
</tr>
<tr>
<td>3543</td>
<td>16:56</td>
<td>Orbital and palpebral lymphomas</td>
<td>ROBERT P Y , Flausse R - Limoges</td>
</tr>
<tr>
<td>3544</td>
<td>17:14</td>
<td>Imaging and Biopsies</td>
<td>VAN GINDERDEUREN R - Leuven</td>
</tr>
<tr>
<td>3545</td>
<td>17:32</td>
<td>Medical treatment of Lymphoma in 2015</td>
<td>BORDESSOULE D - Limoges</td>
</tr>
</tbody>
</table>
**LC: Oxidation and defense in the ocular lens**

First, experimental evidence for apoptosis in the lens after in vivo oxidative stress will be presented. Then, the spatial distribution of active caspase-3 in the lens and its response to in vivo oxidative stress after exposure to UVR will be reviewed. Subsequently, response in the immunoproteasome in human lens epithelial cells during oxidative stress will be reviewed. Thereafter, the role of estrogen as an antioxidant in the lens will be presented based on experimental and clinical data. Finally, evidence for protection against in vivo oxidative stress with the extrinsic antioxidant caffeine will be presented.

**SÖDERBERG P , ZETTERBERG M**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3551</td>
<td>16:20</td>
<td>Apoptosis in the lens after oxidative stress induced by in vivo exposure to UVR</td>
<td>GALICHANIN K - Stockholm</td>
</tr>
<tr>
<td>3552</td>
<td>16:38</td>
<td>Active caspase-3 in the lens and its response to oxidative stress induced by in vivo exposure to UVR</td>
<td>TALEBIZADEH N - Uppsala</td>
</tr>
<tr>
<td>3553</td>
<td>16:56</td>
<td>The immunoproteasome in human lens epithelial cells during oxidative stress</td>
<td>PETERSEN A , Zetterberg M - Göteborg</td>
</tr>
<tr>
<td>3554</td>
<td>17:14</td>
<td>Estrogen as an antioxidant in the lens</td>
<td>ZETTERBERG M - Mölndal</td>
</tr>
<tr>
<td>3555</td>
<td>17:32</td>
<td>Caffeine, an in vivo oxidation protectant in the lens</td>
<td>KRONSCHLAGER M , Yu Z , Talebizadeh N , Söderberg P - Freiburg</td>
</tr>
</tbody>
</table>

**MBGE: Identification of novel mouse models for hereditary eye disorders**

The mouse is one of the most frequently used models for genetic eye diseases. Therefore, it is of particular importance to have standardized phenotyping procedures allowing a fast and reliable diagnosis of genetic defects affecting the eye. Therefore, several mouse phenotyping centers have been established and are coordinated on an international level (International Mouse Phenotyping Consortium -IMPC; http://www.mousephenotype.org/). In Europe, four mouse clinics (Munich, Strasbourg, Harwell and Cambridge) exist and are screening for eye disorders. We would like to discuss the different strategies to identify as many eye disorders in the mouse as possible on the most efficient way under high-throughput conditions. Moreover, selected recent findings will be reported which can be used as models for several hereditary eye disorders.

**GRAW J**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3561</td>
<td>16:20</td>
<td>Novel mouse phenotypes identified in the eye screen of the German Mouse Clinic</td>
<td>AMARIE O V , Fuchs H , Gailus-Durner V , Hrab de Angelis M , Graw J - Neuherberg</td>
</tr>
<tr>
<td>3563</td>
<td>17:04</td>
<td>The eye screen design in Czech Centre for Phenogenomics and selected models for eye diseases</td>
<td>ANTOSOVA B , Smolikova J , Zilova L , Lachova J , Bendova M , Machon O , Kozmik Z - Prague</td>
</tr>
<tr>
<td>3564</td>
<td>17:26</td>
<td>Angiography reveals novel features of the retinal vasculature in mice</td>
<td>RUBERTE J - Ceradanyola del Valles</td>
</tr>
</tbody>
</table>
16:20 - 17:50 | GALLIENI 5

G: Free paper session - Experimental glaucoma

STALMANS I , BRON A

3571  16:20  The Effect of Hypertension on Intraocular Pressure and Apoptosis of Retinal Ganglion Cell Through ET-1 Signaling Pathway Activation in Trabecular Meshwork of Hypertension Rat Model

3572  16:32  TrkB signaling in Müller glia stimulates neuroprotection after optic nerve injury
HARADA T , Namekata K , Guo X , Kimura A , Harada C - Tokyo

3573  16:44  Downregulating the Myocardin-related transcription factor/ Serum response factor (MRTF/ SRF) pathway is a novel therapeutic approach to prevent post-surgical fibrosis in glaucoma.

3574  16:56  In vivo modified peripheral glia enhance regenerative capacity in a rat retina

3575  17:08  MMP-9 null mice display elevated IOP due to reduced aqueous humor drainage from the trabecular meshwork

3576  17:20  Neuroprotective modifications in retinal Müller cells due to oxidative stress and energy restriction
TOFT-KEHLER A K , Gurunbaram R , Brandstrup C , Desler C , Rasmussen L , Skytt D , Kolko M - Copenhagen
EVER General Assembly

1. President’s address by Bart Leroy
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Marcela Votruba
5. Report of the Treasurer, Steffen Heegaard:
   - approval of the accounts 2014
   - discharge to the directors
   - approval budget for 2015
6. Results of the elections
7. Presentation of the board 2016
8. Future congresses
9. Miscellanea
10. Handover of chain of office
Friday, Oct 9 - Congress Dinner

20:00 - 23:00 | NEGRESCO
EVER Congress dinner in Negresco
EVER 2015
Saturday, Oct 10 - First morning session

8:00 - 8:30 | HERMES
Coffee and Croissants

8:30 - 10:00 | HERMES
RV: Diabetic macular edema in vitrectomized eyes

Conventional theory explains that poor visual outcomes following surgical treatment of proliferative diabetic retinopathy are the result of macular ischemia, long standing traction retinal detachment of the macula or advanced fibrovascular proliferation beyond surgical repair. In some cases, cystoid macular edema (CME) may be a prominent finding on optical coherence tomography (OCT) and may account for the observed limited visual outcomes following pars plana vitrectomy (PPV) surgery. In the present SIS, we present the spectrum of conditions where CME has been reported after PPV, the importance of imaging technology in the management of CME and will concentrate on CME post PPV surgery in diabetic patients. Pharmacokinetic data and clinical efficacy data of treatment with anti-VEGF agents and periocular and intravitreal steroids are presented for the management of CME in diabetic vitrectomized eyes.

XIROUT , ZAMBARAKJI H

4111 8:30 Introduction: DME in vitrectomized eyes
XIROUT - Glyfada

4112 8:48 Imaging of DME in vitrectomized eyes
POURNARAS JA - Lausanne

4113 9:06 Pharmacokinetics of anti-VEGF and steroid agents in vitrectomized eyes with diabetic macular edema
PAPASTEFANOU V - London

4114 9:24 The role of Anti-VEGFs in the management of DME in vitrectomized eyes
KOURENTIS C - Athens

4115 9:42 Steroids agents in the management of vitrectomized eyes with diabetic macular edema
ZAMBARAKJI H , Papastefanou V , Dooley I - London

8:30 - 10:00 | RHODES 1
Subspecialty exam and diploma in Europe: Why, when and how

The EBO has gained worldwide respect for its efforts on harmonizing education and training in general ophthalmology within Europe. The comprehensive EBO Diploma examination, organised annually since 1995, awards successful candidates the title of the Fellow of the European Board of Ophthalmology (FEBO), and is the most evident result of such efforts. More recently the EBO has established a Subspecialty European Board of Ophthalmology Diploma Examination with the goal to increase standards of knowledge and care in various subspecialties. The EBO is realising this goal by close collaboration with different European ophthalmological subspecialty societies who are actively taking part in the organization and realization of the EBO Subspecialty Examinations allowing an official and standardized evaluation and awarding of knowledge in various specialties. The first of these subspecialty examinations to be introduced is in the field of glaucoma and is developed in close collaboration with the European Glaucoma Society (EGS). The goals, the organisation and requirements to sit the subspecialty exam as well as the first experience with the FEBO-Glaucoma exam and Diploma will be presented.

RINGENS P , GRUPCHEVA H

4121 8:30 Why do we need a subspecialty exam?
ACLIMANDOS W - London

4122 8:48 What are the general requirements for candidates to sit the exam
MIDENA E - Padova

4123 9:06 How does EBO manage expertise of MCQ’s?
TASSIGNON M - J - Edegem

4124 9:24 EBO-EGS exam in glaucoma; our first experience in 2015?
SUNARIC MEGEVAND G - Geneva

4125 9:42 Future plans: Exams in retina, paediatrics, cataract and cornea
CREUZOT C - Dijon
### COS: Infectious keratitis

**8:30 - 10:00 | RHODES 2**

**This session will give focus on the pathology and promising new therapies of infectious Keratitis.**

**GRIFFITH M, BEUERMAN R**

<table>
<thead>
<tr>
<th>Session Number</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4131</td>
<td>8:30</td>
<td>Infectious keratitis and the distribution in Asia</td>
<td>BEUERMAN R - Singapore</td>
<td></td>
</tr>
<tr>
<td>4134</td>
<td>9:36</td>
<td>Antibiotic resistance and new types of antimicrobials</td>
<td>BEUERMAN R - Singapore</td>
<td></td>
</tr>
</tbody>
</table>

### PO: OOG Ocular Oncology Group 1

**8:30 - 10:00 | RHODES 3**

**DESJARDINS L, KIVELÄ T**

<table>
<thead>
<tr>
<th>Session Number</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4141</td>
<td>8:30</td>
<td>Uveal melanoma and other cancers</td>
<td>DESJARDINS L, Villaret J, Cassoux N, LumbrosoLeRouic L, Levy C, Plancher C, Savignoni A - Paris</td>
<td></td>
</tr>
<tr>
<td>4142</td>
<td>8:42</td>
<td>Uveal melanoma in Finnish patients with congenital ocular melanocytosis</td>
<td>MAMUNUR R, Kivelä T - Helsinki</td>
<td></td>
</tr>
<tr>
<td>4143</td>
<td>8:54</td>
<td>Spectral-domain EDI-OCT in small uveal melanoma and «pseudomelanomas»</td>
<td>SAAKYAN S, Neroev V, Myakoshina E, Zaitseva O - Moscow</td>
<td></td>
</tr>
<tr>
<td>4144</td>
<td>9:06</td>
<td>BAP1 correlates with metastasis in polyploid uveal melanoma</td>
<td>KILIC E, Yavuzyigitoglu S, Mensink H, Vaarwater J, Naus N, Paridaens D, De Klein A - Rotterdam</td>
<td></td>
</tr>
<tr>
<td>4145</td>
<td>9:18</td>
<td>Proteomic analysis of the uveal melanoma (UM) secretome reveals novel insights and potential biomarkers</td>
<td>ANGI M, Kalirai H, Coupland S - Liverpool</td>
<td></td>
</tr>
</tbody>
</table>
### 8:30 - 10:00 | RHODES 4

**IM: Free paper session - Mechanisms in inflammatory disease to outcomes of novel therapies, part 2**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4151</td>
<td>Comparison of retinal and choroidal involvement in tuberculous chorioretinitis in a non-endemic area.</td>
<td>MASSY R, Herbst C P - Sierre</td>
<td></td>
</tr>
<tr>
<td>4152</td>
<td>Impact of disease modifying anti-rheumatic drugs (DMARDs) on the uveitis risk in juvenile idiopathic arthritis</td>
<td>TAPPEINER C, Klotsche J, Schenck S, Niewerth M, Minden K, Heiligenhaus A - Bern</td>
<td></td>
</tr>
<tr>
<td>4155</td>
<td>Long-Term Safety of Intravitreal Sirolimus for the Treatment of Non-infectious Uveitis (NIU) of the Posterior Segment: 12-Month SAKURA Study 1 Results</td>
<td>BODAGHI B, Pavesio C, Alfredo A C, Valentine M E - Paris</td>
<td></td>
</tr>
<tr>
<td>4156</td>
<td>Ophthalmologic manifestations of the granulomatosis with polyangiitis (Wegener)</td>
<td>TOUETE A, Touitou V, Bodaghi B, Lehoang P, Saadoun D, Hie M, Schoindre Y - Le Kremlin Bicetre</td>
<td></td>
</tr>
</tbody>
</table>

### 8:30 - 10:00 | GALLIENI 1+2

**NSPH: ABC in retina structure and function**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4161</td>
<td>General structure of the retina</td>
<td>GRZYBOWSKI A - Poznan</td>
<td></td>
</tr>
<tr>
<td>4162</td>
<td>Retinal vasculature structure and function</td>
<td>SCHMETTERER L - Vienna</td>
<td></td>
</tr>
<tr>
<td>4163</td>
<td>The RPE/photoreceptor complex</td>
<td>OSBORNE N - Oxford</td>
<td></td>
</tr>
<tr>
<td>4164</td>
<td>Retinal glial cells</td>
<td>REICHENBACH A - Leipzig</td>
<td></td>
</tr>
<tr>
<td>4165</td>
<td>The On/OFF system pathway of the retina</td>
<td>CASTELO-BRANCO M - Coimbra</td>
<td></td>
</tr>
</tbody>
</table>
8:30 - 10:00 | GALLIENI 5

**ACB: Free paper session - Molecular and morphological studies in ocular diseases**

**PETROVSKI G , KOLKO M**

**4171**  
8:30  
MicroRNA-124 regulates transforming growth factor 1-induced epithelial-mesenchymal transition in the retinal pigment epithelium by Down-regulating expression of the RhoG  
JUN J H , Joo C K - Daegu

**4172**  
8:42  
Spontaneous and mechanically induced Ca2+ activity changes in hESC-RPE cells during maturation  
ABU KHAMIDAKH A , Juuti-Uusitalo K , Caetano dos Santos F , Skottman H , Hytinen J - Tampere

**4173**  
8:54  
Inflammasome activation by UVB irradiation in human corneal epithelial cells  
KAUPPINEN A , Korhonen E , Piippo N , Hytti M , Kaarniranta K - Kuopio

**4174**  
9:06  
Anatomical digital image analysis of the angle and optic nerve - a novel method for glaucoma imaging  

**4175**  
9:18  
Fisetin and Luteolin decrease inflammation and oxidative stress-induced cytotoxicity in ARPE-19 cells  
HYTTI M , Piippo N , Korhonen E , Kaarniranta K , Kauppinen A - Kuopio

**4176**  
9:24  
cis-Urocanic acid prevents inflammation and cell death in UVB-treated ARPE-19 cells  
KORHONEN E , Piippo N , Hytti M , Kaarniranta K , Kauppinen A - Kuopio

**4177**  
9:30  
Anterior lens epithelium in cataract patients with retinitis pigmentosa - scanning and transmission electron microscopy study  
ANDJELIC S , Drašlar K , Hvala A , Hawlina M - Ljubljana

**4178**  
9:36  
The study of needle tip aspirates and entry sites after intravitreal injections with different needle types  
LYTVYNCHUK L , Savytska I , Sergiienko A , Binder S , Petrovski G - Lviv
### RV: Retina / Vitreous

#### Poster Session 3: Saturday, Oct 10

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>S001</td>
<td>Posterior vitreous detachment: more a case of the fibronectin interface than the inner limiting membrane?</td>
<td>Etienne I, Jonckx B, Feyen J - Leuven</td>
</tr>
<tr>
<td>S002</td>
<td>Improvement in retinal vessel oxygen saturation after vitrectomy</td>
<td>Lim S L, Tan L, Perera S - Singapore</td>
</tr>
<tr>
<td>S005</td>
<td>Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage</td>
<td>Zahaf A, Zghal I, Fekih O, Zayani M, Mahjoub A, Bouguila H, Nacef L - Tunis</td>
</tr>
<tr>
<td>S006</td>
<td>Management of Acute Submacular Haemorrhage: Royal Free Hospital Experience</td>
<td>Sim SY, Elhouseini Z, Maragkos I, Asaria R - London</td>
</tr>
<tr>
<td>S007</td>
<td>Management of Unexplained Haemorrhagic PVD at Southampton Eye Casualty Clinic</td>
<td>Shalaby A, Tossounis C, Andrew M - Southampton</td>
</tr>
<tr>
<td>S009</td>
<td>The use of intraoperative spectral domain optic coherence tomography in vitreoretinal surgery: The evaluation of efficacy.</td>
<td>Lytvynchuk L, Glittenberg C, Binder S - Lviv</td>
</tr>
<tr>
<td>S010</td>
<td>Epiretinal membrane peeling for eyes with asteroid hyalosis: a case-control study</td>
<td>Mouna A, Conart J B, Kurun S, Ameloot F, Berrod J P - Vandoeuvre les Nancy</td>
</tr>
<tr>
<td>S012</td>
<td>Clinical outcome of YAG laser vitreolysis (Ultra Q Reflex®) for the treatment of floaters</td>
<td>Kim E, Kim H K, Yoo TY - JeonJu</td>
</tr>
<tr>
<td>S014</td>
<td>Wide-Field Angiography in the management of retinal vasculitis</td>
<td>El Mat ri Hassa Iri A, Chebil A, Bouadi M, Ort F, El Matri L - Tunis</td>
</tr>
<tr>
<td>S015</td>
<td>Toxoplasma chorioretinitis: value of polymerase chain reaction and intraocular antibody production in a patient with negative anti-Toxoplasma gondii serology</td>
<td>Roels D, Nerinckx F, Leroy B P, Padalke E, De Schryver I - Ghent</td>
</tr>
<tr>
<td>S016</td>
<td>Intravitreal Cysticercosis</td>
<td>Halfeld Furtado de Mendonca R, De Oliveira Maia JR. O - Rome</td>
</tr>
<tr>
<td>S017</td>
<td>Choroidal thickness in patients with central serous chorioretinopathy: Assessment of hallar’s and sattler’s layers</td>
<td>Kim SW, Chung Y R, Kim J W, Lee K - Seoul</td>
</tr>
<tr>
<td>S018</td>
<td>Our experience with anti-VEGF treatment on central serous retinopathy</td>
<td>Papavasileiou E, Younis S - London</td>
</tr>
</tbody>
</table>
10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous

S019  
Mineralocorticoid receptor’s antagonists in treatment of central serous chorioretinopathy  

S020  
Oral eplerenone as a first line treatment in chronic central serous chorioretinopathy: A case series evaluation  

S021  
Novel SRPK1 inhibitors specifically target alternative splicing in human primary retinal epithelial cells  

S022  
Association between drusen and blood test results in a colony of 1,174 monkeys  
NISHIGUCHI K, Yokoyama Y, Fujiyama Y, Furukawa T, Ono F, Shimozawa N, Togo M, Suzuki M, Nakazawa T - Sendai

S023  
Age Macular Degeneration-Lipidomic Study: Relevance and interest of Lipidomic study in screening, follow-up and etiopathogeny of AMD  
GONZALEZ C, Bertrand-Michel J - Toulouse

S024  
AMD Drusenoid deposits “L” Lipid type, characterization, structural analysis with multimodal imaging and morphology-structural software  
GONZALEZ C, Lay B - Toulouse

S025  
AMD Drusenoid deposits “P” Protein-Cellular Type: Characterization and Evolution. Multimodal imaging and OCT, OCT en Face, Evaluation and Interest.  
GONZALEZ C - Toulouse

S026  
Long term outcomes in a real life setting treatment by anti-vascular endothelial growth factor for wet age-related macular degeneration  

S027  
Efficacy of intravitreal Aflibercept in patients with neovascular AMD who were previously treated with Ranibizumab based on a Treat and Extend protocol  
TURKSEVER C, Prunte C, Hatz K - Baselland

S028  
Visual outcome following treatment with aflibercept in patients with neovascular age-related macular degeneration  
SANDER B, Rasmussen A, Lund-Andersen H - Glostrup

S029  
The protective effect of anti-blue lens against photo-induced cell death  
YU WY, Shan SW, To C H, Chan H H L - Hong Kong

S030  
Microbiology of conjunctiva sac in intravitreal injections.  
GRZYBOWSKI A, Gaca-Wysocka M, Paluch M - Olsztyn

S031  
Endophthalmitis associated with intravitreal Ranibizumab: Microbiology and visual outcomes.  
PENWARDEN A, Weston K, Lockwood A - Portsmouth

S032  
Functional Expression of Toll-Like Receptors in Human Retinal and Choroidal Vascular Endothelial Cells  
STEWART E, Wei R, Branch M, Sidney L, Amoaku W - Nottingham

S033  
Spontaneous oscillations in the diameter of retinal arterioles from normal persons decrease with age.  
RAGUNATHAN S, Taborsky J, Bek T - Aarhus

S034  
Real Time, In Vivo Analysis of the Onset of Retinogenesis: Assessment of the Retinal Vascular Plexus, Electrophysiological Response and Architecture in Neonatal Mice  
DENIRO M, AlQahtani A, AlAhmar S, AlMohanna F - Riyadh
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>S035</td>
<td>Effects of selective retina therapy on retinal oxygen saturation compared to conventional</td>
<td>Kim J R, Roh Y J</td>
<td>Seoul</td>
</tr>
<tr>
<td></td>
<td>photocoagulation in rabbits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S036</td>
<td>The effects of nitroglycerine and COX-inhibition on retinal vessel diameters during hypoxia</td>
<td>Kay A M, Petersen L, Bek T</td>
<td>Aarhus</td>
</tr>
<tr>
<td>S037</td>
<td>Lack of tone response in retinal arterioles secondary to electrical field stimulation</td>
<td>Kratholm N, Simonsen U, Jensen P S, Kringelholt S, Bek T</td>
<td>Aarhus C</td>
</tr>
<tr>
<td>S038</td>
<td>New generation analysis of thrombin generation in retinal vein thrombosis</td>
<td>Fruschelli M, Capozzoli M, Scapellato C, Calzoni P, Puccetti L</td>
<td>Siena</td>
</tr>
<tr>
<td>S039</td>
<td>Comparison of the lamina cribrosa thickness of patients with unilateral branch retinal vein</td>
<td>Sagon M, Lim S H, Kim M, Chang W</td>
<td>Daegu</td>
</tr>
<tr>
<td></td>
<td>occlusion and normal subjects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S040</td>
<td>Effect of intravitreal bevacizumab on choroidal thickness in eyes with retinal vein occlusion</td>
<td>Kuoliene K, Malysko K, Cimbalas A, Asoklis R</td>
<td>Vilnius</td>
</tr>
<tr>
<td></td>
<td>and diabetic macular oedema</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S041</td>
<td>Evolution of hiperreflective points after intravitreal dexamethasone implant injection in</td>
<td>Almenara Michelle N, Ascaso F J, Idoate A, Caramello C, Sanchez J I,</td>
<td>Zaragoza</td>
</tr>
<tr>
<td></td>
<td>patients with macular edema associated with retinal vein occlusion</td>
<td>Berniolas J, Cristobal J A</td>
<td></td>
</tr>
<tr>
<td>S042</td>
<td>Macular Infarction Following Intravitreal Triamcinolone Injection for Treatment of Central</td>
<td>KIMT K, Lee J H, Lee MY</td>
<td>Gyeonggi-do</td>
</tr>
<tr>
<td></td>
<td>Retinal Vein Occlusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S043</td>
<td>Retinal vein occlusion in a patient with jugular vein compression by metastasis of carcinoma of</td>
<td>Perez Navarro I, Ascaso F J, Sanchez J I, Esteban O, Martinez M, Del</td>
<td>Zaragoza</td>
</tr>
<tr>
<td></td>
<td>the oral tongue</td>
<td>Buey M A, Nunez E</td>
<td></td>
</tr>
<tr>
<td>S044</td>
<td>Intraarterial thrombocytic material revelative of essential thrombocytaemia in a 59-year-old</td>
<td>Rospond-Kubiak I, Oszkinis G, Kociecki J</td>
<td>Poznan</td>
</tr>
<tr>
<td></td>
<td>woman</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S045</td>
<td>Retinal Vessel Oxygen Saturation and its implications in myopia</td>
<td>Heitmar R</td>
<td>Birmingham</td>
</tr>
<tr>
<td>S046</td>
<td>Assessment of choroidal thickness in high myopic glaucomatous eyes using SD OCT</td>
<td>El Matri L, Chebil A, Hassaini A, Maamouri R, Kort F, Chaker N</td>
<td>Tunis</td>
</tr>
<tr>
<td>S047</td>
<td>Adjunctive photodynamic therapy for type 1 choroidal neovascularization associated with</td>
<td>Kim N, Lee W K</td>
<td>Seoul</td>
</tr>
<tr>
<td></td>
<td>thickened choroid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S048</td>
<td>Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of</td>
<td>Malcles A, Russo A, Agard E, El-Chehab H, Dot C</td>
<td>Lyon</td>
</tr>
<tr>
<td></td>
<td>Aflibercept: report of 4 cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S049</td>
<td>Spontaneous subretinal pigment epithelium hemorrhage</td>
<td>Hallef Furtado De Mendonca R, De Oliveira Maia JR</td>
<td>Rome</td>
</tr>
<tr>
<td>S050</td>
<td>Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes</td>
<td>Abu El Asrar A, De Hertogh G, Van den Eynde K, Alam K, Van Raemdonck K</td>
<td>Riyadh</td>
</tr>
<tr>
<td></td>
<td>and through endothelial-to-mesenchymal transition (EndoMT)</td>
<td>Opdenakker G, Van Damme J, Geboes K, Struyf S</td>
<td></td>
</tr>
<tr>
<td>S051</td>
<td>Stimulation of TLR4 Increases Angiogenic and Anti-Angiogenic Gene Expression in Choroidal</td>
<td>Stewart E, Wei R, Uribe M, May S, Amoaku W</td>
<td>Nottingham</td>
</tr>
<tr>
<td></td>
<td>Endothelial Cells</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous

S052 Development of Diabetic Retinopathy in a 22-Week Old Homozygous Ins2Akita Mouse: A Case Study
DENIRO M, AlQahtani A, AlAhmar S, AlMohanna F - Riyadh

S053 Correlation of Different Circulating Endothelial Progenitor Cells to Stages of Diabetic Retinopathy in patients with type 2 diabetes mellitus
WU Z, Ty M, Wang F - Wuxi

S054 Dexamethasone Reverses the Effects of High Glucose on Human Retinal Endothelial Cells In Vitro
STEWART E, Saker S, Amoaku W - Nottingham

S055 The effect of glucose and insulin on the susceptibility of cultured photoreceptor-like cells to hypoxia
LAYTON C, DE MORAES G - Greenslopes

S056 Insulin-induced dilatation of porcine retinal vessels in vitro is most pronounced in precapillary arterioles
JENSEN P S, Bek T - Aarhus C

S057 Prevalence of diabetic retinopathy in children and adolescents with type 1 diabetes in Helsinki, Finland, 7-15 years after diagnosis
GRASBECK S, Gräsbeck T, Miettinen P J, Summanen P A - Helsinki

S058 Hospital prevalence of visual of visual impairment caused by diabetic retinopathy

S059 Prognostics factors of poor functionally response in ranibizumab treatment for diabetic macular edema
JULLIEN M, Deken-Delannoy V, Labelette P - Lille

S060 Correlation of hyperreflective foci, status of photoreceptor layer, and visual acuity in diabetic macular edema
CHEBIL A, Ben Abdallah M, Kart F, Hassnairy A, Maamouri R, El Matri L - Tunis

S061 Automatic method to distinguish manifestation areas of early diabetic retinopathy from image artefacts by using L*u*v* colour space
SUZUKI N, Yamane K - Numazu

S062 ChoroidalThickness and Systemic Examination in Diabetic Patients without Diabetic Retinopathy

S063 Evaluation of intraocular pressure, choroidal and retinal thickness measurements using optical coherence tomography in non-diabetic haemodialysis patients

S064 Retinal Layers Changes in Diabetic Patients without Diabetic Retinopathy

S065 Heterogeneous choroidal thickness pattern in diabetic patients without diabetic retinopathy

S066 Focal choroidal changes on diabetic macular edema
DUARTE L, Ruão M, Gallego R - Santa Maria da Feira

S067 Correlation of visual acuity and central macular thickness in diabetic macular edema
EL MATHI HASSAIRI A, Chebil A, Ben Abdallah M, Maamouri R, Chaker N, El Matri L - Tunis
S068  Fundus photography as a screening method of diabetic retinopathy in children and adolescents with type 1 diabetes 
Outcome of the first fundus photography at the age of 9 to 17 years  
GRASBECK T, Gräsbeck S, Miettinen P J, Summanen P A - Helsinki

S069  The effect of panretinal photocoagulation and additive Intravitreal bevacizumab injections on central retinal vessel diameters in diabetic retinopathy  
PARK J M, Lee S J - Busan

S070  Intravitreal anti-VEGF treatment for refractory diabetic macular edema  
PAPAVASILEIOU E, Quijano C, Younis S - London

S071  Switching to ranibizumab for diabetic macular edema with persistent fluid on bevacizumab: Who is likely to benefit from the switch?  
LEE J H, Lee W K - Seoul

S072  Effect of intravitreal dexamethasone implant (Ozurdex®) in the glycemic control of patients with diabetic macular edema  

S073  Efficacy and safety of ranibizumab in diabetic macular edema: real life study  

S074  Outcomes of using intravitreal ranibizumab to treat patients with ischaemic diabetic maculopathy.  
BEGUM S, Lockwood A, Mourtzouko S - Portsmouth

S075  Role of SD-OCT in the follow-up of a patient with macular edema associated with mucopolysaccharidosis type II (Hunter syndrome) undergoing idursulfase enzyme replacement therapy  

S076  Use of directional optical coherence tomography and selected landmarks to determine foveal topography and microstructure. A strategy to characterize differences between normal and prematurity cases.  
SJOSTRAND J, Rosén R, Nilsson M, Popovic Z - Mölndal

S077  Optical Coherence Tomography and Fundus Autofluorescence evaluation in an animal model of Retinal Degeneration  

S078  Three optic disc pit maculopathy case studies by optical coherence tomography images supporting the role of cerebrospinal fluid in this pathology  

S079  Indocyanine green angiography findings in Stargardt disease  
EL MATRI L, Chebib A, Charfi H, Largueche L, Hassaïri A - Tunis

S080  Repeatability of wide-field autofluorescence lifetime imaging at the human retina in healthy volunteers  
KLEMM M, Dietzel A, Nagel E, Schweitzer D - Ilmenau

S081  Characteristics of Artifacts Associated with Ultra-Wide Field Fundus Image  

S082  Agreement between ophthalmoscopy and ultrawide field image analysis in an outpatient clinic setting  
RV: Retina / Vitreous

S083 Wide field imaging in patients treated with vigabatrin
VARDI K, Brugniant C, Motte J, Ducasse A, Arndt C - Reims

S084 An algorithm combining two lesion-detection methods of retinal microaneurysms for the reduction of human workload
OMETTO G, Bek T, Al-Diri B, Hunter A - Aarhus

S085 Comparisons of retinal sensitivity obtained by microperimetry with two different fixation targets in normal individuals
NIZAWAT T, Kitahashi M, Yamamoto S - Chiba

S086 Postoperative Endophthalmitis: Incidence, Causes and Comparison Between Medical and Surgical Treatment in a United Kingdom Region in the Last 10 Years
SHALABY A, Di Simplicio Cherubini S, Lockwood A, Newsom R - Southampton

S087 Endogenous panophthalmitis caused by sphiogomonas paucimobilis; A postpartum devastating rare condition
OZCAN A A, Esen E - Adana

S088 Intraocular Pharmacokinetics of Povidone-iodine and the Effect of Repeat Injection with low concentration on the Experimental S. epidermidis Endophthalmitis

S089 Tolerance of Dexamethasone intravitreal implant in GAO patients according to their initial treatment and repeated intravitreal injections.
VIE A L, Kodjikian L, Malcles A, Agard E, El Chehab H, Russo A, Dot C - Lyon

S090 Intra-ocular pressure spike after Aflibercept and Ranibizumab intravitreal injections
EL CHEHAB H, Agard E, Russo A, Malcles A, Dot C - Lyon

S091 Background ophthalmological changes following subretinal injection in the brown norway rat
VEZINA M, Li C, Bussieres M - Senneville

S092 Clinical guidelines for acute exposure to laser pointer radiation
LOFGREN S, Hengstler J, Jans E - Stockholm

S093 Cystoid macular edema associated with retinitis pigmentosa resolved by a dexamethasone intravitreal implant

S094 Impact of Storage Temperature on Gene Expression of Cultured ARPE-19 Cells
PASOVIC L, Eidet J R, Olistad O K, Chen D F, Lyberg T, Utheim T P - Oslo

S095 Transcription factors involved in cell death and regeneration in AGEs exposed retinal neurons
OSHITARI T, Bikbova G, Yamamoto S - Chiba

S096 Expression of histamine receptors in the gerbil retinal neurons
MIYACHI T, Imada H, Ohkuma M, Sakai K - Toyoake-shi

S097 Research on ophthalmic examination apparatus to diagnose multiple diseases which result in loss of eyesight
SUZUKI N, Yamane K - Numazu

S098 Subthreshold Micropulse Yellow Laser (577nm) Photocoagulation for Subfoveal Serous Pigment Epithelium Detachment
PARK H - Daegu
Keynote Lecture by Bita ESMAELI

Introduction by Steffen HEEGAARD

Multidisciplinary treatments for malignant eyelid tumors: surgical and non-surgical options, sentinel lymph node biopsy, and surveillance

ESMAELI B - Houston, Texas

Summary
Malignant tumors of the eyelid are varied in their presentation and stage. Surgical treatments and reconstructive outcomes for each stage and histology will be reviewed. Adjuvant local treatments such as radiation therapy as well as non-surgical medical treatments will also be discussed. Indications and clinical cases where sentinel lymph node biopsy may be beneficial and other recent advances in the field will be reviewed.

Award of the EVER Certificate of Honour

Biography Bita Esmaeli:
Dr Bita Esmaeli is a Professor of Ophthalmology in the Department of Plastic Surgery at The University of Texas M. D. Anderson Cancer Center, where she has an orbital oncology and oncologic ophthalmic plastic surgery practice since 1998.
Dr Esmaeli’s practice focus is surgical treatment of orbital tumors, lacrimal gland carcinomas, eyelid cancers, melanoma of eyelid and conjunctiva, and reconstructive surgery in the periocular region including lacrimal surgery. Dr Esmaeli has authored over 160 peer-reviewed manuscripts, over 55 invited articles and book chapters, has spearheaded several clinical trials, and has participated in numerous research protocols at M. D. Anderson Cancer Center. She has received many prestigious awards and honors including the Merrill Reeh Pathology Award and the Research Award from the American Society of Ophthalmic Plastic and Reconstructive Surgery, the American Academy of Ophthalmology Senior Achievement Award, Best Doctors in America, and Top Doctors Award. Dr Esmaeli’s research interests include molecular signature of ocular and orbital tumors, tissue banking, eye and vision-sparing treatment strategies for orbital and adnexal cancers, and ocular side effects of cancer therapy. Dr. Esmaeli helped establish the Ophthalmology Service as a comprehensive full-time service at M. D. Anderson Cancer Center in 1998. She served as the Director of Service from 1998 to 2001 and the Chief of Ophthalmology from 2001 to 2004. She is the Program Director for an ASOPRS-sponsored fellowship in oculoplastic surgery and orbital oncology at M. D. Anderson Cancer Center.
### HERMES

**IM: ARVO session: Sweetening the inflammatory response to combat the rise in retinal disease**

**Dick A**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4211</td>
<td>11:30</td>
<td>Introduction and overview</td>
<td>Dick A - Bristol</td>
<td></td>
</tr>
<tr>
<td>4212</td>
<td>11:40</td>
<td>Parainflammation, ageing and loss of control</td>
<td>Xu H - Belfast</td>
<td></td>
</tr>
<tr>
<td>4213</td>
<td>12:00</td>
<td>Obesity, degeneration and senescence</td>
<td>Sennlab F - Paris</td>
<td></td>
</tr>
<tr>
<td>4214</td>
<td>12:20</td>
<td>Feeding microglia to regulate vascular responses</td>
<td>Langmann T - Cologne</td>
<td></td>
</tr>
</tbody>
</table>

### Rhodes 1

**G: Free paper session - Surgery and blood flow**

**Griesshaber M, Abegao Pinto L**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4221</td>
<td>11:30</td>
<td>Canaloplasty with the Stegmann canal expander – two years results</td>
<td>Griesshaber M, Schoetzau A, Stegmann R - Basel</td>
<td></td>
</tr>
<tr>
<td>4222</td>
<td>11:42</td>
<td>Risk of trabeculectomy with an initial diagnosis of glaucoma versus ocular hypertension in Gloucestershire, UK.</td>
<td>McNaught A, Turner S, Ivanova K, Crabb D - Cheltenham</td>
<td></td>
</tr>
<tr>
<td>4223</td>
<td>11:54</td>
<td>A minimally invasive approach to sub-conjunctival outflow: 1 year results of an ab-interno gelatin stent in combination with preoperative MMC injection for the treatment of primary open angle glaucoma.</td>
<td>Stalmans I, Fea A, Reitsamer H, Lavin C - Leuven</td>
<td></td>
</tr>
<tr>
<td>4224</td>
<td>12:06</td>
<td>Glaucoma patients have a significant decrease in retrobulbar blood flow velocities during general anesthesia</td>
<td>Abegao Pinto L, Vandewalle E, Willekens K, Van keer K, Van Calster J, Stalmans P, Vertommen J, Deckers K, Marques-Neves C, Stalmans I - Lisbon</td>
<td></td>
</tr>
<tr>
<td>4227</td>
<td>12:30</td>
<td>Biomechanical properties of eyes with asymmetrical glaucoma defect</td>
<td>Cellini M, Gizzi C, Finzi A, Campos E C - Bologna</td>
<td></td>
</tr>
<tr>
<td>4228</td>
<td>12:36</td>
<td>Multicenter Clinical Trial of High-Intensity Focused Ultrasound Treatment in Glaucoma Patients without Previous Filtering Surgery</td>
<td>Apfel F, Denis P, Rouland J F, Renard J P, Bron A - Laxou</td>
<td></td>
</tr>
</tbody>
</table>
11:30 - 13:00 | RHODES 2

**COS: Unmet needs and innovation in ophthalmology**

This session will focus on unmet Needs and new developments in ophthalmology.

**FUCHSLUGER T, STEFANSSON E**

- 4231 11:30 Corneal neovasculariation: a translational perspective  
  **FERRARI G** - Milan

- 4232 11:48 New perspectives in dry eye treatment  
  **BARABINO S** - Sanremo

- 4233 12:06 New developments in DMEK and endothelial cell therapy  
  **FUCHSLUGER T** - Erlangen

- 4234 12:24 Non-antagonistic influences of intrastromal corneal ring on primary human microvascular endothelial cells from adult donors in a tissue culture system  
  **STORSBERG J, Träg S, Messner A, Rehfeldt S, Klöpzig S, Jentzen V, Bohrjch J, Schmidt C** - Potsdam

- 4235 12:42 Information technology in ophthalmology. www.retinarisk.com  
  **STEFANSSON E** - Reykjavik

11:30 - 13:00 | RHODES 3

**PO: OOG Ocular Oncology Group 2**

**ANGI M, JAGER MJ**

- 4241 11:30 Integrated multi-omic analysis of human retinoblastoma identifies novel regulatory networks  
  **SURESHBABU V, Mallipatna A, Guha N, SA D, Gundimeda S, Padmanabhan A, Shetty R, Ghosh A** - Bangalore

- 4242 11:42 Anatomic features of choroidal naevi: Swept-source optical coherence tomography vs Enhanced depth imaging tomography. Preliminary results in 31 patients  

- 4243 11:54 Human choroidal nevi histopathology revisited  
  **MADIGAN M C, VADER M, TON H, VAN DER VELDEN P, JAGER M** - Sydney

- 4244 12:06 The Liverpool Uveal Melanoma Prognosticator Online (LUMPO) for prognosing metastasis free survival in the absence of cytogenetic data after ruthenium brachytherapy for uveal melanoma  
  **ROSPOND-KUBIAK I, Wroblewska-Zierhoffer M, Twardosz-Pawluk H, Kociecki - Poznan**

- 4245 12:12 Immunohistochemical characterization of a retinal hamartoma  
  **VAN GINDERDEUREN R, STALMANS P** - Leuven
11:30 - 13:00 | RHODES 4
FRO - Belgian Fund for Research in Ophthalmology 1

CASPERS L, TASSIGNON MJ

4251  11:30  RNA sequencing in keratoconus: unraveling the molecular pathways
        VALGAEREN H - Edegem

4252  11:42  Development of micro needle for retinal vein cannulation
        WILLEKENS K - Leuven

4253  11:54  Serine proteases as potential therapeutic targets for ocular inflammation and dry eye syndrome
        JOOSSEN C - Wilrijk

4254  12:06  Automatic detection of early keratoconus using topography and biomechanical measurements in the corneal horizontal and vertical axis
        RUIZ HIDALGO I - Edegem

4255  12:18  Tissue engineering in ophthalmology: regenerating the anterior cornea using self-aligning recombinant human collagen nanoscaffolds and corneal epithelial stem cells
        HAAGDORENS M - Edegem

4256  12:30  In vitro functional characterisation of tissue engineered corneal endothelial grafts
        VAN DEN BOGERD B - Edegem

4257  12:42  An in vitro and ex vivo study into the role of Müller cells in nanoparticle-based retinal gene therapy after intravitreal injection
        PEYNSHAERT K - Gent

4258  12:54  Detailed characterization of structural, functional and behavioral changes in a laser-induced mouse model for glaucoma
        GEERAERTS E - Leuven

11:30 - 13:00 | GALLIENI 1+2

NSPH: New approaches to the prevention of myopia

High myopia is a major cause of uncorrectable visual impairment. It imposes major challenges and costs for refractive correction and for the treatment of associated pathological complications. In the last 60 years, there has been a marked increase in the prevalence of high myopia in younger generations in developed countries in East and Southeast Asia, and there are signs of a similar, but less pronounced increases in North America and Europe. In some parts of the world, 70-90% of children completing high schools are now myopic, and as many as 20% may be highly myopic. It is now clear that myopia results from excessive axial elongation of the eye and this greater rate of axial elongation appears to be environmentally driven. Experimental studies have examined the biochemical mechanisms involved in regulation of axial elongation. From these studies, some options have emerged for preventing the development of myopia or slowing myopic progression.

GRZYBOWSKI A, MORGAN I

4261  11:30  Pathology of high myopia
        OHNO-MATSUI K - Tokyo

4262  11:45  Epidemiology and the protective effects of time outdoors
        MORGAN I, Rose K - Ainslie

4263  12:00  Optical reduction of peripheral hyperopic defocus
        TORII H, Negishi K, Tsubota K - Tokyo

4264  12:15  Atropine treatment
        GRZYBOWSKI A - Poznan

4265  12:30  5. 7-methylxanthine treatment
        TRIER K - Hellerup

4266  12:45  Defocus Incorporated Soft Contact (DISC) lens
        LAM C S, Tang W C, To C H - Hong Kong
RV: Free paper session - Imaging and RPE

**SCHMETTERER L, LUMBROSO B**

**4271** 11:30  The Silk-protein Sericin Induces Rapid Melanization of Cultured Retinal Pigment Epithelial Cells by Activating the NF-κB Pathway  
*PASOVIC L, Utheim T P, Reppe S, Lyberg T, Olstad O K, Eidet J R - Oslo*

**4272** 11:42  Cell penetrating peptide constructs: A novel drug delivery to the eye  
*SCOTT R, Hill L, De Cogan F, O’Neill J, Logan A - Birmingham*

**4273** 11:54  The improvement of Spoke-Wheel pattern foveoschisis in a patient with X-linked retinoschisis treated with topical dorzolamide observed by high-resolution adaptive optics camera  
*GOCHO K, Akeo K, Kameya S, Yamaki K, Mizota A, Takahashi H - Inzai*

**4274** 12:06  Concordance between ophtalmologists and paramedical professionals in screening for retinal abnormalities with ultrawide field imaging  
*DURBANT E, Vardi K, Bordet J, Barbe C, Garcia T, Angioi-Duprez K, Arndt C - Reims*

**4275** rf 12:18  Research on ophthalmic examination apparatus to diagnose multiple diseases which result in loss of eyesight  
*SUZUKI N, Yamane K - Numazu*
13:00 - 14:00 | RHODES 1

**Update in the management of DME, RVO and Uveitis**

**CREUZOT C, BODAGHI B**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Management of RVO – Update on new clinical data and recommendations of treatment</td>
<td>BAILLIF S</td>
<td>Marseille</td>
</tr>
<tr>
<td>13:15</td>
<td>Management of Uveitis - Update on new clinical data and recommendations of treatment</td>
<td>BODAGHI B</td>
<td>Paris</td>
</tr>
<tr>
<td>13:30</td>
<td>Management of DME – Update on new clinical data and recommendations of treatment</td>
<td>CREUZOT C</td>
<td>Dijon</td>
</tr>
<tr>
<td>13:45</td>
<td>Discussion: C. Creuzot, B. Bodaghi and S. Baillif</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**EVER 2015**  
Saturday, Oct 10 - Afternoon session

### RV: Silicone oil (SiO) complications

The use of silicone oil (SiO) as an internal tamponade agent in cases of complex retinal detachment with proliferative vitreoretinopathy (PVR) has become common, but it also may lead to postoperative complications if it is not surgically removed later. This symposium will document the safety and effectiveness of intravitreal injections in the silicone oil-filled eye, the possible complications from the migration of emulsified silicone and, finally, it will provide a review and discussion of the surgical management of these conditions.

**GRZYBOWSKI A, ASCASO F**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>4411</td>
<td>14:00</td>
<td>Safety and effectiveness of intravitreal injections in the silicone oil-filled eye</td>
<td>ASCASO F - Zaragoza</td>
</tr>
<tr>
<td>4412</td>
<td>14:15</td>
<td>Silicone oil use in trauma</td>
<td>WEINBERGER D - Tel Aviv</td>
</tr>
<tr>
<td>4413</td>
<td>14:30</td>
<td>Silicone oil-induced anterior segment complications</td>
<td>AVITABILE T - Catania</td>
</tr>
<tr>
<td>4414</td>
<td>14:45</td>
<td>Controversies on heavy SiO endotamponade</td>
<td>LE MER Y - Paris</td>
</tr>
<tr>
<td>4415</td>
<td>15:00</td>
<td>Complications after SiO removal</td>
<td>KIILGAARD J F - Copenhagen</td>
</tr>
<tr>
<td>4416</td>
<td>15:15</td>
<td>Neuronal complications of intravitreal SiO</td>
<td>GRZYBOWSKI A - Poznan</td>
</tr>
</tbody>
</table>

### SIS

**G: Untrabitional (sic) glaucoma surgery**

For almost 50 years, trabeculectomy has been considered the ‘gold standard’ procedure in the surgical management of the Glaucoma patient. The operation undoubtedly works well in many surgeons’ hands, and over the last 20 years small changes in surgical technique have improved the safety profile of guarded sclerostomy. ‘Tube’ surgery has also long been widely advocated and debate rages about which of these two mainstream treatments should be the de facto surgery for glaucoma. In a continued attempt to improve the surgical risk/benefit ratio, there have more recently been advocated other surgical glaucoma procedures, which may in time take on the mantle of ‘standard of care’. Our SIS presents a selection of these new treatments as a basis for a robust discussion of why and how we offer surgery to control our patients’ disease with the ultimate aim of preserving their vision as effectively and safely as possible.

**BLOOM P**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4421</td>
<td>14:00</td>
<td>Turn off the tap: Inflow surgery comes of age with ECP</td>
<td>BLOOM P, Clements C, Sharkawi E, Grieshaber M - London</td>
</tr>
<tr>
<td>4422</td>
<td>14:22</td>
<td>Back to the future: The return of angle surgery</td>
<td>SHARKAWI E - Lausanne</td>
</tr>
<tr>
<td>4423</td>
<td>14:44</td>
<td>Down under the sclera: Deep sclerectomy</td>
<td>CLEMENT C - Gordon</td>
</tr>
<tr>
<td>4424</td>
<td>15:06</td>
<td>Coming full circle: Canal surgery with / without implants</td>
<td>GRIESHABER M - Basel</td>
</tr>
</tbody>
</table>
COS: Toric intraocular lenses – Calculation and clinical aspects

This session covers diagnostics, calculation, patient selection, pre- and postoperative care in lens replacement by toric iol.

LANGENBUCHER A, SZENTMARY N

4431 14:00 Indications, patient selection, pre- and postoperative patient care
       SZENTMARY N - Homburg/Saar

4432 14:18 Instrument assisted diagnostics – biometry, topography and wave-front analysis
       EPPIG T, SPIRA C, SEITZ B, SZENTMARY N, LANGENBUCHER A - Homburg/Saar

4433 14:36 How to calculate toric intraocular lenses in clinical practice?
       LANGENBUCHER A, SZENTMARY N, SEITZ B, SPIRA C, EPPIG T - Homburg

4434 14:54 Intraoperative optical coherence tomography (iOCT) in toric IOL implantation.
       WYLEGALA E - Katowice

4435 15:12 Surgical aspects of toric lens implantation, from perioperative marking to axis re-adjustment
       BARRAQUER R I - Barcelona

OOG: Ocular Oncology Group 3

ZOGRAFOS L, ROMANOWSKA DIXON B

4441 14:00 Correlation between radiation dose and damage to optic disc and macula in eyes treated with ruthenium brachytherapy
       ESPENSEN C A, FOG L S, KLEMP K, AZNAR M C, SPECHT L, KIILGAARD J F - Copenhagen

4442 14:12 Dexamethasone 0.7-mg intravitreal implant in patients with radiation macular edema after proton beam therapy for choroidal melanoma: 2-year results.
       BAILLIF S, MASCHI C, CAUJOLLE J P - Nice

4443 14:24 Radiation complications, Toxic Tumor Syndrome prevention

4444 14:36 Proton beam irradiation of choroidal hemangiomas after unsuccessful photodynamic therapy
       ZOGRAFOS L, SCHALENBOURG A - Lausanne

4445 14:48 Stereotactic radiation therapy of diffuse choroidal hemangioma in Sturge-Weber syndrome
       SCHALENBOURG A, ZOGRAFOS L, PICA A - Lausanne

4446 15:00 Choroidal osteoma in deep range imaging OCT (DRI-OCT)
       MARKIEWICZ A, ROMANOWSKA-DIXON B, BODGALI A, JAKUBOWSKA B - Krakow
### Ever 2015 Programme Book

**Saturday, Oct 10 - Afternoon session**

**FRO - Belgian Fund for Research in Ophthalmology**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 15:30</td>
<td>RHODES 4</td>
<td>An innovative mouse model for retinal alpha-synucleinopathy: taking a now look on Parkinson's disease</td>
<td>DE GROEF L - Leuven</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Unraveling the molecular and cellular mechanisms underlying deleterious ROCK signaling in neuronal survival and axonal growth</td>
<td>LEFEVERE E - Leuven</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Identification of the gene signature of retinal endothelial cells during classical experimental autoimmune uveitis, Th1- and Th17-dependent uveitis</td>
<td>LIPSKI D - Brussels</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Development of a portable retinal oximeter using a hyperspectral image sensor</td>
<td>VAN KEER K - Leuven</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>3D printed human recombinant collagen scaffolds for corneal tissue engineering: determination of cell-scaffold interactions</td>
<td>MATTHYSSEN S - Antwerpen</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Functional characterization of RCBTB1 as novel disease gene for syndromic retinal dystrophies</td>
<td>ASCARI G - Ghent</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Integrated transcriptomics and genomics to identify hidden genetic variation of FRMD7 or novel candidate genes in idiopathic infantile nystagmus</td>
<td>ALMOALLEM B - Ghent</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Role of the transcription factor TonEBP/NFAT5 in the inflammatory response induced by hyperosmolar stress in RPE cells</td>
<td>LIBERT S - Anderlecht - Brussels</td>
</tr>
</tbody>
</table>

**NSPH: Orbit meets neuro-ophthalmology**

Actualised management for different neuro-orbit disorders like optic nerve, intra orbital tumours and Graves’ orbitopathy will be discussed by a panel of experienced speakers with different backgrounds.

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 15:30</td>
<td>GALLIENI 1+2</td>
<td>Acute exophthalmos in children</td>
<td>DE POTTER P - Bruxelles</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Update in management of optic nerve glioma (part 2)</td>
<td>PARS A - Paris</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>A novel method for measuring outcome of orbital decompression in Graves' orbitopathy</td>
<td>BALDESCHI L - Bruxelles</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td></td>
<td>Orbital implantation of biocompatible magnets for the treatment of intractable nystagmus</td>
<td>VERITY D H, Kennard C, Pankhurst Q, Geoffrey E R - Tadworth - Surrey</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
<td>Abstracts</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>4471</td>
<td>The prevalence and incidence of glaucoma in Denmark in a fifteen year period: A nationwide study</td>
<td>KOLKO M, Horwitz A, Thygesen J, Jeppesen J, Torp-Pedersen C - Roskilde</td>
<td></td>
</tr>
<tr>
<td>4472</td>
<td>Optic nerve head hemorrhage and vitreous traction.</td>
<td>WILLEKENS K, Pinto L A, Vandewalle E, Stalmans P, Stalmans I - Leuven</td>
<td></td>
</tr>
<tr>
<td>4473</td>
<td>Localized changes in retinal nerve fiber layer reflectance intensity are related to localized functional loss in glaucoma</td>
<td>GARDINER S, Demirel S, Reynaud J, Fortune B - Portland</td>
<td></td>
</tr>
<tr>
<td>4474</td>
<td>Visual field screening by opticians with Damato Multifixation Campimetry Online (DMCO)</td>
<td>OLSEN A S, Damato B, La Cour M, Kolko M - Copenhagen</td>
<td></td>
</tr>
<tr>
<td>4475</td>
<td>Comparison of preservative-free latanoprost and bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial.</td>
<td>STALMANS I, Cordeiro F, Hommer A, Oddone F, Ribeiro L, Sunaric Mégevand G, Rossetti L - Leuven</td>
<td></td>
</tr>
<tr>
<td>4477</td>
<td>How accurate are optometrist referrals for glaucoma in the NICE era?</td>
<td>BOBAT H, Begum S, Lockwood A, Kirwan J F - Portsmouth</td>
<td></td>
</tr>
<tr>
<td>4478</td>
<td>A pilot study of survey on patient satisfaction and its meaning in an Glaucoma outpatient</td>
<td>POURJAVAN S, Vanhaecht K - Brussels</td>
<td></td>
</tr>
</tbody>
</table>
15:30 - 16:00 | HERMES

**Prize award ceremony and conclusion of the congress**

Chair: Aki Kawasaki, President EVER 2016

Introduction by Marcela Votruba, Programme Secretary

- Travel awards presentation by the section chairs
- Poster prize presentations by the section chairs
- Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2015 Bart Leroy

---

**EVER Award Ceremony 2014**

---

**EVER Award Ceremony 2014**
Awardees of the EVERf Research Fellowships 2015

• Dr. Sepehr FEIZI, Iran
  host institute: Queens Medical Centre, Nottingham, UK

• Dr. Sabina SAPETA, Poland
  host institute: Medical University of Vienna, Austria
European University Professors of Ophthalmology

EUPO 2016
Neuro-ophthalmology and Strabismus

October 7-8, 2016
Nice, France
In conjunction with EVER 2016
www.eupo.eu

Acta Ophthalmologica
Edited by: Einar Stefánsson

Why should you read the journal?

- Top class research - our impact factor now stands at 2.844*, with a ranking of 13/57 in the ISI Ophthalmology category
- Coverage that's relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye
- Official publication of EVER, Dutch and all five Nordic Ophthalmological Societies

Visit www.actaophthalmologica.com for more information

Members of EVER receive FREE online access to Acta Ophthalmologica as part of their membership.

*2014 JCR, Thomson Reuters
Join us at our symposium at the EVER 2015 Congress:

**A rare breakthrough in mitochondrial medicine: changing the patient journey in LHON**

Friday 9 October, 12:30–13:30
Acropolis Convention Center

For more information, please visit us at our booth at EVER or go to [www.santhera.com](http://www.santhera.com)
Bridging disciplines and disparities: Connecting eye research with health outcomes

February 5 – 8, 2017
Brisbane Convention and Exhibition Centre
Brisbane, Australia

arvo.org/arvo-asia
ABEGAO PINTO, L.: 3125, 4224, 4226, F002
ABERDAM, D.: 2654
ABU EL ASRAR, A.: 2218, 2451, S050
ABU KHAMIDAKH, A.: 4172
ACLIMANDOS, W.: 4121
AGARD, E.: S072
AHMED, F.: 1122
AINSBURY, L.: 3261
AL-SHABRAWEY, M.: 2452
ALDAHAM, S.: F055, F057
ALMENARA MICHELENA, C.: S041, S093
ALMOALLEM, B.: 4457
AMADIO, M.: T005, T008
AMARIE, O.: 3561
ANDJELIC, S.: 4177, T014
ANDROUDI, S.: 1132
ANGI, M.: 4145
ANTOSOVA, B.: 3563
APTEL, F.: 4228, F004
ARJAMA, O.: T004
ASCARI, G.: 4456
ASCASO, F.: 3271, 4411
ASCHINGER, G.: F038
ASNAGLI, H.: 2571
ASOKLIS, R.: F105
AUDO, I.: 1253
AUFFARTH, G.: 1365
AVITABLE, T.: 4413
AYDIN YAZ, Y.: T035
BACQUET, J.: F069
BADIAN, R.A.: T032, T053
BAILLIF, S.: 4442
BALDESCHI, L.: 4463
BARABINO, S.: 4232
BARON, A.J.: 2234
BARRAQUER, R.I.: 4435
BARRY, P.: 3254
BATSON, J.: 2241
BAUDOT, A.: T023
BAUDOUIN, C.: 2331
BAY, P.: 3254
BECHEL, J.: 3421
BEIKO, G.: 1363
BERROD, J.: 2414, 3114
BESOMBES, G.: F014
BEUERMAN, R.: 2271, 3233, 4131, 4134
BEYER, E.: 3461
BHARTI, K.: 2672
BIFRATE, D.: 2532
BIRKELDH, U.: F068, F088
BITOUN, P.: 2546
BLACK, G.C.: 1252, 3464
BLACKLEY, Z.: F040
BLOM, N.: 1346, T081
BLOOM, P.: 4421
BOBAT, H.: 4477, F007
BODAGHI, B.: 1235, 2157, 4155
BOGDALI, A.: F084
BONNEAU, D.: 2264
BONNEL, S.: F010
BORDERIE, V.: 2551, 3131
BORDI, S.: 3545
BROU, S.: F082
BORGUAT, F.X.: 2164, 2561, 2563, 2565
BOSCHI, A.: 2163
BOYCHUK, I.: F094, F095
BREHON, A.: 2556, T089
BREMOND-GIGNAC, D.: 2655, 3457, F100
BRISGUE, D.: 3144
BROU, S.: 2541
BUI QUOC, E.: 2443
BUSHUYEVA, N.: F049, T076
BUSIN, M.: 3132
BYON, I.: S088
BYUN, Y.: 2236, T028
CAHUZAC, A.: 2113
CALDER, V.: 3173, 3533
CALONGE, M.: 2272
CALVAS, P.: 2653
CARAMELLO, C.M.: F074, T072
CARDIGOS, J.: 2215, S062
CARELLI, V.: 2463
CARRASQUILLO, K.G.: 2472
CASANOVA, C.: F066
CASSEUX, N.: 1221, 1224, 3542
CASTELO-BRANCO, M.: 4165
CELLINI, M.: 4227, F003
CHALONS, P.: F039
CHARLIER, J.: 3472
CHAUHAN, B.: 1321
CHEBIL, A.: S060, T016
CHIAMBARETTA, F.: 2656
CHO, M.: F098
CHO, S.Y.: F099, F101
CIMBOLINI, N.: T031
CLARKE, F.: F018
CLEMENT, C.: 4423
CORDEIRO SOUSA, D.: 2541, 4476, F006, F037
CORDEIRO, M.F.: 2621, 3224
COSCAS, F.: 2611
COSCAS, G.: 2612, 3215
COSTA, L.: 3256, 3451, F071
COUPLAND, S.: 3541
COURRIER, E.: T041
CRABB, D.: 2224
Presenting First authors

CRAWLEY, L.: 1121
CREUZOT, C.: 2515, 3112, 3115, 4125
CROUZET, E.: T068, T069
DAL MONTE, M.: F042
DALKE, C.: 3264
DANA, R.: 3534
DAULL, P.: T034
DAVIDSON, A.: 1331
DAVIS, B.: 3223
DE BATS, F.: 2112
DE BLESER, E.: T020
DE BRUYN, D.: F106
DE GROEF, L.: 3575, 4451
DE LAEY, J.J.: 3273
DE LAZZER, A.: 2522
DE POTTER, P.: 4461
DEL BUEY, M.A.: T044, T066
DELBARRE, M.: T079
DENIRO, M.: S034, S052
DESCHASSE, C.: 2413
DE JACOBS, L.: 1223, 2641, 4141
DIAMOND, J.: 1124
DIAZ VALLE, D.: 2333, T048
DICK, A.: 1131, 1136, 4211
DOAN, S.: 2237, T040, T085
DOBROWOLSKI, D.: 1242
DRASCHL, P.: F073
DUA, H.S.: 1143, 1145, 1352, 3134
DUARTE, L.: S066
DURBANT, E.: 4274
EDWARD, D.: 3446
EIDET, J.R.: 2231, T051
EL CHEHAB, H.: S090
EL MATRI, L.: S046, S079
ELDRED, J.: 3152
EPPIG, T.: 4432
ESPEENSEN, C.A.: 4441
ESPINASSE, M.: 3442
ESTEBAN, O.: T009, T012
ETIENNE, I.: S001
EVANS, C.: 3163
FARAJ, L.: 1344, T058
FEUZ, M.: 2666
FERRUCCI, G.: 1212
FERRARI, G.: 4231
FERREIRA, J.: 1113, 2214, S064
FILIFE, H.: 2243, F076, T059
FLECK, O.: 2524
FLORES, M.: T093
FRÈRE, A.: 4153
FRUSCHELLI, M.: 2662, S038
FUCHS, C.: 3235, 4233
GABISON, E.: 2652, 3172
GABRIELLE, P.: 2523
GAILLARD, R.: F023
GALICHANIN, K.: 3551
GALLAR, J.: T056
GAMA, L.: 2543
GANDOLFI, S.: 2623
GARDNER, P.: 3161
GARDINER, S.: 4473, F030
GARHÖFER, G.: 2143, F044
GARWAY-HEATH, D.: 1322
GEERAERTS, E.: 4258
GHULAM, M.: 2453
GIULVEZAN, S.: F051
GOCH, K.: 4273
Gonzalez, C.: 2526, S023, S024, S025
GRAJESKI, L.: F079
GRÅSBECK, S.: S057
GRÅSBECK, T.: S068
GRAW, J.: 3462
GRIEBEL, M.: 4221, 4424
GRIFFITH, M.: 4133
GRIVET, D.: 3441, F086
GRUENERT, A.: 2434
GRZYBOWSKI, A.: 1361, 2528, 3274, 4161, 4264, 4416, S030
GUALINO, V.: 2665, 3511
GUERRIER, G.: T060
GUINDOLET, D.: 2432, T070
GUTHOFF, R.F.: 2133, 2633
HAAGDORENS, M.: 4255
HABIBI, I.: T017
HADJISTILIANOU, T.: F082
HALFELD FURTADO DE MENDONCA, R.: F107, S016, S049
HAMEL, C.: 1251
HAMILTON, R.: 3522
HAMRAH, P.: 3531
HAOUAS, M.: S026
HAAgDORENS, M.: 4255
HABIBI, I.: T017
HADJISTILIANOU, T.: F082
HARKER, C.: 2432, T070
HE, Z.: 2431
HEEGAARD, S.: 4445
HEISSIGEROVA, J.: 4154
HEITMAR, R.: S045
HERBERT, C.P.: 1135, 1234, 2154
HERRMANN, R.: F063
HIROTA, Y.: F104
HOLDER, G.: 1254, 3244
HOMMER, A.: 2122
HOR, G.: T062
HORWITZ, A.: F021
HOUTMAN, A.C.: 2441
<table>
<thead>
<tr>
<th>Name</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRARAT, L.</td>
<td>S073</td>
</tr>
<tr>
<td>HUDSON, C.</td>
<td>2144</td>
</tr>
<tr>
<td>HWANG, H.</td>
<td>3252</td>
</tr>
<tr>
<td>HWANG, K.Y.</td>
<td>F072</td>
</tr>
<tr>
<td>HYTTI, M.</td>
<td>4175, T001</td>
</tr>
<tr>
<td>IDOATE, A.</td>
<td>S008</td>
</tr>
<tr>
<td>IMBEAU, L.</td>
<td>F058</td>
</tr>
<tr>
<td>IRSCH, K.</td>
<td>3454</td>
</tr>
<tr>
<td>ISMAIL, D.</td>
<td>T057</td>
</tr>
<tr>
<td>JACKSON, I.</td>
<td>3562</td>
</tr>
<tr>
<td>JAGER, M.J.</td>
<td>T054</td>
</tr>
<tr>
<td>JEANCOLAS, A.</td>
<td>F087</td>
</tr>
<tr>
<td>JENSEN, P.S.</td>
<td>S056</td>
</tr>
<tr>
<td>JEPPESEN, H.</td>
<td>T067</td>
</tr>
<tr>
<td>JOHNSTON, R.</td>
<td>2225</td>
</tr>
<tr>
<td>JOOSSEN, C.</td>
<td>4253</td>
</tr>
<tr>
<td>JULIENNE, R.</td>
<td>T061</td>
</tr>
<tr>
<td>JULIEN, M.</td>
<td>S059</td>
</tr>
<tr>
<td>JUMELLE, C.</td>
<td>T073, T074</td>
</tr>
<tr>
<td>JUN, J.H.</td>
<td>4171</td>
</tr>
<tr>
<td>JUNG, J.W.</td>
<td>T050</td>
</tr>
<tr>
<td>KABURAKI, T.</td>
<td>2155</td>
</tr>
<tr>
<td>KADZIAUSKIENE, A.</td>
<td>F036</td>
</tr>
<tr>
<td>KAEPER, P.</td>
<td>2562, 2564</td>
</tr>
<tr>
<td>KARANJIA, R.</td>
<td>3453</td>
</tr>
<tr>
<td>KATAMISH, T.</td>
<td>1142, 3133</td>
</tr>
<tr>
<td>KAUPP, J.A.</td>
<td>A4173</td>
</tr>
<tr>
<td>KAWASAKI, A.</td>
<td>1151, 3243</td>
</tr>
<tr>
<td>KAYA, M.</td>
<td>S036</td>
</tr>
<tr>
<td>KEPP, J.</td>
<td>S011</td>
</tr>
<tr>
<td>KESTELYN, P.</td>
<td>2533, 3272</td>
</tr>
<tr>
<td>KHAIROULLAH, M.</td>
<td>1233</td>
</tr>
<tr>
<td>KHAN, A.</td>
<td>1333</td>
</tr>
<tr>
<td>KILGAARD, J.F.</td>
<td>2673, 4415</td>
</tr>
<tr>
<td>KILIC, E.</td>
<td>4144</td>
</tr>
<tr>
<td>KIM, E.</td>
<td>S012</td>
</tr>
<tr>
<td>KIM, G.A.</td>
<td>F032</td>
</tr>
<tr>
<td>KIM, J.</td>
<td>T075</td>
</tr>
<tr>
<td>KIM, J.R.</td>
<td>S035</td>
</tr>
<tr>
<td>KIM, N.</td>
<td>S047</td>
</tr>
<tr>
<td>KIM, S.E.</td>
<td>1341</td>
</tr>
<tr>
<td>KIM, S.H.</td>
<td>F031</td>
</tr>
<tr>
<td>KIM, S.W.</td>
<td>S017</td>
</tr>
<tr>
<td>KIM, T.K.</td>
<td>S042</td>
</tr>
<tr>
<td>KIM, Y.G.</td>
<td>F017</td>
</tr>
<tr>
<td>KISSELVA, T.</td>
<td>2134</td>
</tr>
<tr>
<td>KIVELA, T.</td>
<td>1222, 1353, 2644, 2645</td>
</tr>
<tr>
<td>KIVINEN, N.</td>
<td>T007</td>
</tr>
<tr>
<td>KLEMM, M.</td>
<td>S080</td>
</tr>
<tr>
<td>KNOP, E.</td>
<td>2471</td>
</tr>
<tr>
<td>KOEV, K.</td>
<td>F059, F060</td>
</tr>
<tr>
<td>KOKONA, D.</td>
<td>T082</td>
</tr>
<tr>
<td>KOLKO, M.</td>
<td>4471, F024</td>
</tr>
<tr>
<td>KOOPMANS, S.</td>
<td>3155</td>
</tr>
<tr>
<td>KORHONEN, E.</td>
<td>4176, T002</td>
</tr>
<tr>
<td>KOTECHA, A.</td>
<td>2221, 3524</td>
</tr>
<tr>
<td>KOURENTIS, C.</td>
<td>4114</td>
</tr>
<tr>
<td>KOURT, P.</td>
<td>F090</td>
</tr>
<tr>
<td>KRASTEL, H.</td>
<td>3475, F052</td>
</tr>
<tr>
<td>KRATHOLM, N.</td>
<td>S037</td>
</tr>
<tr>
<td>KREPS, E.</td>
<td>F061</td>
</tr>
<tr>
<td>KRONSLAGER, M.</td>
<td>3555, T078</td>
</tr>
<tr>
<td>KUDRYAVTSEVA, O.</td>
<td>2661</td>
</tr>
<tr>
<td>KUOLIENE, K.</td>
<td>S040</td>
</tr>
<tr>
<td>LABAGETTE, P.</td>
<td>2577, T100</td>
</tr>
<tr>
<td>LABETOU, M.</td>
<td>F033, T038</td>
</tr>
<tr>
<td>LACHAPELLE, P.</td>
<td>3471</td>
</tr>
<tr>
<td>LAGALI, N.</td>
<td>2173</td>
</tr>
<tr>
<td>LAM, C.</td>
<td>4266</td>
</tr>
<tr>
<td>LAMBREHT, P.</td>
<td>2534</td>
</tr>
<tr>
<td>LANGENBUCHER, A.</td>
<td>4433</td>
</tr>
<tr>
<td>LANGMAN, T.</td>
<td>4214</td>
</tr>
<tr>
<td>LARSEN, D.A.</td>
<td>F096</td>
</tr>
<tr>
<td>LARSEN, L.M.</td>
<td>2212</td>
</tr>
<tr>
<td>LASUDRY, J.</td>
<td>3141</td>
</tr>
<tr>
<td>LAUDERDALE, J.</td>
<td>2651</td>
</tr>
<tr>
<td>LAWRENSON, J.</td>
<td>2521</td>
</tr>
<tr>
<td>LAYTON, C.</td>
<td>S055</td>
</tr>
<tr>
<td>LAZREG, S.</td>
<td>1345, T029, T080</td>
</tr>
<tr>
<td>LE, M.</td>
<td>3512, 4414</td>
</tr>
<tr>
<td>LEAL, I.</td>
<td>2542</td>
</tr>
<tr>
<td>LEE, J.H.</td>
<td>S071</td>
</tr>
<tr>
<td>LEE, S.H.</td>
<td>F016</td>
</tr>
<tr>
<td>LEE, S.J.</td>
<td>F097</td>
</tr>
<tr>
<td>LEE, W.</td>
<td>F029</td>
</tr>
<tr>
<td>LEFEVERE, E.</td>
<td>4452</td>
</tr>
<tr>
<td>LEINONEN, M.</td>
<td>3473</td>
</tr>
<tr>
<td>LEMATRE, S.</td>
<td>3444</td>
</tr>
<tr>
<td>LEMIJ, H.</td>
<td>3523</td>
</tr>
<tr>
<td>LENAERS, G.</td>
<td>2462</td>
</tr>
<tr>
<td>LEANDERI, A.</td>
<td>3171</td>
</tr>
<tr>
<td>LEROY, B.</td>
<td>1255, 3242</td>
</tr>
<tr>
<td>LEVIZEI, N.</td>
<td>3111</td>
</tr>
<tr>
<td>LEVIN, L.</td>
<td>2622</td>
</tr>
<tr>
<td>LEYS, A.</td>
<td>3165</td>
</tr>
<tr>
<td>LEYSEN, I.</td>
<td>2475</td>
</tr>
<tr>
<td>LI, D.</td>
<td>3164</td>
</tr>
<tr>
<td>LIBERT, S.</td>
<td>4458</td>
</tr>
<tr>
<td>LIM, S.L.</td>
<td>2415, S002</td>
</tr>
<tr>
<td>LIPSKI, D.</td>
<td>4453</td>
</tr>
<tr>
<td>LIRAVI, P.</td>
<td>F026</td>
</tr>
<tr>
<td>LISH, W.</td>
<td>3232</td>
</tr>
<tr>
<td>LISHKOVA, P.</td>
<td>1334, 3463</td>
</tr>
<tr>
<td>LOCKWOOD, A.</td>
<td>F022</td>
</tr>
<tr>
<td>LODGE, A.</td>
<td>2675</td>
</tr>
<tr>
<td>LOEFFLER, K.</td>
<td>2642, 3142</td>
</tr>
<tr>
<td>LÖFGREN, S.</td>
<td>S092</td>
</tr>
<tr>
<td>LOIS, N.</td>
<td>3212</td>
</tr>
<tr>
<td>Author</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>LONGSTAFF, S.</td>
<td>1123</td>
</tr>
<tr>
<td>LOPEZ TORRES, L.T.</td>
<td>T019</td>
</tr>
<tr>
<td>LOUKOVAARA, S.</td>
<td>2664</td>
</tr>
<tr>
<td>LUMBRASO, B.</td>
<td>2613</td>
</tr>
<tr>
<td>LUNA, C.</td>
<td>T055</td>
</tr>
<tr>
<td>LYNCH, A.</td>
<td>2433</td>
</tr>
<tr>
<td>LYTTEYNCHUK, L.</td>
<td>2417, 4178, S009, T015</td>
</tr>
<tr>
<td>MADIGAN, M.</td>
<td>4243</td>
</tr>
<tr>
<td>MAGILL, H.</td>
<td>S004</td>
</tr>
<tr>
<td>MALCLES, A.</td>
<td>S048</td>
</tr>
<tr>
<td>MAMUNUR, R.</td>
<td>4142</td>
</tr>
<tr>
<td>MANCEZAK, H.</td>
<td>2476</td>
</tr>
<tr>
<td>MANU, M.D.</td>
<td>F064, F065</td>
</tr>
<tr>
<td>MARKIEWICZ, A.</td>
<td>4446</td>
</tr>
<tr>
<td>MARQUES-NEVES, C.</td>
<td>3122</td>
</tr>
<tr>
<td>MARTINEZ, M.</td>
<td>S078, T045</td>
</tr>
<tr>
<td>MARTINUZZI, A.</td>
<td>2261</td>
</tr>
<tr>
<td>MARUYAMA, K.</td>
<td>2156</td>
</tr>
<tr>
<td>MASCHI, C.</td>
<td>2667</td>
</tr>
<tr>
<td>MASSY, R.</td>
<td>4151</td>
</tr>
<tr>
<td>MATEO OROBIA, A.J.</td>
<td>T077</td>
</tr>
<tr>
<td>MATHIS, T.</td>
<td>2111</td>
</tr>
<tr>
<td>MATSUSHIMA, H.</td>
<td>1364</td>
</tr>
<tr>
<td>MATTHYSSEN, S.</td>
<td>4455</td>
</tr>
<tr>
<td>MAYUMI, N.</td>
<td>F075</td>
</tr>
<tr>
<td>MAZY, R.</td>
<td>3521</td>
</tr>
<tr>
<td>MCAUGHT, A.</td>
<td>2223, 4222</td>
</tr>
<tr>
<td>MEKKI, M.B.</td>
<td>2474</td>
</tr>
<tr>
<td>MELLER, D.</td>
<td>3234</td>
</tr>
<tr>
<td>METZ, G.</td>
<td>F108</td>
</tr>
<tr>
<td>MEUNIER, A.</td>
<td>T021</td>
</tr>
<tr>
<td>MIDEA, E.</td>
<td>2513, 4122</td>
</tr>
<tr>
<td>MILLERET, C.</td>
<td>2442</td>
</tr>
<tr>
<td>MIRANDA, M.</td>
<td>F041</td>
</tr>
<tr>
<td>MIRZA, N.</td>
<td>F050</td>
</tr>
<tr>
<td>MIYACI, E.</td>
<td>S096</td>
</tr>
<tr>
<td>MOE, M.</td>
<td>2174</td>
</tr>
<tr>
<td>MOORE, T.</td>
<td>2172</td>
</tr>
<tr>
<td>MORGAN, I.</td>
<td>4262</td>
</tr>
<tr>
<td>MORGAN, J.E.</td>
<td>2421</td>
</tr>
<tr>
<td>MORYN, E.</td>
<td>3474</td>
</tr>
<tr>
<td>MORREALE BUBELLA, R.</td>
<td>T097</td>
</tr>
<tr>
<td>MOULIN, A.</td>
<td>3443</td>
</tr>
<tr>
<td>MOUNA, A.</td>
<td>2418, S010</td>
</tr>
<tr>
<td>MOURAUX, F.</td>
<td>3143</td>
</tr>
<tr>
<td>MUNOZ - NEGRETE, F.J.</td>
<td>2575, F009, F012, T098</td>
</tr>
<tr>
<td>MURA, M.</td>
<td>1214</td>
</tr>
<tr>
<td>MURPHY, C.</td>
<td>2574</td>
</tr>
<tr>
<td>NATH, M.</td>
<td>F045</td>
</tr>
<tr>
<td>NERI, P.</td>
<td>1133</td>
</tr>
<tr>
<td>NNESS, C.</td>
<td>F081</td>
</tr>
<tr>
<td>NEVES, C.</td>
<td>1111</td>
</tr>
<tr>
<td>NGUYEN, D.</td>
<td>2557, T090</td>
</tr>
<tr>
<td>NGUYEN, P.</td>
<td>F053</td>
</tr>
<tr>
<td>NI GABHANN, J.</td>
<td>2232</td>
</tr>
<tr>
<td>NINCLAUS, V.</td>
<td>F102</td>
</tr>
<tr>
<td>NISHIGUCHI, K.</td>
<td>S022</td>
</tr>
<tr>
<td>NIZAWA, T.</td>
<td>S085</td>
</tr>
<tr>
<td>NORDMANN, J.</td>
<td>2711, 2712</td>
</tr>
<tr>
<td>NORK, T.M.</td>
<td>2423</td>
</tr>
<tr>
<td>NORMANDO, E.M.</td>
<td>1323</td>
</tr>
<tr>
<td>NOWINSKA, A.</td>
<td>1244</td>
</tr>
<tr>
<td>NUBILE, M.</td>
<td>1141</td>
</tr>
<tr>
<td>NYKTER, M.</td>
<td>2274</td>
</tr>
<tr>
<td>O’ROURKE, M.</td>
<td>2572</td>
</tr>
<tr>
<td>OH, J.R.</td>
<td>S081</td>
</tr>
<tr>
<td>OHNO-MATSUI, K.</td>
<td>2161, 4261</td>
</tr>
<tr>
<td>OLEN, A.S.</td>
<td>4474</td>
</tr>
<tr>
<td>OMETTO, G.</td>
<td>S084</td>
</tr>
<tr>
<td>OPDENAKKER, G.</td>
<td>2251</td>
</tr>
<tr>
<td>OSBORNE, N.</td>
<td>2141, 4163</td>
</tr>
<tr>
<td>OSHITARI, T.</td>
<td>S095</td>
</tr>
<tr>
<td>OZCAN, A.A.</td>
<td>F020, S087</td>
</tr>
<tr>
<td>PAHUJA, N.</td>
<td>2555, T088</td>
</tr>
<tr>
<td>PAPASTEFANOU, V.</td>
<td>4113, 4242</td>
</tr>
<tr>
<td>PAPAVASILEIOU, E.</td>
<td>S018, S070</td>
</tr>
<tr>
<td>PAQUES, M.</td>
<td>3211, 3514</td>
</tr>
<tr>
<td>PARK, H.</td>
<td>S098</td>
</tr>
<tr>
<td>PARK, H.J.</td>
<td>F083</td>
</tr>
<tr>
<td>PARK, J.M.</td>
<td>S069</td>
</tr>
<tr>
<td>PARS, C.</td>
<td>1152, 1153, 3456, 4462, F109</td>
</tr>
<tr>
<td>PASOVIC, L.</td>
<td>4271, S094</td>
</tr>
<tr>
<td>Patel, S.</td>
<td>2553</td>
</tr>
<tr>
<td>PATERNO, J.</td>
<td>T003</td>
</tr>
<tr>
<td>PENWARDEN, A.</td>
<td>2527, S031</td>
</tr>
<tr>
<td>PEREZ CARRASCO, M.J.</td>
<td>F070</td>
</tr>
<tr>
<td>PEREZ NAVARRO, I.</td>
<td>F025, S043</td>
</tr>
<tr>
<td>PETERSEN, A.</td>
<td>3553</td>
</tr>
<tr>
<td>PETERSEN, L.</td>
<td>2245, F047</td>
</tr>
<tr>
<td>PETROVSKI, G.</td>
<td>2175</td>
</tr>
<tr>
<td>PEYNSHAERT, K.</td>
<td>4257</td>
</tr>
<tr>
<td>PIippo, N.</td>
<td>T006</td>
</tr>
<tr>
<td>PILOTZ, F.</td>
<td>T046, T047</td>
</tr>
<tr>
<td>PILSON, Q.</td>
<td>2235, T084</td>
</tr>
<tr>
<td>PINNA, A.</td>
<td>F013, T026</td>
</tr>
<tr>
<td>PISSELLA, P.J.</td>
<td>2332</td>
</tr>
<tr>
<td>PLEYER, U.</td>
<td>1134, 1232, 1351</td>
</tr>
<tr>
<td>POURJAVAN, S.</td>
<td>3525, 4478, F008</td>
</tr>
<tr>
<td>POURNARAS, C.</td>
<td>2514, 2614</td>
</tr>
<tr>
<td>POURNARAS, J.</td>
<td>1215, 3113, 3513, 4112</td>
</tr>
<tr>
<td>PRAYTANANSINGH, S.</td>
<td>3571</td>
</tr>
<tr>
<td>PROKOSCH-WILLING, V.</td>
<td>3425</td>
</tr>
<tr>
<td>PUELL, M.</td>
<td>F054</td>
</tr>
<tr>
<td>RAGEADE, D.</td>
<td>2435</td>
</tr>
<tr>
<td>RAGUNATHAN, S.</td>
<td>S033</td>
</tr>
<tr>
<td>RAJIV KUMAR, N.</td>
<td>1347, T082</td>
</tr>
<tr>
<td>RAMAZANOVA, K.</td>
<td>2132</td>
</tr>
<tr>
<td>REICHENBACH, A.</td>
<td>4164</td>
</tr>
</tbody>
</table>
The ARVO Annual Meeting brings together 11,000 global researchers to explore cutting-edge science, collaborate with their peers and connect with people who will ultimately benefit from the work.

Abstract submission:
arvo.org/am
MAYE, W.: 3153
MAYUMI, N.: F075
MAZHARIAN, A.: F010
MAZY, R.: 3521
MCKIE, L.: 3562
MCLEAN, I.: 2172
MCNAUGHT, A.: 2223, 4222
MEHANNA, C.: T060
MEIER, T.: F018
MEKKI, M.B.: 2474
MELLER, D.: 3234
MENSINKH, H.: 4144
MERLE, H.: 3452
MESSMER, E.: T037
MESSNER, A.: 4234
METZ, G.: F018
METZIG, C.: 2211, 2212
MEUNIER, A.: T021
MICHAEL, R.: F067
MIDENA, E.: 4228, F005
MIDENA, G.: 1114
MIETTINEN, P.J.: S057, S068
MILLERET, C.: 2442
MINDEN, K.: 4152
MIRANDA, M.: F041
MIRZA, N.: F060
MITCHELL, A.: F022
MIYACHI, E.: S096
 Mizota, A.: 4273
MOCKEVICITE, E.: F091, S083
MOE, M.: F081, 2174
MOHAMMAD, G.: 2252
MOK, J.W.: 3162
MOLASY, M.: F028
MOLEIRO, A.: 2242, F046
MOLENBERGHS, G.: 4286, F002
MONTEIRO-GRILLO, M.: 2543
MONTENEGRO, G.A.: F067
MONTAYO, J.: T012
MOONS, L.: 3575, F033
MOORE, J.: 2172
MOORE, T.: 2172
MORAES-FILHO, M.: 3453
MORAWSKI, K.: 4443
MORGADO, J.: F037
MORGAN, I.: 4262
MORGAN, J.E.: 2421
MORISSE, T.: S096
MORYN, E.: 3474
MORREALE BUBELLA, R.: T097
MORRIS, J.: 2241, S021
MOTHESES, N.: F050
MOTTE, J.: S083
MOUINGA, A.: F010
MOULIN, A.: 3443
MOURA, A.: 2414, 2418, S010
MOURINH, G.: S072
MOURIAUX, F.: T037, 3143
MOURTZOUKO, S.: S074
MRUKWA-KOMINEK, E.: T038
MUKHINA, A.: F094
MUNCH, M.: F090
MUNIER, F.: T017, T016
MUNOZ - NEGRETTE, F.J.: F257, F009, F012, T098
MURA, J.: 1214
MURPHY, C.: 2574, 2322, T057
MURPHY, C.G.: 2235, T084
MURRAY, I.J.: F050
MYAKOSHINA, E.: 4143
NA, K.S.: 2236, 3162, T028
NAICEF, L.: S005, T054
NADAL-NICOLAS, F.M.: 2422
NAGEL, E.: S080
NAIKOKO, O.: F089
NAKAZAWA, T.: S022
NAMEKATA, K.: 3572
NANGOUMOUSSO, T.: 2435
NATH, M.: F045
NAU.S, N.: 4144
NEFF, F.: 3264
NEGISHI, K.: 4263
NERI, P.: 1133
NERINCX, F.: S015
NEROEV, V.: 4143
NESSBIT, A.: 2172
NESS, C.: F081
NEUMANN, M.: F027
NEWSOM, R.: S086
NGUYEN, D.T.: 2557, T090
NGUYEN, P.M.: F053, F073
NGUYEN, Q.D.: 4154
NI DUBHGHAILL, S.: T043
NI GABANN, J.: 2235, 2574, T084, 2232
NICKELLS, R.W.: 2423
NICOLAISEN, B.: F081
NICOLAS, M.: 3443
NICOLAU, R.: T060
NIELSEN, K.: 1346, T081
NIEWERTH, M.: 4152
NIUS, I.: 3165
NILSSON, M.: F068, F088, S076
NINCCLAUS, V.: F106, F102
NISHIGUCHI, K.: S022
NIZAWA, T.: S085
NOER, A.: F081
NOLAN, R.: 3562
NORDMANN, J.P.: 2711, 2712
NOREIKYTE, M.: S063
NORK, T.M.: 2423
NORMANDO, E.M.: 1323
NOWINSKA, A.: 1244
NUBILE, M.: 1141
NUENEZ, E.: F025, T009, S043
NYKETER, M.: 2274
ONEILL, J.: 4272
ORourke, M.: 2572
OBLANCA-LLAMAZARES, N.: 2575, F009, T098
ODDONE, F.: 4475, F005
OGUNDELE, A.: T037, T038
OH, J.R.: S081
OH, S.: F031
OKHUMA, K.: S096
OHINO-MATSUI, K.: 2161, 4261
OHOTO, K.: 2155
OJALA, M.: 3473
OKINAGA, K.: 2155
OLDAK, M.: T022, T063
OMIERE, C.: T069, F039
OLSEN, A.S.: F111, 4474
OLSTAD, K.O.: 4271, S094
OMETTO, G.: S084
ONO, F.: S022
OPPENAKKER, G.: 2251, 2218, S050
ORDUNA, E.: T065
ORGUEL, S.: H015
ORTIN-MARTINEZ, A.: 2422
OSBORNE, N.: 2141, 4163
OSHIHATA, F.: T104, S095
OSTADIMOGHADDAM, H.: T025, T071
Wednesday, October 7, 2015

12:00 - 13:30
- RV: Diabetic retinopathy: A neurodegenerative disease
  FERREIRA J - VUJOSEVIC S
- G: Virtual review: Setting new standards in glaucoma care
  CRAWFYL-L - AHMED F
- IM: EBO course: Intraocular inflammation and infection
  BODAGHI B - HERBORT CP
- COS: How to perform deep anterior lamellar keratoplasty
  DUA HS
- NSPH: Papilloedema and its Mimics: What's new in pseudotumor cerebri syndrome?
  SATMARY G - KAWASAKI A - PAPAS P
- HERVEY-Acta Lecture: Regulating the body clock – The unrecognised role of the eye
  MAUGET-FAYSSE M - WOLFF B
- EVER-Past president lecture: Retinal Vein Occlusions : From pathophysiological mechanism to clinical therapeutical issues
  POURNARAS C - ZOGRAFOS L
- European Ophthalmology Heritage Lecture: Visual impairment in opera characters
  SCHMETTERER L - GUTHOFF RF
- Opening Ceremony: Welcome by the President EVER 2015

13:30 - 16:00
- RV: Macular hole surgery: New facts and tips for a successful result
  PAPPAS G
- PO: Mistakes in the diagnosis of fundus tumors
  DESJARDINS L - ZOGRAFOS L
- EBO course: Intraocular inflammation and infection (Part 2)
  BODAGHI B - HERBORT CP
- COS: In vivo confocal microscopy in corneal disorders
  WYLEGALA E - SEDMOWSKI A
- MBGE: Grand rounds in ophthalmic genetics
  LEROY B - HAMEL C

16:00 - 17:30
- Coffee break
- Opening Ceremony: Welcome by the President EVER 2015 - LEROY B
- EVERY/ Fellowship highlights - SCHMETTERER L
- EVER Past president lecture: Retinal Vein Occlusions: From pathophysiological mechanism to clinical therapeutical issues - POURNARAS C
- European Ophthalmology Heritage Lecture: Visual impairment in opera characters - AYDIN P
-EVER Welcome Reception

17:30 - 18:30
- RV: Diabetic retinopathy: Part 1
  CREUZOT G - STAURENGHI G
- RV: Diabetic retinopathy: Part 2
  VIDO-SANZ M - NORK M
- RV: Macular hole surgery: New facts and tips for a successful result
  PAPPAS G
- Women 4EVER
  DESJARDINS F - KAWASAKI A
- G: OCT in glaucoma: Clinical and experimental applications
  NORMANDO EM - GARWIN HEATH D - CORDEIRO MF
- MBGE: Monogenic corneal disorders
  LISKOWA P - DAVIDSON AE
- COS: Free paper session - Cornea and ocular surface inflammation
  GICOUEL JJ
- How to publish - hints and "tricks"....
  PLEYER U
- LC: But doctor, will this IOL last my lifetime?
  GRZYBOWSKA A - BEIXO G
- PBP: Retinal and choroidal blood flow and oxygenation
  HARDARSON S - SIN M

19:00 - 20:30
- Industry-sponsored evening symposium: How to create a new generation of glaucoma patient?
  NORRIS M - LEYS A - LAUDERDALE J D
- ACB: Inflammation, wound healing and tear proteomes
  LISKOVA P - DAVIDSON AE
- NSPH: An update on aniridia
  CRAWLEY L - AHMED F
- COS: How to perform deep anterior lamellar keratoplasty
  DUA HS
- HERVEY-Acta Lecture: Regulating the body clock – The unrecognised role of the eye
  MAUGET-FAYSSE M - WOLFF B
- EVER-Past president lecture: Retinal Vein Occlusions : From pathophysiological mechanism to clinical therapeutical issues
  POURNARAS C - ZOGRAFOS L
- European Ophthalmology Heritage Lecture: Visual impairment in opera characters
  SCHMETTERER L - GUTHOFF RF
- Opening Ceremony: Welcome by the President EVER 2015
- EVERY/ Fellowship highlights - SCHMETTERER L
- EVER Past president lecture: Retinal Vein Occlusions: From pathophysiological mechanism to clinical therapeutical issues - POURNARAS C
- European Ophthalmology Heritage Lecture: Visual impairment in opera characters - AYDIN P
-EVER Welcome Reception

Thursday, October 8, 2015

07:30 - 08:00
- Coffee and Croissants

08:00 - 09:30
- RV: Focus on fundus autofluorescence imaging: review and perspectives
  MAUGET-FAYSSE M - WOLFF B
- G: All you ever wanted to know about the EOS!
  STALMANS I - HOMMER A
- PBP: Ultrasound course
  SCHMETTERER L - KISSELEVAT
- PBP: Relationship between retinal neovascularization, dja and blood vessels
  GARNÖFER G
- IM: Uveitis in the East and West
  NERI P - TAKEUCHI M

09:45 - 10:25
- EVER-Acta Lecture: Regulating the body clock – The unrecognised role of the eye - FOSTER R

10:30 - 12:00
- RV: Free paper session - Diabetes
  CREUZOT C - STAURENGHI G
- G: Lifetime risk of blindness from glaucoma
  KOTCEWA A - MCNAUGHT A
- COS: Free paper session - Year film exploration and dry eye
  DOAN S - GICOUEL JJ
- PBP: Free paper session - Pharmacology / drug delivery / physiology
  OSBORNE N - GARNÖFER G
- IM: Inflammation in diabetic retinopathy-part 1
  ABU EL ASRAR A
- MBGE: Mitochondrial optic neuropathies - classical disease and novel manifestation
  VOTRUBA M - YU-WAI-MAN P
- ACB: Corneal stem cells - from benchside to bedside
  PETROVSKI G - MOE M
- ACB: Inflammation, wound healing and tear proteomes
  LIUSTALO H - BEUERMAN R

12:00 - 13:00

13:10 - 13:45
- Ophthalmic Research Lecture: Degenerative myopia and its treatment - WIEDEMANN P

13:45 - 15:15
- RV: Free paper session - Surgery
  BERRIO J - POURNARAS C
- G: Does glaucoma affect only retinal ganglion cells in the retina?
  VIDAL-SANZ M - NORK M
- COS: Free paper session - Cornea bioengineering
  THURET G - LYNCH A
- NSPH: The role of the corpus callosum in binocularity and strabismus
  TEN TUSCHER M
- IM: Inflammation in diabetic retinopathy-part 2
  ABU EL ASRAR A
- MBGE: Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies
  VOTRUBA M - YU-WAI-MAN P
- ACB: New wine in new tubes - The re-advancement of scleral lenses in ocular surface diseases
  KNOOP E - MEKKI MB

15:15 - 16:00
- Poster session 1: • Anatomy / Cell Biology • Molecular Biology / Genetics / Epidemiology • Cornea / Ocular Surface • Immunology / Microbiology
- Poster area

16:00 - 17:30
- RV: Diabetic retinopathy and macular edema
  CREUZOT C - MIDENA E
- RV: Free paper session - AMD
  LEYS A - LAWRENSON J
- G: New and/or under diagnosed entities in glaucoma
  STEVENS AM - KESTELYN P
- G: Free paper session - Imaging and biomechanics
  CORDEIRO MF - CORDEIRO SOUSA D
- COS: Free paper session - Ocular surface anatomy updates
  BORDIERE V - RUGGERI A
- NSPH: Nystagmus and non-nystagmic abnormal spontaneous eye movements
  BORRIJAT FX - KAESSER P
- RV: Free paper session - Retinal vasculopathy
  LEYS A - BAILLY S

17:30 - 19:00
- RV: New developments in OCT/Angiography
  POURNARAS C - ZOGRAFOS L
- G: Neuroprotection in glaucoma: Coming of age?
  CORDEIRO MF - LEVIN L
- COS: Corneal imaging
  SCHMETTERER L - GUTHOFF RF
- PO: It is a masked! Eye cancer lurking behind innocent appearances
  KIVELÄ T - DESJARDINS L
- RV: Free paper session - Retinal vasculopathy
  LEYS A - BAILLY S
- ACB: RPE Transplantation. From lab to the clinic
  LIUSTALO H - KAARINANTA K

19:00 - 20:30
- Industry-sponsored evening symposium: How to create a new generation of glaucoma patient?
  NORRIS M - LEYS A - LAUDERDALE J D
- ACB: Inflammation, wound healing and tear proteomes
  LISKOVA P - DAVIDSON AE
- NSPH: An update on aniridia
  CRAWLEY L - AHMED F
- COS: How to perform deep anterior lamellar keratoplasty
  DUA HS
- HERVEY-Acta Lecture: Regulating the body clock – The unrecognised role of the eye
  MAUGET-FAYSSE M - WOLFF B
- EVER-Past president lecture: Retinal Vein Occlusions : From pathophysiological mechanism to clinical therapeutical issues
  POURNARAS C - ZOGRAFOS L
- European Ophthalmology Heritage Lecture: Visual impairment in opera characters
  SCHMETTERER L - GUTHOFF RF
- Opening Ceremony: Welcome by the President EVER 2015
- EVERY/ Fellowship highlights - SCHMETTERER L
- EVER Past president lecture: Retinal Vein Occlusions: From pathophysiological mechanism to clinical therapeutical issues - POURNARAS C
- European Ophthalmology Heritage Lecture: Visual impairment in opera characters - AYDIN P
-EVER Welcome Reception
EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2015. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER 2015 - programme book